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The role of the calcineurin/NFAT signaling pathway and its regulation 
in muscle diseases 
Manal Al Zein, PhD  
Concordia University, 2013 
  
 Elevations in intracellular calcium activate the phosphatase Calcineurin (Cn) and 
its downstream target the Nuclear Factor of Activated T cells (NFAT), leading to the 
expression of genes involved in skeletal muscle growth and cardiac remodeling. In this 
thesis, we set out to investigate the role of the Cn/NFAT signaling pathway in the 
progression of two muscle diseases: Duchenne Muscular Dystrophy (DMD), which is 
characterized by the loss of the functional protein dystrophin, and cardiac hypertrophy. 
First, to understand the roles of Cn and Cn regulators in DMD, we used mdx mice crossed 
with mice expressing transgenes that manipulate the Cn/NFAT pathway. For instance, the 
expression of the transgene Parvalbumin (PV) in mdx mice leads to attenuation of Cn 
activity and reduction in the expression of utrophin, a protein that compensates for the 
loss of dystrophin. Our results show that strategies promoting Ca2+/Cn signaling are 
considered an effective countermeasure in the treatment of DMD and that Cn regulators 
might have a critical role in the progression of the disease. Secondly, the role of the 
NFATc2 transcription factor in Cn-dependent cardiac hypertrophy is emphasized using 
adult NFATc2 knockout mice in the presence and absence of biochemical stress. Here we 
show a cardio-protective role for NFATc2 in normotensive hearts, but not in hearts 
exposed to stress. Together, the results of this thesis provide a better understanding of the 
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Chapter 1 : General Introduction
2 
 
1.1 Muscle structure, contraction and development 
1.1.1 Muscle structure and contraction 
 
 Muscle tissue is a highly vascularized organ used for contraction. All muscles 
show biochemical specialization which allows them to produce body movement [1]. 
There are three basic types of muscle tissue: skeletal, cardiac and smooth (Figure 1.1). 
Skeletal muscle cells are long, cylindrical, voluntary-controlled, multi-nucleated and 
striated cells formed by fusing hundreds of myoblasts end-to-end. Skeletal muscles 
stabilize the position of the skeleton, generate heat and protect internal organs. Cardiac 
muscle cells (cardiomyocytes) are long, branched involuntary-controlled cells that are 
mono-nucleated but still show a striated pattern. Intercalated discs connect these cells 
whose main functions are to circulate blood and maintain blood pressure. Smooth muscle 
cells are mono-nucleated, involuntary-controlled cells with no striations. They are found 
in the walls of hollow internal structures such as blood vessels, urinary bladder, 
respiratory, digestive and reproductive tracts. Smooth muscles function to move foods, 
urine and reproductive tract secretions, regulate the diameter of blood vessels and control 
the width of respiratory passage ways [1]. 
 
Figure 1.1: The general structures of skeletal, cardiac and smooth muscles [1] 
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 Each skeletal muscle fiber is enveloped by a plasma membrane called the 
sarcolemma, which surrounds a cytoplasm (called sarcoplasm) and contains a 
Sarcoplasmic Reticulum (SR). Most of the cytoplasm is occupied by cylindrical bundles 
of contractile proteins called myofibrils, each of which measures approximately 1-2 µm 
in diameter. The sarcomere is the repeating subunit of myofibrils and the functional unit 
of muscle contraction [2]. Filamentous actin (f-actin), titin and nebulin are the three 
filament systems of the sarcomere that interact with the Z-disc (also known as the Z-band 
or Z-line), which forms the borders of the sarcomere (Figure 1.2), whereas myosin-based 
thick filaments do not directly interact with the Z-disc [3]. Those thick filaments are 
located in the central portion of the sarcomere, while the thin filaments that are composed 
of actin, are situated at the extremities of the functional unit and bind myosin to perform 
the muscle contraction process. 
 During contraction, myosin heads bind to actin. This interaction is regulated by 
two proteins, tropomyosin and troponin, which are bound to the thin filaments and are 
capable of covering the binding sites for myosin. At this stage, myosin cannot bind to 
actin and thus, muscle contraction is inhibited [2]. In a process known as excitation-
contraction coupling, a nerve impulse triggers the release of the neurotransmitter 
Acetylcholine (Ach) from the presynaptic terminus into the synaptic cleft. The released 
Ach binds to its receptor (AchR) on the postsynaptic muscle surface, and induces a 
conformational change causing this channel to open for ion flux. For instance, Na+ influx 
leads to membrane depolarization and propagation of an action potential. This action 
potential is transmitted into the Transverse tubules (T-tubules; special extensions of the 
sarcolemma) where it opens the SR Ca2+ channel. Upon the increase of sarcoplasmic Ca2+ 
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concentration, troponin binds Ca2+, causing a conformational change, which pulls 
tropomyosin away from its blocking position. Consequently, as the actin binding sites 
become uncovered for myosin to bind, the contraction process begins [2]. 
 
Figure 1.2: A schematic drawing of the sarcomere [4] 
The f-actin-containing thin filaments anchor at the Z-disc and interdigitate with the myosin-
containing thick filaments at the level of the A-band. Costameric proteins ensure lateral force 
transduction and linkage to the sarcolemma and its associated protein complexes. 
 
1.1.2 Skeletal muscle development 
 
  The process of generating muscle (myogenesis) is divided into several stages [5]. 
The initial muscle fibers of the body are created by mesoderm, which is a derived 
structure that develops during embryonic development. Subsequently, additional fibers 
are formed from the template fibers [5, 6]. In the course of maintaining homeostasis, 
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adult skeletal muscle relies on a compensatory mechanism for the turnover of terminally 
differentiated cells. This compensatory mechanism involves activation of satellite cells 
that are capable of differentiation into new fibers [7, 8]. Satellite cells can be activated 
after damage caused by mechanical stress or chemical injection [9, 10]. In both 
embryonic myogenesis and regeneration of skeletal muscle processes, there are common 
transcription factors and signaling molecules that are utilized (Figure 1.3) [5].  
 
Figure 1.3: Transcription factors regulating myogenesis [11] 
Muscle progenitors that are involved in embryonic muscle differentiation skip the quiescent 
satellite cell stage and directly become myoblasts. Some progenitors remain as satellite cells in 
postnatal muscle and form stem and committed cells. Six1/4 and Pax3/7 are master regulators of 
early lineage specification, whereas Myf5 and MyoD commit cells to the myogenic program. 
Expression of the terminal differentiation genes required for the fusion of myocytes and the 
formation of myotubes, are performed by both myogenin (MyoG) and MRF4. 
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 Myogenesis is a well-controlled process that is separated into two steps: 1) 
proliferation of cells and 2) differentiation and maturation of proliferated cells. The basic 
helix-loop-helix Myogenic Determination factor (MyoD) is capable of transforming a 
group of cell types such as fibroblasts into cells that fuse into myotubes [12]. Myogenic 
factor 5 (Myf5), myogenin and Muscle Regulatory Factor 4 (MRF4, also known as 
Myf6) are three other myogenic basic helix-loop-helix factors which induce myoblast 
traits in non-muscle cell lines [13, 14]. Collectively, these four transcription factors are 
referred to as Myogenic Regulatory Factors (MRFs) [15]. Each of these factors has a 
critical function in myogenesis. While Myf5 has a role in myoblast proliferation, MyoD 
and myogenin promote myoblast differentiation [16-18], and MRF4 is essential for 
myoblast maturation [19, 20]. The Paired box (Pax) 3 and 7 are additional factors 
involved in satellite cell differentiation and proliferation, as well as in the myogenesis 
process [21, 22]. Additionally, myostatin, an important negative regulator of muscle 
mass, is present in satellite cells and myoblasts [23]. Interestingly, myostatin 
overexpression downregulates Pax7 expression while myostatin inhibition upregulates 
Pax7 expression [24]. Moreover, the Sine oculis-related homeobox transcription factors 
(Six) 1 and 4 are also master regulators of early lineage specification. Thus, Six1 and 4 
proteins act as cofactors to activate Six target genes such as Pax3 and MRFs [25]. 
1.1.3 Cardiac muscle development 
 
 Cardiac muscle development (cardiogenesis) is an additive process in which 
additional layers of complexity are added throughout the evolution of a simple structure 
(linear heart tube) [26]. The earliest stages of heart development are nearly identical 
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among all vertebrates unlike the subsequent septation of the chambers and the outflow 
tract, which vary between species depending on utilization of the lungs [26]. The heart 
field is the region of the embryonic mesoderm that contains the cardiac progenitor cells. 
The mesodermal cells are committed to the heart by the early gastrulation stage. These 
pre-heart cells migrate toward the anterior embryonic pole to condense in bilateral areas 
of the splanchnic mesoderm. Soon after formation, the precardiac areas migrate to the 
embryonic midline, fuse under the endodermal foregut and form the primitive tubular 
heart. The precardiac mesoderm contains both endocardial and myocardial precursors 
[27]. In vivo, precardiac mesodermal cells express transcription factors including  
Transforming Growth Factors as TGFβ1, TGFβ2 and activin A, which regulate the 
expression of α-Myosin Heavy Chain (α-MyHC), an initial marker of cardiac 
differentiation [27, 28]. Furthermore, cell-cell interactions within the precardiac 
mesoderm also may have a significant influence on cardiac differentiation. At the organ 
level, the adequate integration of the different heart components ultimately results in the 
development of heart shape and function [28]. 
 Cardiac looping arises from the coordinated integration of the different 
components of the heart tube [27]. The mechanisms involved in looping are still under 
discussion. After the initial fusion of the paired primordial cells, a single heart tube is 
formed in the embryonic midline. This primitive heart represents the future trabeculated 
part of the right ventricle. Continued fusion of the paired primordium brings about the 
merging of the trabeculated part of the left ventricle, the atrium and the sinus venosus, 
which are progressively incorporated into the developing heart [29]. The myocardium is 
formed throughout looping of a single population of developing myocytes. Molecular 
8 
 
modifications in cellular proliferation, transformation, migration and death are thought to 
be involved in the process of looping, but the relative contributions of these cellular 
mechanisms are still unknown [29]. When looping is complete, the heart progressively 
acquires an adult configuration. Internally, independent septa develop in the atrial and 
ventricular chambers, the bulbus cordis, and the atrioventricular canal. These septa 
reunite in the center of the heart to transform the cardiac tube into a four chambered 
organ (two atria and two ventricles; left and right) (Figure 1.4). This system is connected 
to the blood entry system by the inferior and the superior vena cavae from one side and 
by the pulmonary veins from the other side [30].  
 
 
Figure 1.4: A schematic drawing of cardiac mesoderm differentiation [31] 
 
 In the formed heart, it is critical to distinguish between the working myocardium 
(whose main function is contraction) and the conduction system (which is responsible for 
generation and conduction of the electrical impulse from the sinusal node formed at the 
atrial junction) [32]. The conduction system comprises separate components with distinct 
functions. The Sino-Atrial Node (SAN), which contains the leading pacemaker, generates 
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the impulse that is subsequently conducted, via the atrial myocardium toward the Atrio-
Ventricular Node (AVN), with a delay. The impulse is then rapidly transmitted from the 
AVN via the bundle branches and the Peripheral Purkinje Network (PPN) to ensure a 
coordinated activation of the ventricular myocardium from apex to base. Hence, the 
development of the conduction system does not require the invention of new building 
blocks, but a remodeling of existing components [32]. 
1.1.4 Muscle fiber types 
 
 Skeletal muscles comprise fiber types with distinctive contractile and metabolic 
properties. Scientists used to distinguish skeletal muscles based on their colors as red or 
white and on their contractile properties as fast and slow. However, during the last 40 
years, the classification of muscle fiber types changed such that now four major fiber 
types are recognized in adult mammalian skeletal muscles [33]. Since 1968-1970, fast-
white muscles have been identified as those specialized for phasic activity, whereas slow-
red muscles are those dedicated for more continuous activity [34]. Using histochemical-
physiological studies, fast-twitch fibers have been shown to display large variations in 
levels of Succinate Dehydrogenase (SDH) as an indication of variable resistance to 
fatigue [35]. Simultaneously, two fast fiber populations (named type IIa and IIb), which 
are distinct from the slow type I fibers have been identified [36, 37]. Additionally, 
skeletal muscle fibers can be classified into slow oxidative, fast-twitch oxidative 
glycolytic and fast-twitch glycolytic muscle fibers based on the levels of glycolytic and 
oxidative enzymes they possess [38]. Biochemical analysis also identified a third fast 
fiber type called type IIx or IId which has a strong SDH staining [39, 40] with an 
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intermediate maximal velocity of shortening between that of IIa and IIb fibers [41, 42]. 
The properties of the major skeletal muscle fiber types are demonstrated in Figure 1.5. 
  Fiber type switching is possibly induced by electric stimulation that causes 
changes in nerve activity [43]. For instance, phasic high-frequency electrical stimulation 
leads to a slow-to-fast fiber switch in the direction I→ IIa→ IIx→ IIb, whereas tonic-low 
frequency electrical stimulation causes a fast-to-slow switch in the direction IIb→ IIx → 
IIa →I [43]. Moreover, fast muscles have the capacity to adapt in the range IIb↔ IIx↔ 
IIa, while slow muscles adapt in the range I↔ IIa↔ IIx [44]. 
 
Figure 1.5: MyHC isoforms in skeletal muscle and their properties [45] 
 
 The classification of muscle fibers in cardiomyocytes is different from that of 
skeletal muscles. Thus, in cardiac cells, there are two types of MyHC protein; α and β. 
The expression of these two isoforms is correlated to the contractile velocity of cardiac 
muscles [46]. However, the skeletal slow MyHC and the cardiac β-MyHC are the same 
isoform [47]. Cardiomyocytes expressing α-MyHC are found in adult hearts, have a more 
contractile velocity and are quicker to fatigue than β-MyHC. In contrast, cardiomyocytes 
expressing more β-MyHC are present in fetal and developing hearts, have a great 




Figure 1.6: Cardiac MyHC isoforms and their properties (information taken from [47]) 
 
 Like in skeletal muscles, several pathological stimuli cause a shift in the MyHC 
composition from α to β [46]. β-MyHC is re-activated in cardiovascular diseases that 
usually cause pathophysiological cardiac growth and hypertrophy, leading to heart failure 
and death [49]. 
1.2 Muscle function and signal transduction 
1.2.1 Calcium and calmodulin 
 
 Skeletal muscle plasticity is the ability of muscles to adapt to variations in activity 
and work [50]. This process is linked to the Ca2+ handling system, which displays 
Ca2+ influx into the cells via depolarization and Ca2+ release to the SR [51]. The Ca2+ 
handling system controls all functions of muscle including contraction and relaxation. 
The major mechanism involved in the latter process is the troponin-tropomyosin system, 
which is restricted to skeletal and cardiac muscles and has been previously described in 
depth [51]. 
A variety of Ca2+ binding proteins such as Calmodulin (CaM), calpains, Calcineurin 
(Cn), sorcin and annexins might be important for muscle performance and plasticity, 
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although they are not directly involved in the process of muscle contraction and 
relaxation. The Ryanodine Receptor (RyR) causes release of Ca2+ from the SR (Figure 
1.7). Additionally, the high-affinity Ca2+-binding protein Parvalbumin (PV) facilitates 
Ca2+ translocation from the myofibril to the SR in fast muscle fibers [51]. The SR-
ATPase, in turn regulates Ca2+ uptake into the SR. Inside the SR, Ca2+ binds to the high-
capacity and low affinity Ca2+-binding protein calsequestrin. Elevated cytoplasmic Ca2+ 
may cause a variety of muscle diseases, leading to changes in muscle fiber transcription 
and transformation, necrosis and apoptosis [51]. The Ca2+ handling process and the 
effects of elevated cytoplasmic Ca2+  levels are explained in Chapter 2 of this thesis. 
 
Figure 1.7: A schematic presentation for the Ca2+ binding proteins involved in the Ca2+ 
cycle[51] 
 CaM is one of the major Ca2+ binding proteins that is involved in many signaling 
pathways. It is a small protein of 148 residues (17 kDa), containing four EF-hand motifs 
that bind Ca2+ [52]. The term EF-hand refers to the two COOH-terminal α-helical 
sequence stretches, which are oriented in a perpendicular position and present in a large 
number of Ca2+ binding proteins. Each motif binds one Ca2+ ion in the central loop region 
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[53-55]. In the absence of Ca2+, CaM appears in a closed or semi-open conformation 
[52]. When the intracellular Ca2+ [Ca2+]i levels increase, Ca
2+ binds to the Ca2+ binding 
loops, causing conformational changes in the EF-hand motifs from the semi-open to the  
more ‘open’ shape (Figure 1.8), promoting the binding of other target proteins including 
kinases and phosphatases [51]. Furthermore, CaM might have a regulatory role in other 
muscle activities such as metabolism and activation of CaM-dependent Protein Kinases 
(CaMK) including glycogen synthase kinase and CaMK II, and phosphatases including 
Cn [56-58].  
 
Figure 1.8: The crystal structure of calmodulin (Song Tan, University Park, PA 2001) 
1.2.2 Calcineurin (Cn) 
 
 Cn is a Calcium/Calmodulin (Ca2+/CaM) dependent serine-threonine phosphatase 
that plays an important role in cell signaling and the immune system. The administration 
of immunosuppressive drugs such as Cyclosporine A (CsA) and FK506, decreases Cn 
activity [59, 60]. Cn exists as a heterodimer comprising the Calcineurin A (CnA) subunit 
with catalytic activity and the Calcineurin B (CnB), which is a calcium binding subunit 
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that helps regulate Cn activity (Figure 1.9A). CnA is made up of two domains; the 
catalytic domain, which is located at the N-terminal region and the regulatory domain, 
which is located at the C-terminal region. The regulatory domain has three binding sites; 
CnB, CaM and autoinhibitory binding domains [61]. At rest, the [Ca2+]i levels are low 
and thus the autoinhibitory domain covers the catalytic domain of CnA and renders Cn in 
an inactive conformation (Figure 1.9B). The opposite takes place during physical activity, 
where the [Ca2+]i levels increase and Ca
2+ binds to the CnB subunit, causing a 
conformational change that releases the inhibition caused by the autoinhibitory domain 
(Figure 1.9C). This in turn exposes the CaM binding domain where activated CaM binds 
to activate Cn phosphatase activity [62, 63]. 
 CnAα, CnAβ and CnAγ are three genes that encode for CnA. The first two are 
ubiquitously expressed, whereas CnAγ is expressed only in brain and testis [61, 64]. 
CnAβ exists in two splice variants, CnAβ1 and CnAβ2, whose proteins differ in their C-
terminal domains [61]. CnAβ1 lacks the typical autoinhibitory domain present in CnAβ2, 
which is replaced by an alternative C-terminal domain, generated by the translation of 
intronic sequences [64]. It is noteworthy that CnAβ1 displays a cardio-protective function 
via activation of the Akt (a protein kinase) and Serum and Glucocorticoid-regulated 




Figure 1.9: Calcineurin structure and its active and inactive conformations[52] 
(A) The heterodimeric structure of calcineurin consists of two subunits catalytic-regulatory 
(calcineurin A) and a Ca2+-binding (calcineurin B). Calcineurin A contains two domains, the N-
terminal catalytic and C-terminal regulatory, which consists of three domains: the calcineurin 
binding site, calmodulin binding site and an auotoinhibitory site. (B) In resting skeletal muscle 
cells where the intracellular Ca2+ level is low, calcineurin is in the inactive conformational state. 
Increased intracellular Ca2+ levels activate calmodulin which, in turn, binds to the heterodimer 
calcineurin, inducing its active conformational changes. (C) In its active stable conformational 
state, the auotoinhibitory domain has been displaced from the catalytic domain where the nuclear 




 Cn interacts with numerous transcription factors, scaffolding and cytoskeleton 
proteins. Thus, Cn regulates various functions in muscle, which potentially affect both 
skeletal and cardiac muscles [66]. For instance, the hypertrophy of skeletal muscle cells 
in culture is induced by activating Cn, while inhibition of Cn blocks the hypertrophy 
induced by Insulin Growth Factor-I (IGF-I) [67, 68], suggesting that Cn has a prominent 
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role in skeletal muscle hypertrophy either alone or with other signals that might be 
important for activation of Cn-dependent genes [69, 70]. Additionally, when CsA is 
administered to heat-stressed Wistar rats exercised at 41°C for 60 minutes, a smaller 
hypertrophic response is induced in their soleus muscles [71].  
1.2.3 NFAT proteins; structure and regulation 
 
 Cn regulates several signaling pathways through dephosphorylation of a majority 
of proteins such as the Nuclear Factor of Activated T cells (NFAT) [72]. NFAT proteins 
belong to the Rel-family of transcription factors and have a molecular weight that varies 




Figure 1.10: The primary structure of NFAT proteins [73] 
The NHR includes the calcineurin-docking site, the nuclear localization signal (NLS), the serine-
rich regions (SRRs) and the SPXX-repeat motifs (SPs). An inducible phosphorylation site has 
also been described in the N-terminal transactivation domain (TAD) of NFAT. The RHR contains 
the DNA-binding domain, points of contact with FOS and JUN, which allows the formation of 
the synergistic NFAT–FOS–JUN–DNA quaternary complex. The phosphoserines that are 
targeted by calcineurin dephosphorylation are located in the SP2, SP3 and SRR1 motifs.  
 
 
 NFAT transcription factors consist of five isoforms; The first four including 
NFATc1 (also called NFAT2, or NFATc), NFATc2 (also called NFAT1, or NFATp), 
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NFATc3 (also called NFAT4, or NFATx) and NFATc4 (also called NFAT3) reside in the 
cytoplasm in unstimulated cells but rapidly move to the nucleus in response to 
stimulation triggered by Ca2+ mobilization [74]. Therefore, these isoforms have well-
known roles in both skeletal and cardiac muscles [72, 75]. The fifth one is called NFAT5 
or Tonicity-response Enhancer-Binding Protein (TonEBP) and is insensitive to Cn 
signaling due to the absence of SPRIEIT sequence. The latter sequence allows Cn to bind 
to NFAT and dephosphorylate thirteen serine residues of the NFAT protein [76]. 
 Structurally, NFAT consists of three domains: a conserved N-Homology Region 
(NHR), a conserved Rel-Homology Region (RHR) and a non-conserved C-Terminal 
Domain (CTD). The first 407 amino acid residues form the N-homology region, which 
contains a Transactivation Domain (TAD) required for NFAT binding to the promoter 
region of genes and transcriptional initiation, a Cn docking domain that contains the 
SPRIEIT sequence, a Nuclear Localization Signal (NLS), Serine-Rich Regions (SRR) 
and repeating Ser-Pro-X-X motifs (SP) (X refers to any amino acid). Additionally, there 
is a Nuclear Export Signal (NES) but its exact location in the NFAT primary structure is 
still unknown [77, 78]. Residues 408 to 677 constitute the RHR domain, which is 
conserved among all Rel proteins [79]. Finally, residues from 678 to 928 form the CTD 
whose role is still unclear due to the discrepancy in the length of this domain among 
NFAT isoforms. Yet, many scientists suggest that it may be responsible for NFAT 
transcriptional activity [75, 80]. Having this critical structure, an important question 
could be raised, how does NFAT shuttle between the nucleus and the cytoplasm? 
 In resting cells, NFAT proteins are located in the cytoplasm. Upon activation, 
they become dephosphorylated by Cn and then transported to the nucleus [74, 81]. To 
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examine how phosphorylation controls localization and function of NFAT, the Okamura 
group in 2000 used a combination of mass spectrometry and systematic mutational 
analysis. They showed that thirteen out of fourteen conserved phosphoserine residues of 
NFAT  are dephosphorylated by Cn, in an event that contributes to NFAT transcriptional 
activity [82]. Upon dephosphorylation, the NES sequence of NFAT is hidden, whereas 
the NLS sequence becomes unmasked allowing NFAT to enter the nucleus. Inside the 
nucleus, a number of kinases phosphorylate the same serine residues of NFAT that are 
targeted by Cn, and thus regulate NFAT transcriptional activity. Those kinases include 
the Mitogen Activated Protein Kinase (MAPK) family that consists of p38, Janus-N-
Terminal Kinase (JNK) and Extracellular-Regulated Signal Kinases (ERK). Other 
kinases include Casein Kinase (CK) and Glycogen-Synthase Kinase3-β (GSK3-β) [83-
86]. Upon rephosphorylation, the NES sequence becomes re-exposed whereas the NLS 
sequence becomes masked, leading to the nuclear export of NFAT back to the cytoplasm 
[82]. Those regulatory kinases are classified into maintenance kinases that phosphorylate 
NFAT in the cytoplasm preventing its nuclear import, and export kinases that 
phosphorylate NFAT in the nucleus promoting its nuclear export. GSK3-β acts as an 
export kinase on the SPXX repeat motifs; SP2 and SP3 of NFATc1 and on SP2 of 
NFATc2 [73, 87], whereas CK functions as both a maintenance and an export kinase on 
SRR1 of NFATc2 [88]. Furthermore, JNK phosphorylates NFATc1, while p38 





1.2.4 Cn/NFAT signaling and Duchenne muscular dystrophy 
 
 Activation of Cn signaling is initiated in response to increased levels of [Ca2+]i, 
which binds to Cn and activates its phosphatase activity. It has been shown that Cn 
signaling can distinguish between different patterns in the amplitude of changes in [Ca2+]i 
[89, 90]. Cn signaling activity responds to sustained, low-amplitude release of [Ca2+]i, 
which is characteristic of nerves innervating slow muscles [89]. However, phasic nerve 
activity, which is characteristic of nerves innervating fast fibers leads to high-amplitude 
of [Ca2+]i that is insufficient to activate the Cn pathway [89].  
 Activation of Cn leads to dephosphorylation and nuclear localization of 
dephosphorylated NFAT, which in turn binds to the promoter regions of many genes and 
potentiates their expressions [91-93]. Some of these genes, such as utrophin, are 
implicated in skeletal muscle diseases, whereas others are linked to cardiac hypertrophy. 
The autosomal gene utrophin is one of the most critical downstream targets of NFAT. 
The therapeutic value of this gene arises from the high degree of sequence identity that it 
shares with the dystrophin gene [94]. 
 The dystrophin gene encodes for the muscle sarcolemmal protein dystrophin, 
which is 427 kDa and an integral part of the Dystrophin-Associated Protein Complex 
(DAPC) family [95]. Three tissue-specific promoters of dystrophin include brain (B), 
muscle (M), and purkinje (P) [96]. The M promoter drives high levels of dystrophin 
expression in skeletal muscles and cardiomyocytes [96, 97]. Dystrophin is linked to the 
sarcolemma of normal muscle by DAPC, which is composed of at least 10 different 
proteins (Figure 1.11). Together with other members of DAPC, dystrophin links the 
20 
 
extracellular matrix with the actin network [98]. Structurally, dystrophin contains four 
separate regions (Figure 1.12); an actin binding domain at the NH2 terminus, a central rod 
domain composed of 24 repeating units giving the molecule a flexible rod-like structure, 
a WW domain that mediates the interaction between β-dystroglycan (a member of 
DAPC) and dystrophin, a cysteine-rich domain and a COOH-terminal domain [94].  
 
Figure 1.11: Dystrophin associated protein complex. Modified from [94] 
Dystrophin binds to cytoskeletal actin at its NH2 terminus. At its COOH terminus, dystrophin is 
associated with a number of integral and peripheral membrane proteins. β-dystroglycan binds to 
dystrophin and completes the link between the actin-based cytoskeleton and the extracellular 
matrix.  
  
 Duchenne Muscular Dystrophy (DMD) is a neuromuscular disease caused by loss 
of dystrophin [95]. Becker Muscular Dystrophy (BMD) is a much milder form of the 
disease, where patients have much longer survival than DMD [94]. Both disorders are 
characterized by muscle wasting and early death, and caused by mutations in the gene 
encoding dystrophin leading to truncated, non-functional protein [94]. Many mutations 
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have been identified in DMD and BMD affecting almost all domains of dystrophin [94]. 
DMD mutations lead to the absence or much reduced levels of dystrophin protein, due to 
premature termination of translation associated with protein instability. BMD mutations 
lead to some partially functional but smaller dystrophin protein, due to the expression of 
truncated transcripts without affecting the reading frame [94]. Early results show that the 
cysteine-rich domain is not deleted in BMD, and mutations in this domain and the 
COOH-terminal domain cause severe clinical phenotypes, suggesting that these domains 
are critical for dystrophin function [94].  
Studies have shown that the regulation of [Ca2+]i is disrupted in dystrophic muscle 
fibers due to abnormal fluxes of Ca2+ from the SR  [94, 99], leading to extensive cycles 
of degeneration and regeneration accompanied by invasion of free radicals and related 
oxidative stress [99, 100]. The loss of functional dystrophin, mechanical disruption of the 
sarcolemma and activation of the Ca2+-dependent protein calpain lead to Ca2+ leakage 
and the triggering of a pathophysiological Ca2+ concentration in the cytosol [101, 102]. 
 Currently, there is a limited efficacy for the pharmacological interventions to treat 
patients with DMD [94]. Glucocorticoids have been used to minimize the inflammatory 
responses, as well as to enhance the respiratory function of patients [103]. Yet, the side 
effects of steroids might negatively affect the progression of the disease. Furthermore, 
non-steroidal anti-inflammatory drugs have been shown recently to ameliorate muscle 
morphology and reduce macrophage infiltration, without affecting the levels of the 
dystrophin-homologue protein utrophin [104]. Several studies have shown that 
upregulating utrophin protein levels at the muscle sarcolemma can compensate for the 
loss of dystrophin in dystrophin-deficient animal models [105, 106]. In addition, exon 
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skipping in combination with other measures very often has been considered for 
correcting the gene defect in DMD and expressing the missing dystrophin protein [107-
109]. Additionally, Deflazacort has been considered the "gold standard" drug therapy in 
DMD [110, 111], as it reduces muscle fiber necrosis caused by membrane damage [112, 
113]. In addition to its anti-inflammatory effect, Deflazacort upregulates Cn/NFAT 
pathway activity, which increases utrophin expression [114, 115]. Therefore, utrophin has 
been considered a strong candidate among therapeutic strategies for treating DMD [105].  
 The utrophin gene is located on chromosome 6 in humans and on chromosome 10 
in mice, and encodes a protein with a predicted molecular mass of 395 kDa [116, 117]. 
The predicted structure of utrophin shares similarity with dystrophin, and both proteins 
have conserved binding domains (Figure 1.12). Utrophin is highly expressed in most 
organs including smooth, skeletal and cardiac muscles in addition to vascular endothelia 
and platelets [118-120]. In healthy adult muscle fibers, utrophin is confined to the 
Neuromuscular Junctions (NMJ) [119], but in developing muscle, it is located at the 
sarcolemma [121, 122]. Unlike utrophin, dystrophin accumulates in the cytoplasm 
(Figure 1.13) [123, 124]. Acetylcholine receptors (AchR) clusters colocalize with 
utrophin at the NMJ in developing muscle and in cultured muscle cells [125-127]. In 
myasthenia gravis, an autoimmune neuromuscular disorder caused by circulating 
antibodies that block AchRs at the NMJ, utrophin is also lost from the NMJ [128, 129]. 
In DMD, utrophin can relocalize to the sarcolemma and compensate for the lack of 




Figure 1.12: Dystrophin and utrophin protein structures. Modified from [94] 
 
 An 800 bp fragment of the utrophin promoter is essential for its expression in 
muscle. The promoter contains: 1) an E-box motif, which is a characteristic motif for 
muscle specific proteins and binds myogenic transcription factors [131, 132] and 2) an N-
box motif essential for directing synapse-specific gene expression [133]. There are two 
different isoforms of utrophin; utrophin-A and utrophin-B. Utrophin-A is expressed in 
mature skeletal muscle fibers and utrophin-B is expressed in the endothelial cells [105, 
134]. Both isoforms contain different 5’ exons and are transcribed from different 
promoters. In skeletal muscles, the A and B transcripts are relatively equal [134]. Since 
utrophin-B promoter does not contain an N-box motif, it might not induce the synapse-
specific expression of utrophin-B transcripts and this explains the presence of utrophin 




Figure 1.13: Schematic diagram showing dystrophin in the cytoplasm and utrophin at the 
NMJ [136] 
 
The mdx mouse model has been developed to study and represent DMD, as it 
lacks the full-length dystrophin protein due to a point mutation in exon 23 of the 
dystrophin gene, leading to a premature stop codon [99]. The lack of functional 
dystrophin protein in mdx mice leads to reduced stability of the sarcolemma and necrosis 
of muscle fibers during a crisis period at 3-4 weeks of age [137, 138]. After this period, 
extensive degeneration and regeneration of muscle fiber continues, leading to increased 
proportions of myofibers with centrally located nuclei (a marker for muscle necrosis and 
regeneration), large variations in myofiber size, elevated levels of muscle enzymes and 
defective regulation of energy metabolism [137, 139, 140], until mice eventually die due 
to muscle wasting and respiratory failure [141]. It is clear that DMD and mdx mice share 
common features of the disease including the onset, progression, complexity and severity 
[94]. Therefore, the mdx mouse has been considered a key resource in the identification 
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of dystrophic pathophysiology and potential therapies [94]. However, Cn serum levels 
are shown to be lower in DMD patients than mdx mice [142] possibly due to insufficient 
utrophin and impairment of muscle regeneration. To study the importance of utrophin, 
other knockout (-/-) mice have been generated. Utrophin-/- mice do not show any 
obvious functional abnormalities, but do exhibit reduced numbers of AchRs [143]. Mice 
deficient for both dystrophin and utrophin show more severe progressive muscular 
dystrophy than mdx mice, resulting in premature death [144, 145]. Thus, the double 
mutant mouse may provide a useful model for studying human DMD disease and 
potential therapies using utrophin [146, 147]. 
Targeting Cn/NFAT signaling is essential to prevent the progression of DMD, 
knowing that transgenic mice overexpressing Cn (CnA*), where the C-terminal 
autoinhibitory domain is cleaved, display shifting towards slower MyHC fiber-type, 
upregulation of utrophin around the sarcolemma and improvement of sarcolemmal 
integrity [105, 106]. Inhibition of the latter pathway using CsA, leads to skeletal muscle 
degeneration and impairment of the muscle regeneration process [148]. Interestingly, this 
mechanism is supported by the finding that Deflazacort attenuates the progression of 
DMD via activating Cn/NFAT signaling, which mediates gene expression [115]. 
However, caution should be taken as the increase in Cn levels also might cause severe 
side effects such as cardiac hypertrophy [149]. Accordingly, DMD patients are 
susceptible to heart failure when activated Cn is used to alleviate the dystrophic 
symptoms. The process of upregulating utrophin at the muscle sarcolemma of slow 
muscle fibers in mdx mice via the Cn/NFAT pathway is thoroughly explained in Chapter 
2 of this thesis. 
26 
 
In addition to utrophin, overexpressing the Heat Shock Protein 70 (HSP70) in 
mdx and mdx/utrophin-/- mouse models has been shown to play a role in the rescue of the 
dystrophic phenotype [150]. The mechanism by which HSP70 improves the dystrophic 
symptoms is still unclear. However, HSP70 binds to and enhances the function of the 
Sarcoplasmic Reticulum-Ca2+-ATPases (SERCA) in the removal of [Ca2+]i from the 
cytoplasm by an unknown mechanism [151]. Further, overexpression of HSP70 in rat 
soleus muscles protect skeletal muscle from atrophy [152]. These effects might explain 
the importance of targeting HSP70 for the treatment of muscle dystrophy. 
1.2.5 Cn/NFAT signaling and cardiac hypertrophy 
 
 The role of Cn signaling in cardiac hypertrophy has been under debate for many 
years. Several studies have shed light on the ability of Cn to trigger reprogramming of 
gene expression and hypertrophic growth in the heart upon release of [Ca2+]i  [81, 149]. 
The immunosuppressant drugs CsA and FK506 are highly specific inhibitors of Cn and 
therefore, can block hypertrophic responses in neonatal cardiomyocytes which have been 
exposed to hypertrophic agonists. Thus, such drugs can be used in treatment of cardiac 
hypertrophy associated with heart diseases [153]. Moreover, the direct Cn modulators 
such as Modulatory Calcineurin-Interacting Protein (MCIP) (recently known as RCAN), 
also can block the hypertrophic response in cultured cardiomyocytes [154]. 
 The Cn/NFAT pathway is initiated upon [Ca2+]i release and activation of Cn. 
Subsequently, Cn dephosphorylates members of the NFAT family, specifically NFATc4, 
which translocates to the nucleus and binds to the promoter of the cardiac-restricted Zinc 
finger transcription factor GATA4 (Figure 1.14) [155]. The two conserved Zinc fingers 
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of GATA4, are required for binding to the consensus DNA sequences 5'-
(A/T)GATA(A/G)-3' [156-158]. GATA4 has been shown to regulate the expression of 
cardiac structural genes during development [159-161]. Many cardiac fetal genes are 
activated during physiological and/or pathological heart growth [156]. However, the 
major ones highlighted in Chapter 4 of this thesis are β-MyHC, Atrial Natriuretic Peptide 
(ANP) and Brain Natriuretic Peptide (BNP). Thus, binding of NFATc4 to GATA4 leads 
to the activation of those fetal cardiac genes, which are responsible for physiological 
cardiac growth during heart development. However, in adult hearts, the activation of 
these genes would be responsible for pathological cardiac growth [155]. It is noteworthy 
that in CnA* mice, other Cn-dependent signaling events are augmented. For instance, 
specific c-Jun N-terminal kinases are activated [162, 163]. Additionally, Calmodulin-
dependent protein Kinase (CaMK), a potent inducer of cardiac hypertrophy, is also 
activated where it targets the Histone Deacetylase (HDAC) protein complexes, leaving 
HDAC free (Figure 1.14) [164-166].  
 Furthermore, the relative Heart Weight to Body Weight (HW/BW) ratio of CnA* 
transgenic mice is three-fold higher than that of Wild-Type (WT) counterparts. These 
mice also display a two-fold increase in Cross Sectional Area (CSA) of cardiomyocytes 
and are more susceptible to death than WT mice. Such effects are blocked by treating 
CnA* mice with CsA [149]. GATA4 also is phosphorylated by GSK3-β, a negative 
regulator of cardiac hypertrophy. This phosphorylation leads to the export of GATA4 
from the nucleus and thus minimizes the consequences of cardiac hypertrophy [167, 168]. 
Other kinases that target GATA4 include ERK1/2 and P38 MAPK that phosphorylate 
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GATA4 at serine 105, leading to increased DNA binding affinity during heart failure 
[169, 170]. 
 
Figure 1.14: Ca2+ signaling pathways implicated in cardiac hypertrophy [153] 
1.2.6 IGF-1-Akt signaling and cardiac hypertrophy 
 
 Stimulation of cardiac hypertrophy is not restricted to Cn. Other signaling 
pathways have been shown to play a critical role in this process [171]. One major 
pathway is the IGF-1-Akt/PKB pathway. The importance of Akt, a Protein Kinase B, 
(PKB) in heart diseases is based on previous data showing that short-term activation of 
the IGF-1-Akt/PKB pathway induces compensatory cardiac hypertrophy. Moreover, Akt-
/- mice are not subject to physiological cardiac hypertrophy as are WT mice. On the 
contrary, mice overexpressing Akt demonstrate severe heart failure, suggesting an 
important role for Akt in cardiac hypertrophy [172, 173]. 
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 At the inner surface of the plasma membrane, IGF-1 binds to the receptor tyrosine 
kinase IGF-1 Receptor (IGF-R). This binding leads to the phosphorylation of Insulin 
Receptor Substrate (IRS) by the IGF-R. In turn, phosphorylated IRS activates 
Phosphatidyl-Inositol-3-Kinase (PI3K) to phosphorylate membrane phospholipids, giving 
rise to Phospho-Inositide-3,4,5-tri-Phoshate (PIP3) from Phospho-Inositide 4,5-bi-
Phosphate (PIP2). At this stage, the inactive Akt translocates from the cytoplasm to the 
inner surface of the plasma membrane. This leads to a conformational change of Akt 
followed by its phosphorylation by Phospho-Inositide-Dependent Kinase 1 (PDK1) at 
Threonine 308, which causes its activation. Akt in turn, represses the transcription factors 
of the Foxo family, and inhibits protein degradation and activation of the mammalian 
Target Of Rapamycin (mTOR) and GSK3-β proteins that stimulate protein synthesis 
(Figure 1.15) [174].  
 
Figure 1.15: The involvement of the IGF-1-Akt pathway in protein synthesis and 
degradation; (Modified from [65] and [175]) 
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The insulin-like growth factor 1 (IGF1)-Akt pathway controls muscle growth via mammalian 
target of rapamycin (mTOR) and Foxo. The internal feedback loops that control the IGF1-Akt 
pathway are indicated in red. The dotted line indicates that the effect of Akt on mTOR is indirect 
and mediated by other proteins. Protein synthesis is mediated by the activation of cardio-
protective signaling via CnAβ1 and ATF4 in the heart. 
 
 
 Foxo factors regulate the transcriptional regulation of a ubiquitin ligase called 
Muscle Atrophy F-box (MAFbx) (also called atrogin-1) and Murf-1, leading to protein 
degradation via the proteosome [175]. There are two isoforms of mTOR; mTORC1 and 
mTORC2 [176]. While mTORC2 is required for Akt phosphorylation and activation, 
mTORC1 phosphorylates S6  Kinase (S6K), which phosphorylates S6 and thus stimulates 
protein synthesis [177]. 
 To control the IGF-Akt pathway, two feedback loops exist; a negative one which 
inhibits IRS phosphorylation by S6K leading to degradation and altered localization, and 
a positive one where mTORC2 phosphorylates Akt at Serine 473 and Threonine 308, by 
which Akt is activated and protein synthesis is stimulated [178, 179]. Other factors 
involved in the Akt pathway include the β1 isoform of the CnA subunit (CnAβ1), which 
has an essential role in the activation of Akt and thus, is sufficient to produce a protective 
mechanism [64, 65]. It is possible that CnAβ1 enters the Akt pathway below PI3K 
(Figure 1.15) and then interacts with mTORC2 through its C-terminal domain, which is 
critical for the activation of Akt [65]. Further, the Activating Transcription Factor 4 
(ATF4) is considered a potential mediator of the cardio-protective effect produced by 
CnAβ1. ATF4 is also a downstream target of mTORC1, and has been shown to activate 
the amino acid biosynthesis program and induce the expression of a protective growth 
factor [65, 180, 181]. The role of both the Cn/NFAT and Akt pathways in cardiac 
hypertrophy are explained in Chapter 4 of this thesis. 
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1.3 Direct calcineurin modulators 
 
 It has been postulated that the direct Cn modulators are part of a feedback 
inhibition mechanism to control the regulation of the Cn/NFAT pathway and expression 
of myofiber genes [182, 183]. The importance of the Cn modulators originated from 
studying different kinds of cardiac myopathy and heart hypertrophy, where the majority 
of these proteins exhibit a cardio-protective effect [4, 184, 185]. Since utrophin 
expression in skeletal muscles is regulated by Cn [105], studying the direct regulators of 
Cn might be essential when seeking pharmacological interventions for DMD. Therefore, 
we are interested in studying these modulators in skeletal muscles to see if they have a 
protective role in certain diseases such as muscle dystrophy, especially when various 
manipulations in the Cn/NFAT pathway are conducted. Some of these modulators are Z-
line proteins, such as the Calcineurin-Interacting proteins (Calsarcins) and Muscle LIM 
Protein (MLP), while others have direct interactions with Cn and/or NFAT, such as 
Regulator of Calcineurin 1 (RCAN 1) and Calcineurin Inhibitor (CAIN). In both cases, 
these modulators are major regulators for Cn activity (Figure 1.16). 
1.3.1 Z-line proteins 
 
 The Z-lines are defined as the lateral boundaries of the basal contractile unit of the 
myocyte (Figure 1.2) [3]. The Z-disc consists of parallel layers of α-actinin, which is a 97 
kDa actin-binding cytoskeletal protein and a member of the dystrophin family, in which 
the central rod domain is used for interaction with actin and titin filaments from 
neighboring sarcomeres [186]. It has been shown that α-actinin is essential for stabilizing 
the muscle sarcolemma at the beginning of the contraction process [187]. Yet, other 
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proteins can partially substitute for the loss of α-actinin function during 
myofibrillogenesis (the assembly of myofibrils in skeletal muscles) [188]. Z-disc-
associated proteins play a major role in mechanotransduction, a process by which 
biomechanical stress is sensed by cardiac myocytes and translated to cardiac hypertrophy 
[189-191].  
 
Figure 1.16: Classes of calcineurin binding and regulatory proteins (modified from [192]) 
 
 Calsarcins, a family of Cn-interacting proteins, tether Cn to α-actinin at the Z- line 
of cardiac and skeletal muscle cells and inhibit Cn activity, which in turn affects utrophin 
regulation [184, 193]. Members of this family include calsarcin-1 and calsarcin-2, which 
are expressed in developing cardiac and skeletal muscles during embryogenesis. In 
addition, calsarcin-1 is expressed specifically in adult cardiac and slow twitch skeletal 
muscles, whereas calsarcin-2 is restricted to fast-twitch skeletal muscles [194]. Calsarcin-
3 is expressed specifically in skeletal muscle and is enriched in fast-twitch muscles [195]. 
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All members of this family bind to α-actinin, colocalize with Cn and interact with the 
following Z-line proteins: telethonin, γ filamin, ZASP/oracle and myotilin (reviewed in 
[190]). It has been reported that mice overexpressing calsarcin-1 are protected against 
Angiotensin II (Ang II)-induced cardiac hypertrophy, whereas calsarcin-1-/- mice suffer 
from sensitization to pathological stimuli through pressure overload, excessive Cn 
activity and exacerbated hypertrophy (reviewed in [4]). 
 MLP, also known as Cysteine Rich Protein3 (CSRP3), contains two LIM domains 
(tandem zinc fingers consisting of a cysteine-rich consensus) each followed by a glycine 
rich domain [196]. MLP is tethered to calsarcin-1 and colocalizes with Cn at the 
sarcomeric Z-disc, thereby affecting Cn activity [197]. It has been revealed that MLP is 
found in the sarcomeric Z-discs of different species [197-199], in the cytoplasm where it 
binds with titin [200] and in the nucleus [199]. MLP also binds to the following Z-line 
proteins: α-actinin, telethonin, Zyxin, N-Rap and β-spectrin [4]. Hypertrophy and dilated 
cardiac myopathy are reported in MLP-deficient animals, suggesting MLP negatively 
regulates skeletal and cardiac myofibers [196], whereas overexpression of MLP in 
differentiating myoblasts, promotes myogenic differentiation [200]. 
1.3.2 RCAN 
 
 RCAN belongs to a family of endogenous Cn regulators that are conserved from 
yeast to humans. This Cn regulator functions in a negative feedback loop to inhibit Cn 
activity via its N-terminus [201, 202]. Two different isoforms are identified; RCAN1.1 
and RCAN1.4 [203]. Both bind near or at the catalytic domain of CnA and inhibit its 
activity [204-206].Yet, the expression of the RCAN1.4 isoform is under the control of Cn 
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through the NFAT binding sites located in exon 4 of the RCAN gene [207]. GSK3 
phosphorylates the RCAN1 isoform, allowing it to bind and inhibit Cn activity [201]. 
MAPK can also phosphorylate RCAN1 at five sites giving rise to the phospho-RCAN, 
which is a good candidate for Cn. Nevertheless, this phosphorylation decreases RCAN 
affinity to Cn suggesting that the phosphorylated form reduces the inhibitory effect on Cn 
by RCAN [202]. Binding of RCAN to Cn specifically affects its phosphatase activity, but 
does not interfere with binding of either Ca2+/CaM complex or the regulatory subunit (B) 
to the catalytic subunit (A) of Cn [208]. It has been shown that overexpression of RCAN1 
in mice causes sustained cardiac function after myocardial infarction [185]. Additionally, 
those mice show in vitro and in vivo inhibition of Cn activity through direct association 
with the catalytic subunit [185]. On the contrary, RCAN1-/- mice show reduction in 
cardiac activity, impaired NFAT activation and diminished hypertrophic response to 
pressure overload similar to mice lacking CnAβ1 [185, 209].  
1.3.3 CAIN 
 
 CAIN, also known as Cabin1, is a soluble cytosolic novel Cn-binding 240 kDa 
protein with no significant similarity to any known protein [182]. CAIN is widely 
expressed in various tissues as well as in the brain in a similar manner to Cn, suggesting a 
physiological relationship between the two proteins [182]. Despite its high molecular 
weight, CAIN contains a putative Cn-binding domain through a very small portion of its 
COOH terminus, where binding to Cn leads to inhibition of its catalytic activity [182, 
210]. Moreover, CAIN functions as a scaffolding protein that is linked to other proteins 
like kinases and phosphatases in addition to Cn. Yet, it is not clear so far, whether 
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phosphorylation affects its activity or not [182]. It has been shown that mice 
overexpressing CAIN have repressed NFAT dephosphorylation [211], whereas cain-/- 
mice show no gross defects in Cn activity in vitro compared to their WT counterparts 
[212]. However, the cellular Cn activity of these knockout mice was not measured in vivo 
[213]. The roles of RCAN1, calsarcins and MLP in DMD disease are thoroughly 
discussed in Chapter 3 of this thesis. 
1.4 Thesis organization and hypotheses 
 
 Cn/NFAT is one of the most critical Ca2+ signaling pathways involved in muscle 
adaptation and disease. Further, other pathways might interfere with the regulation of this 
pathway. Thus, it is worth exploring the roles of these molecules, which will provide a 
better understanding of the regulation of Cn and its modulators in both skeletal muscle 
and heart diseases. In this manuscript-based thesis, we used transgenic and knockout 
models in addition to animal breeding to study the role of Ca2+ and Cn in DMD and 
cardiac hypertrophy. For each chapter, I have included background that should be read 
before the manuscript to help understand the basics of the content. Here is a summary for 
the chapters: 
Chapter 2: The role of the Cn/NFAT pathway and the expression of the Heat Shock 
Protein 70 (HSP70) are discussed in transgenic mice overexpressing the Ca2+ buffering 
protein PV in an mdx background. Due to the impairment of Ca2+ signaling and the 
subsequent downregulation of Cn activity, we hypothesize a dramatic exacerbation in the 
pathology of slow muscle fibers of mdx/PV with no changes in HSP70 expression. In this 
chapter, the role of HSP70 is further studied in mdx mice crossed with transgenic mice 
overexpressing either Cn (which upregulates utrophin expression) or Calmodulin-Binding 
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Protein (CaMBP), (which attenuates Cn activity and reduces utrophin expression). 
Herein, we hypothesize a constant HSP70 level with such changes in utrophin expression. 
Chapter 3: The roles of direct Cn modulators are investigated in different transgenic 
models in an mdx background. These regulators have a major feedback mechanism, 
which is essential for regulating Cn activity. Therefore, they may be of great importance 
in the treatment of DMD. In this context, we hypothesize that the expression of these 
proteins would be regulated with changes in Cn activity. Thus, the final objective would 
be to inhibit these inhibitors, for the sake of rendering Cn active through a reasonable 
mechanism that does not cause severe side effects such as cardiac hypertrophy.  
Chapter 4: The role of the NFATc2 transcription factor is studied in the hearts of adult 
NFATc2-/- mice, where we hypothesize that NFATc2 would be more essential in later 
stages of normotensive adult hearts than in young mice. Additionally, the importance of 
this transcription factor is thoroughly revealed in the hearts of NFATc2+/+ and NFATc2-
/- mice stimulated by AngII administration for 14 and 28 days. The objective behind this 
stress, is to inspect the role of NFATc2 and changes in different signaling molecules 









Chapter 2 : Distinct calcineurin-related transgenic 
approaches rescue or exacerbate the dystrophic phenotype 




Manal Al Zein1, Bernard J. Jasmin2 and Robin N. Michel1 
 
 
1Department of Exercise Science, Concordia University, Montreal, QC, Canada, 


















2.1 Background  
 
 
 In Chapter 2, we are interested in looking at the Calcineurin/Nuclear Factor of 
Activated T cells (Cn/NFAT) signaling in mdx mice, an animal model for Duchenne 
Muscular Dystrophy (DMD), particularly in the context of overexpression of the 
transgene Parvalbumin (PV) that attenuates Cn activity [214]. Herein, we shed light on 
the effect of this transgene on the downstream targets of Cn including NFAT and 
utrophin. Unlike previous animal models, the transgene in this study targets [Ca2+]i 
kinetics and causes a shift in Ca2+ oscillations from low to high amplitude spikes, a 
characteristic of fast fibers. These high amplitude spikes are insufficient to activate the 
Cn/NFAT pathway and thus affect utrophin expression and the progression of the disease 
[89, 214]. Additionally, we seek to investigate the role of the Heat Shock Protein 70 
(HSP70) that is linked to the Ryanodine Receptor (RyR) and Sarcoplasmic Reticulum-
Ca2+-ATPases (SERCA), which are considered critical parts of the Ca2+ cycle and play a 
major role in maintaining Ca2+ homeostasis [51]. 
 The results of this chapter are to be submitted for publication to The FASEB 
Journal, which is a premier journal for biomedical and cell biology research. Our work 
emphasizes the effectiveness of the strategies promoting the slower high oxidative 
myofiber program via Ca2+/Cn signaling in the treatment of muscle dystrophy. 
Additionally, they give new insights into the role of HSP70 in rescuing DMD. 




2.2 Abstract  
 
 We have shown the dystrophic phenotype to be rescued by driving the slower 
oxidative myogenic program via Calcineurin/Nuclear Factor of Activated T cells 
(Cn/NFAT) signaling together with an increase in utrophin-A expression (Chakkalakal et 
al., 2004). In this study, we set out to determine the impact of interfering with Ca2+/Cn-
based signaling in targeted dystrophin-deficient myofibers. We thus crossbred mdx mice 
with transgenic mice expressing the Ca2+-buffering protein Parvalbumin (PV), driven by 
the fiber-specific Troponin I slow promoter (TnIs). This approach forced expression of 
this non-native fast Ca2+-regulatory protein in slow fibers, thus lowering their Cn activity. 
Consistent with impairments in Cn, we observed significant reduction in utrophin-A 
expression together with a clear exacerbation of the dystrophic phenotype in mdx/PV 
slow fibers exemplified by several pathological indices. However, a recent study suggests 
an alternate strategy in the rescue of the dystrophic phenotype by overexpressing the Heat 
Shock Protein 70 (HSP70), without necessary changes in utrophin-A expression (Gehrig 
et al., 2012). Therefore, we examined HSP70 expression in mdx mice crossbred with 
mice expressing transgenes either stimulating or attenuating Cn activity. Immunoblotting 
results showed changes in utrophin-A despite constant levels of HSP70, indicating that 
the regulation of these two proteins is not correlated. Further, immunofluorescence 
showed colocalization of HSP70 with MyHC I in transgenic-modified mdx slow fibers 
displaying impaired Cn signaling with exacerbation of the dystrophic phenotype. These 
results not only underscore the therapeutic potential of targeting Ca2+/Cn-based signaling 
intermediates as effective countermeasures for muscle dystrophy, but also raise questions 





"Duchenne Muscular Dystrophy" (DMD), the most prevalent inherited 
neuromuscular disorder, is caused by the loss of the muscle sarcolemmal protein 
dystrophin [95]. Dystrophin is an integral part of the Dystrophin-Associated Protein 
Complex (DAPC) family, which is composed of at least 10 different proteins [94]. 
Together with other members of DAPC, dystrophin links the extracellular matrix with the 
actin network [98]. Many mutations have been identified in the dystrophin gene 
preventing the synthesis of the full length protein in DMD patients [94]. These mutations 
lead to instability of the sarcolemma due to the loss of the linkage provided by dystrophin 
[215, 216]. Currently, pharmacological interventions show limited efficacy in treating 
patients with DMD [193]. 
 It has been shown that the regulation of intracellular calcium concentration [Ca2+]i 
is disrupted in dystrophic muscle fibers [99]. In healthy muscles, excitation of muscle 
fiber via a motor nerve generates an action potential that spreads along the sarcolemma 
and the Transverse tubular system (T-tubules). Accordingly, the Dihydropyridine 
Receptor (DHPR), senses the membrane depolarization, causes conformational changes 
and activates the Ryanodine Receptor (RyR) leading to the release of Ca2+ from the 
Sarcoplasmic Reticulum (SR) [217]. In addition, the rapid re-uptake of Ca2+ ions is 
facilitated by the Sarcoplasmic Reticulum-Ca2+-ATPase (SERCA) enzymes and the Ca2+ 
binding protein calsequestrin [101]. The disruption in [Ca2+]i kinetics in DMD is caused 
by abnormal fluxes of Ca2+ from the SR (reviewed in [94]), leading to chronic 
inflammation and extensive cycles of degeneration and regeneration accompanied by 
invasion of free radicals and related oxidative stress [99, 100]. Such impairment of Ca2+ 
41 
 
handling in DMD occurs due to loss of functional dystrophin, mechanical disruption of 
the sarcolemma and activation of the Ca2+-dependent protein calpain, leading to Ca2+ 
leakage and the triggering of a pathophysiological Ca2+ concentration in the cytosol [101, 
102]. 
 Utrophin, a neuromuscular junctional protein that shares a high degree of 
sequence identity with dystrophin, has been considered a strong candidate among 
therapeutic strategies for treating DMD [105]. Several studies have shown that 
upregulating utrophin at the muscle sarcolemma, compensates for the loss of dystrophin 
in DMD and dystrophin-deficient animal models [218, 219]. Along with these findings, 
studies on the mdx mouse, an animal model of DMD, have shown that overexpression of 
utrophin in skeletal muscles results in improvement of the pathological symptoms of the 
disease [220-222]. The relevance of utrophin as a therapeutic target for DMD has been 
correlated to its location. Thus, utrophin normally accumulates at the neuromuscular 
junction sites of slow and fast muscle fibers but extrajunctionally along the sarcolemma 
in slow fibers [98]. In the mdx mouse, utrophin expression is upregulated within 
extrajunctional regions of slow but not fast fibers via stimulation of the 
Calcineurin/Nuclear Factor of Activated T cells (Cn/NFAT) pathway. This event explains 
utrophin compensation for the loss of dystrophin and the rescuing of the slow fibers but 
not their fast counterparts, leading to degeneration and eventual death [98]. 
 Of the two isoforms of utrophin, only utrophin-A is expressed in mature skeletal 
muscle fibers and is under the regulation of the Cn/NFAT pathway, whereas utrophin-B 
is expressed in endothelial cells [105, 133, 134]. To this end, we have previously shown 
that utrophin-A expression in slow muscle fibers is regulated by the Cn/NFAT signaling 
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pathway which promotes the slower, high oxidative myofiber gene program [105]. Ca2+ 
and Calmodulin (CaM), a calcium binding protein, are regulators for Cn and CaM Kinase 
(CaMK) activities [216]. These enzymes modulate the activity of various transcriptional 
regulators[89]. Once activated, the phosphatase activity of Cn leads to dephosphorylation 
of NFAT, followed by nuclear translocation and binding to target promoters to stimulate 
the expression of the slower myofiber genes including utrophin [66, 89]. Utrophin-A 
expression also is influenced by nerve-derived factors including agrin and heregulin, 
which promote a series of transcriptional reactions that stimulate the activity of the GA-
Binding Protein (GABP) α and β [223]. When activated, GABP binds to the N-box motif 
of the utrophin-A promoter and stimulates utrophin-A expression [223]. 
 To further establish the role of the Cn/NFAT pathway in regulating utrophin-A 
expression, we and others illustrated the concept that strategies aimed at promoting the 
slower high oxidative myofiber program in muscle play a role in the treatment of DMD 
[98, 224, 225]. In our laboratory, the latter strategy was established by crossbreeding mdx 
mice with transgenic mice expressing an activated form of Cn (CnA*), leading to an 
increase in utrophin-A expression [106]. Moreover, the transgene expression of a small 
peptide inhibitor called Calmodulin-Binding Protein (CaMBP) driven by the fiber-
specific Troponin-slow I promoter (TnIs) in mdx mice, leads to a reduction in the levels 
of utrophin-A and the transcript of slow Myosin Heavy Chain I (MyHC I), thus 
exacerbating the dystrophic phenotype [98]. This strategy establishes the impact of 
interfering with Ca2+/CaM-based signaling in dystrophin-deficient slow myofibers. 
 Another strategy in the rescue of the dystrophic phenotype involves 
overexpressing the Heat Shock Protein 70 (HSP70) in mdx and mdx/utrophin-/- mouse 
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models [150]. Early studies on human DMD tissues have shown elevated levels of 
HSP70 suggesting an autoprotective role for this protein [226]. Further, overexpression 
of HSP70 in rat soleus muscles inhibits skeletal muscle atrophy and therefore is 
cytoprotective [152]. From this perspective, we have shown earlier that constitutive 
expression of HSP70 is restricted to the slower, high oxidative fibers (MyHC I and IIa) in 
rat plantaris [227]. In addition, this heat shock protein binds to and protects the function 
of the SERCA enzymes [151]. The reason for this protection is not very well understood. 
However, it might be due to the ability of HSP70 to prevent protein aggregation [228]. 
Taken together, these findings might explain the potential role of HSP70 in the treatment 
of muscle dystrophy. 
 In this study, we introduce a new approach for targeting the Cn/NFAT pathway 
by forced transgenic expression of the Ca2+ buffering protein Parvalbumin (PV) in slow 
fibers of crossbred mdx mice. PV is an EF-hand protein normally expressed only in fast 
fibers [229], but the transgene is driven by the TnIs, linked to the Haemaglutinin (HA) 
epitope and forced expressed in slow fibers leading to a decrease in Cn activity and a 
turning off of the Cn/NFAT pathway [214]. Our strategy is based on different types of 
nerve activities controlling fast and slow gene expression programs [89]. Tonic motor 
nerve activity, which is characteristic of nerves innervating slow muscles leads to low-
amplitude sustained [Ca2+]i that activates the Cn/NFAT pathway [89]. However, phasic 
nerve activity, which is characteristic of nerves innervating fast fibers leads to high-
amplitude of [Ca2+]i that is insufficient to activate the Cn/NFAT pathway [89]. In 
agreement, PV overexpression in slow fibers, leads to expression of a fast fiber gene and 
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metabolic profile via shifting Ca2+ oscillations from low to high amplitude spikes and 
subsequent attenuation of Cn signaling [214]. 
 The objective of this study is first to investigate if PV overexpression in mdx slow 
muscle fibers would interfere with Cn/NFAT signaling via utrophin and exacerbate the 
dystrophic phenotype. Second, we sought to determine if attenuation of the latter pathway 
and the change in Ca2+ dynamics have influenced HSP70, RyR and SERCA isoform 
expressions. Indeed, PV overexpression led to a prominent exacerbation of the dystrophic 
phenotype in soleus muscles as exemplified by reduction in utrophin-A expression and 
higher hallmarks of mdx cellular damage. However, reduction of utrophin expression was 
not accompanied by differences in HSP70 protein levels between mdx and mdx crossed 
with PV (mdx/PV) mice. In addition, RyR1 (an isoform that is expressed mainly in 
skeletal muscles) was considerably increased in mice expressing the PV transgene, 
whereas SERCA 1 and 2 protein levels did not change between mdx and mdx/PV soleus 
muscles. Additionally, the role of HSP70 was examined in mdx mice crossed with 
transgenes expressing either CnA* (mdx/CnA*) that rescues the dystrophic phenotype, by 
upregulation of utrophin-A [106] or CaMBP (mdx/CaMBP) that exacerbates muscular 
dystrophy, by downregulation of utrophin-A [98]. Our results showed constant HSP70 
levels with either an increase in utrophin-A levels in Tibialis Anterior (TA) muscles of 
mdx/CnA* or a decrease in utrophin-A expression in soleus muscles of mdx/CaMBP 
mice. Finally, immunofluorescence experiments (IFs) showed colocalization of HSP70 
with MyHC I fibers in mdx and mdx/PV mice and with both MyHC I and IIa in 
mdx/CnA* mice but not with utrophin positive fibers. 
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 These results collectively emphasize that strategies promoting the slower high 
oxidative myofiber gene program via Ca2+/Cn signaling are considered effective 
countermeasures in the treatment of DMD, but independent of HSP70. Additionally, they 




 Animal care and experimental procedures were performed in accordance to the 
guidelines of the Canadian Council of Animal Care. Transgenic mice expressing either 
CnA*, CaMBP or PV proteins were generated as described previously [163, 214, 230]. 
Female mdx mice were crossed with CnA*, CaMBP or PV tagged with HA (PV-HA) 
transgenic mice resulting in pups having the dystrophic pathology. Male pups were 
selected for the experiments and the presence of the transgene in PV and mdx/PV mice 
was identified by PCR screening of genomic DNA extracted from tails using primers 
recognizing PV-TnIs (Sigma Genosys). Immunoblotting of soleus proteins using anti-PV 
antibody (Swant) was also performed to detect PV whereas, Extensor Digitorum Longus 
(EDL) tissues were used as a negative control. Wild-Type (WT), PV, CnA*, CaMBP, 
mdx, mdx/PV, mdx/CnA* and mdx/CaMBP of 10-12 week old male mice were utilized 
for all subsequent analyses. 
2.4.2 Mice genotyping 
 
 Mdx genotyping was performed by amplifying DNA from mouse tails as 
described earlier [231]. Briefly, 5 μl of DNA was added to 4 µl Taq buffer with KCl 
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(Fermentas), 2 mM MgCl2 (Fermentas), 0.2 mM dNTP (Invitrogen), 0.66 µM primers 
(Sigma Aldrich) and 1µl Taq DNA polymerase (Fermentas)  yielding a final volume of 
20 μl. The following primers were used; a common forward primer: 5’- 
GCGCGAAACTCATCAAATATGCGTGTTAGTGT-3’, a mutant reverse primer: 5’- 
CGGCCTGTCACTCAGATAGTTGAAGCCATTTTA-3 and a WT reverse primer: 5’- 
GATACGCTGCTTTAATGCCTTTAGTCACTCAGATAGTTGAAGCCATTTTG-3’. 
Cycling conditions were as follows: 1) initial denaturation at 95ºC for two minutes, 2) 
five cycles of first-stage amplification including: denaturation at 95ºC for 20 seconds, 
primer annealing at 60ºC for 20 seconds and extension at 72ºC for 20 seconds, 3) 23 
cycles of the second-stage amplification including: denaturation at 95ºC for 20 seconds, 
primer annealing at 64ºC for 20 seconds and extension at 72ºC for 20 seconds, 4) final 
extension at 72ºC for one minute. PCR products were loaded on a 3% agarose gel stained 
with ethidium bromide and resolved, after electrophoresis, under UV irradiation using the 
Alpha Innotec FluorChem system (Cell Biosciences). 
 Detection of CnA* and CaMBP transgenes was thoroughly described in earlier 
studies [98, 106]. Similarly, PV-HA in PV transgenic mice was identified by extracting 
DNA from mouse tails followed by the addition of 2 μl DNA to 1X Taq buffer with KCl 
(Fermentas), 2 mM MgCl2 (Fermentas), 0.2 mM dNTP (Invitrogen), 0.5 mM primers 
(Sigma Aldrich) and 0.5 µl Taq DNA polymerase (Fermentas) yielding a final volume of 
25 μl. The following forward and reverse primers were used: 5’-CCCACCAGCCC 
AGCTTTTCTA-3’and 5’-TTAGGCGTAGTCGGGCACGTCATATGGGTAGCTTT GG 
CCAC-3’ respectively. Cycling conditions were as follows: 1) initial denaturation at 95ºC 
for five minutes, 2) denaturation at 94ºC for 30 seconds, 3) primer annealing at 65 ºC for 
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one minute and extension at 72ºC for one minute, 4) repeat steps 2 and 3  for 24 cycles, 
5) final extension at 72ºC for ten minutes. PCR products were loaded on 1.5% agarose 
gel stained with ethidium bromide and visualized as described above. 
2.4.3 Muscle extraction and preservation 
 
 Mice were anesthetized by a mixture of 100 mg/ml ketamine hydrochloride 
(Bimeda-MTC Animal Health Inc.) and 20 mg/ml xylazine (Bayer HealthCare) in a 
volume ratio of 1.6:1. A dosage of 0.04 ml/30 g of body weight was administered 
intramuscularly to each mouse. Muscles were extracted and frozen directly in liquid 
nitrogen for biochemical use or embedded with Tissue-Tek Optimum Cutting 
Temperature compound (Fisher Scientific) and frozen in a pool of melting isopentane 
cooled in liquid nitrogen for histology. Samples were then stored at -86ºC until used.  
Animals were euthanized after extraction using CO2 gas.  
2.4.4 Immunofluorescence 
 
 Assessment of NFATc1 nuclear localization was done as described earlier [106]. 
In summary, soleus muscle cross sections (10 µm thick) were fixed with 4% 
Paraformaldehyde (PFA), blocked and permeabilized with 2% goat serum and 0.2% 
Triton X-100, then washed with 1X phosphate buffer saline (PBS) and incubated at 4oC 
overnight with primary antibodies recognizing NFATc1. This was followed by 
incubation with secondary antibodies coupled with fluorescent molecules for one hour, 
with subsequent washing and mounting with Vectashield containing 4',6-diamidino-2-
phenylindole (Dapi) (Vector laboratories). Quantification of NFATc1 nuclear localization 
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was performed by counting the number of myonuclei positively stained for NFATc1 in 
cross sectional views of myofibers and calculating the percentage of nuclear NFATc1. 
 Colocalization of utrophin with MyHC I and IIa was performed as described 
previously [193]. Co-staining was achieved by applying anti-utrophin antibody together 
with either anti-MyHC I or IIa antibodies at 4oC overnight. On the following day, 
secondary antibodies for utrophin detection with secondary antibodies for either MyHC I 
or IIa were applied for one hour. This was followed by washing, mounting with 
Vectashield with Dapi and detection using fluorescent microscopy. Additionally, the 
percentage of fibers with central nucleation in positively stained MyHC I fibers was 
calculated and compared in mdx and mdx/PV mice. Further, the colocalization of HSP70 
with MyHC I, MyHC IIa, MyHC IIb and utrophin was done as previously discussed 
[193]. Serial sections (10 µm thick) were fixed, blocked and incubated with primary and 
secondary antibodies as described above. The same areas were captured at 40X 
magnification to detect the presence or absence of co-staining using a Zeiss Axioplan 
fluorescence microscope mounted with a Lumenera Infinity 3-1C1.4 camera (Ottawa, 
ON, Canada). Negative control slides without primary antibodies revealed the absence of 
background staining at the acquisition time used. Colocalization analysis was performed 
using ImagePro Plus version 6.2 software (Olympus, Markham, ON, Canada). All 
primary and secondary antibodies and their proper conditions are listed in Table 2.1. 
Table 2.1: Antibodies and conditions for immunofluorescence 
PROTEIN   SUPPLIER  1°ANTIBODY 
   (overnight)  
            2°ANTIBODY 
                ( 1 hour) 
 
NFATc1  Santa Cruz# sc-13033  1:50 
 
1:100 Alexa Fluor® 488 Goat anti-




Utrophin   Santa Cruz# sc-15377 1:40 1:100 Alexa Fluor® 546 Goat anti-
rabbit IgG (Invitrogen# A-11010) 
 
MyHC I DSHB# A4.840 1:100 1:200 anti-mouse IgM FITC 
conjugate (Sigma Aldrich# F9259) 
 
MyHC IIa DSHB# SC-71 1:10 1:100  Alexa Fluor® 488 Goat anti-
mouse IgG (Invitrogen# A-11001) 
 
MyHC IIb  DSHB# BF-F3  1:25 1:100 anti-mouse IgM FITC 
conjugate (Sigma Aldrich# F9259) 
 
HSP70 Enzo Life Sciences# 
ADI-SPA-812) 
1:10 1:100 Alexa Fluor® 546 Goat anti-
rabbit IgG (Invitrogen# A-11010) 
 
2.4.5 Fiber typing 
 
 Immunohistochemistry of MyHC I and IIa in slow muscle fibers from mdx and 
mdx/PV mice was conducted using specific antibodies. Briefly, soleus cross sections 
were blocked for one hour, incubated with anti-MyHC I or IIa overnight at 4°C, washed 
and further incubated for two hours with secondary anti-mouse IgM (A8786, Sigma 
Aldrich) and anti-mouse IgG (A8924, Sigma Aldrich) to detect MyHC I and IIa, 
respectively. Slides then were washed for several times, incubated with 3,3'-
diaminobenzidine (DAB) (Thermoscientific) for five minutes and finally dried, mounted 
and visualized. The percentage of fibers stained for each of MyHC I and IIa was 
calculated in three 20X cross sectional views of myofibers from the mid-belly regions of 
soleus muscles, from four animals per group. Cross sectional areas also were measured 





2.4.6 RNA extraction and quantitative real time PCR (qPCR)  
 
 Skeletal muscles were homogenized in a solution of guanidinium thiocyanate 
(Sigma Aldrich), sodium citrate, N-laurylsarcosine (Sigma Aldrich) and 2-
mercaptoethanol (Bioshop), followed by addition of sodium acetate (pH 4.0) with 
vortexing, phenol (Sigma Aldrich) and chloroform:isoamyl alcohol until a white 
emulsion appeared. Samples were cooled on ice for fifteen minutes, and then centrifuged 
at 10,000 x g for ten minutes at 4ºC. Afterwards, two volumes of 99% ethanol were 
added to the aqueous layer with vortexing and centrifugation again at 10,000 x g for ten 
minutes at 4ºC. The ethanol was decanted and the RNA was suspended in 200 μl of 70% 
ethanol and centrifuged at 10,000 x g for ten minutes at 4ºC. The ethanol again was 
decanted and the RNA pellet was dried and suspended in 15 μl of RNAse free H2O 
(Bioshop) per 10 mg of tissue with subsequent vortexing and heating at 70ºC for 3 
minutes. The RNA concentration was measured and its integrity was validated using an 
Eppendorf Biophotometer (Eppendorf) at 260nm. About 2 μg of RNA was mixed with a 
2:1 formamide:ethidium bromide, formaldehyde (Sigma Aldrich), 10X MOPS (pH 7.0) 
and bromophenol blue, heated at 65ºC for ten minutes and loaded on a 1.5% agarose gel 
containing 1X MOPS and formaldehyde. All rRNA bands; 5S, 18S and 28S were 
visualized indicating RNA integrity. The changes in the abundance of utrophin, utrophin-
A, MyHC I and MyHC IIa were assessed using real time PCR. Briefly, 2 µg of freshly 
extracted RNA was reverse transcribed to cDNA using iScript reverse transcription 
supermix (Bio-Rad) and qPCR was performed using gene specific primers together with 
proper reference genes for quantification (CFX96 Real-Time System, Bio-Rad). Relative 
quantities then were normalized by the Real-time System software to the average relative 
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quantities of the 36B4, beta actin and gamma actin housekeeping genes. All primer 
sequences used for qPCR in this study are listed in Table 2.2. 
Table 2.2: Primers for quantitative real-time PCR 
Gene         Forward Primer  Reverse Primer                              Product 
                                                         Size(bp) 
Utrophin 5’- gtttgaggtgcttcctcagc -3’ 5’- gcgctatctggtagctgtcc -3’ 203 
Utrophin-A 5’- tggaccatttttcagattta -3’ 5’- atcgagcgtttatccatttg -3’ 207 
MyHC I 5’- ctcccaaggagagacgactg-3’ 5’-ttaagcaggtcggctgagtt-3’ 252 
MyHC IIa 5’- gaaccctcccaagtacgaca-3’ 5’- taagggttgacggtgacaca -3’ 147 
36B4 5’- gctccaagcagatgcagca -3’ 5’- ccggatgtgaggcagcag -3’ 143 
β- actin 5’- ccagccatgtacgtagccatccag -3’ 5’- cacgcacgatttccctctcagctgt -3’ 244 
γ- actin 5’- acccaggcattgctgacaggatgc-3’ 5’-ccatctagaagcatttgcggtggacg-3’ 216 
2.4.7 Protein extraction and Immunoblotting  
 
 Protein levels of PV, utrophin, HSP70, RyR1, SERCA1 and SERCA2 were 
measured by immunoblotting using extracts from soleus tissues of WT, PV, mdx or 
mdx/PV mice. Similarly, utrophin and HSP70 protein levels were detected in TA muscles 
of mdx and mdx/CnA* mice and in soleus muscles of mdx or mdx/CaMBP mice using 
commercially available primary and secondary antibodies coupled to horse radish 
peroxidase (HRP). Briefly, tissues were homogenized in 1X RIPA buffer solution (6 
µl/mg tissue) consisting of 1X PBS, 1% Igepal, 0.5% Sodium Deoxycholate, 0.1% 
Sodium Dodecyl Sulfate (SDS), 0.001 M Sodium Orthovanadate, 0.01 M Sodium 
Fluoride, 0.01 mg/ml Aprotinin, 0.01 mg/ml Leupeptin and 1 mM 
Phenylmethanesulfonyl fluoride (PMSF). Homogenates were centrifuged at 15,000 x g 
for twenty minutes and the supernatant layers were collected and re-centrifuged. 
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Protein concentrations were measured using Quick Start Bradford dye reagent 
(Bio-Rad), followed by loading 40 µg of soleus or TA and 5 µg of EDL proteins, with 
electrophoresis using SDS-PAGE (5% gel for utrophin and RyR1 and 12% for PV, 
HSP70, SERCA1 and SERCA2) at 120V and transfer at 30V for 90 minutes, using Borax 
(Bioshop), to a Polyvinyl difluoride (PVDF) membrane (Millipore). This was followed 
by blocking for one hour using either 5% non-fat milk in Tween/Tris Buffered Saline 
(T/TBS) or 1% Bovine Serum Albumin (BSA) in 0.1% T/TBS. Primary antibodies were 
incubated on a shaker at a moderate speed and at 4ºC overnight. Membranes then were 
washed and incubated with secondary antibodies (Sigma Aldrich and Cell Signaling) 
coupled to HRP on a shaker at room temperature and moderate speed for one hour, 
followed by washing and developing with enhanced chemi-luminescence reagents 
(Millipore) using the Alpha Innotec FluorChem system (Cell Biosciences). Bands were 
then quantified and their intensities were measured using the Alpha Innotec FluorChem 
software. Alpha tubulin was used as a loading control and groups were normalized to 
WT. All information about antibodies, suppliers and conditions are listed in Table 2.3. 
Table 2.3: Antibodies and their conditions for immunoblotting 
PROTEIN   SUPPLIER  PRODUCT 




     ( 1 hour) 
 
Utrophin  Novacastra  
#NCL-DRP2  
395 1:500 in T/TBS 
 
1:500 in T/TBS 
(anti-mouse)  
 





EDL in 5%milk  
1:2000 for soleus 
and 1:10000 for 
EDL in 5% milk 
(anti-rabbit) 
  
HSP70 Enzo Life Sciences 
#ADI-SPA-810  
70  1:2000 in 
5%milk 






RyR1  Abcam #ab2868  565  1:500 in 
5%milk  
1:5000 in 5%milk 
(anti-mouse)  
 
SERCA1  Pierce # MA3-912 110 1:1000 in 
5%milk  
1:5000 in 5%milk 
(anti-rabbit)  
 
SERCA2  Pierce #MA3-919 110  1:500 in 
5%milk  
1:5000 in 5%milk 
(anti-rabbit)  
 
α-tubulin  Cell Signaling 
#2125  
52  1:2000 in 
5%milk  
1:2000 in 5%milk 
(anti-rabbit)  
 
2.4.8 Assessment of central nucleation and muscle fiber size 
 
 Necrosis and regeneration of soleus muscles was assessed using Hematoxylin and 
Eosin (H&E) to examine the percentage of fibers with centrally located nuclei. 
Hematoxylin stains the nucleus purple, whereas eosin stains the cytoplasm pink. Simply, 
cross sections (10 µm thick) from soleus muscles were stained with H&E, dehydrated 
through a series of alcohol solutions, cleared with xylene and mounted using permount 
(Fisher Scientific). The sections were visualized using a standard light microscope, and 
images were captured and used to count the number of fibers with centrally located 
nuclei. The extent of regeneration occurring in soleus muscles was determined by 
counting the number of fibers having central nucleation relative to the total number of 
fibers and then comparing the average percentage of fibers with central nuclei between 
samples [106]. To assess size variability of fibers within dystrophic mice, a pathological 
feature of mdx mice [232], cross sectional area for each individual fiber was measured 
using ImagePro Plus Software. The average standard deviation from three 20X cross 
sectional views of myofibers from the mid-belly of muscles from four animals per group 
was calculated and the values were compared between mdx and mdx/PV mice. 
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2.4.9 Evans Blue uptake and staining 
 
 Evans Blue dye (EBD) injections were carried out as described elsewhere [233]. 
Briefly, 50 µl/10 g of body weight of EBD (Fisher Scientific) was injected 
intraperitoneally. Muscles were isolated 12 to 16 hours later, frozen in isopentane, then in 
liquid nitrogen and finally removed and stored at -86ºC. Prior to visualizing the tissues 
under the microscope, 10 µm sections were collected, fixed in 4% PFA for 20 minutes, 
washed five times for five minutes with PBS and mounted with Vectashield mounting 
medium. The intensity level of Evans blue dye was determined using ImagePro Plus 
Software by converting images to 8-bit gray scale and determining the total and average 
gray intensity in cytosolic regions of myofibers as a measure of Evans blue dye 
fluorescence. The average gray intensity was then compared between groups with three 
animals per group. Three 10X cross sectional views from soleus mid-belly regions were 
used to obtain average intensities. 
2.4.10 Statistical analyses 
 
 Statistical analyses were performed using the SPSS software program version 
17.0. (IBM SPSS, Chicago, IL, USA). Results were expressed as means ± SEM. 
Statistical differences between individual groups (P<0.05) were analyzed using One Way 
Analysis of Variance (Anova) to test for differences among four groups of different 
phenotypes. Student's t-test was applied when comparing only two groups with one 




2.5.1 Generation and identification of mdx/PV mice  
 
 To assess the role of [Ca2+]i kinetics in a dystrophin-deficient background, we 
generated mdx mice expressing the PV transgene specifically in slow muscle fibers. Our 
previous findings determined that PV-TnIs mice are healthy and capable of breeding 
[214]. PCR-based screening was used to identify animals expressing the PV transgene in 
addition to a spontaneous nonsense mutation in exon 23 of the dystrophin gene in mdx 
mice [234, 235] (Figure 2.1a). Immunoblotting analyses of soleus and EDL muscles from 
WT, PV, mdx and mdx/PV mice demonstrated the presence of endogenous PV in both 
soleus (Figure 2.1b) and EDL (Figure 2.1c) muscles of all mice and the expression of the 
PV-HA transgene solely in soleus muscles of PV and mdx/PV mice with no detectable 
levels in EDL muscles.  
2.5.2 Forced expression of PV transgene leads to impairment of 
downstream Ca2+/CaM-based signaling 
 
 To assess the consequences of impaired CaM signaling in slow muscle fibers 
from mdx/PV mice, we sought to determine the nuclear localization of NFATc1, which 
has been shown to be regulated by the Cn pathway [66, 236, 237]. IFs of soleus muscles 
demonstrated changes in NFATc1 nuclear localization (Figure 2.1d). Quantitative 
assessment revealed a significant decrease in the nuclear localization of NFATc1 in PV, 









Figure 2.1: Forced expression of PV in mdx slow fibers decreases Cn signaling via 
NFATc1 nuclear localization 
(a) Representative photomicrographs depicting DNA products of PV-HA and mdx genotyping, 
using a forward primer from the PV-cDNA and a reverse primer from the HA epitope tag, which 
was inserted at the 3' end of the cDNA to generate a 400 bp product representing the PV-HA 
cDNA. For mdx, the first five nucleotides of the common forward and the mutant reverse primers 
are not present in the dystrophin gene, whereas the first 23 nucleotides of the WT mutant primer 
were chosen arbitrarily to give a larger product (134 bp in WT vs 117 bp in mdx). (b-c) 
Representative immunoblots for PV-HA in soleus (b) and EDL (negative control) (c) muscles 
giving products of 12 kDa for the endogenous PV and 14 kDa for the PV-HA transgene. The 2 
kDa difference is due to the HA epitope tag. (d) Representative photomicrographs for NFATc1 
nuclear localization by IF. Arrows indicate nuclei positively stained for NFATc1. (e) 
Quantification reveals signficant reduction in PV, mdx and mdx/PV compared to WT (*) and in 
mdx/PV compared to mdx (#) (n=3; P<0.05). Scale bars, 20µm. Means ± SEM are shown. 
 
 We previously have assessed alterations in gene expression of fiber type-specific 
genes that may be downstream of a Ca2+-regulated transcriptional pathway. These 
changes are accompanied by the overexpression of PV [214]. We also have shown that 
changes in mRNA levels for these proteins are related to alterations in Cn activity [214]. 
Furthermore, Cn signaling has been shown to be involved in controlling the slow 
oxidative myofiber program, as well as the transcriptional activity of slower isoforms of 
MyHC genes [89, 91, 238-241]. Therefore, we tested the mRNA levels of both MyHC I 
and MyHC IIa. Accordingly, mdx and mdx/PV soleus muscles did not show significant 
differences in the transcript levels of both isoforms (Figures 2.2a and 2.2b). 
 Further, immunohistochemical analyses showed no fiber-type switching between 
MyHC I and MyHC IIa in soleus muscles of mdx/PV compared to mdx mice (Figures 
2.2c and 2.2d), suggesting that the changes in Cn downstream signaling accompanied by 




Figure 2.2: PV expression does not cause fiber type conversions in mdx soleus muscles 
QPCR histograms of mRNA levels of MyHC I (a) and MyHC IIa (b) in soleus muscles of mdx 
and mdx/PV mice. Relative quantities are normalized to 36B4, beta and gamma actin (n=4). AU 
represents Arbitrary Units. (c) Representative photomicrographs of cross sections from mdx, and 
mdx/PV soleus muscles processed to detect MyHC I and MyHC IIa. Fibers labeled with (*) and 
(#) express MyHC I and MyHC IIa respectively and the ones labeled ($) co-express both MyHC I 
and IIa in the different cross sections. Scale bars, 40µm (d) MyHC fiber type proportions in mdx 





2.5.3 Utrophin and utrophin-A expressions are reduced in mdx/PV 
soleus muscles 
 
 Repeatedly, we have correlated changes in utrophin expression with changes in 
Cn activity [98, 106]. In the present study, we hypothesized that the impairment of Cn 
activity driven by PV overexpression would have affected utrophin and utrophin-A 
expression in slow muscle fibers. Indeed, qPCR analyses showed reduction in the mRNA 
levels of both utrophin and utrophin-A in PV compared to WT soleus muscles and in 
mdx/PV compared to mdx soleus muscles (Figures 2.3a and 2.3b). In these experiments, 
EDL was used as a negative control to show first, that expression of the transgene did not 
affect utrophin and utrophin-A expression in EDL mdx/PV muscle fibers and secondly, to 
show the significant differences in the expression of the latter genes between soleus and 
EDL muscle fibers from WT mice, confirming previous semi- quantitative RT-PCR data 
[242]. 
 In agreement with the qPCR results, immunoblotting experiments showed a 
significant reduction of total utrophin protein levels in mdx/PV compared to mdx soleus 
muscles, while mdx muscles showed a significant increase compared to WT and PV 
soleus muscles (Figures 2.3c and 2.3d). 
 Utrophin expression in mdx mice is upregulated within extrajunctional regions of 
slow but not fast fibers, which plays a critical role in compensation for the loss of 
dystrophin. This compensation rescues slow but not fast fibers, which will eventually die 
[98]. Therefore, we next examined whether Cn pathway impairment compromised slow 
fibers due to reduced utrophin expression. IFs revealed reduced utrophin staining in both 
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MyHC I and IIa fibers of mdx/PV soleus muscles, suggesting that these fibers were not 
rescued from damage. However, there was positive utrophin staining in MyHC I fibers of 
mdx soleus muscles indicating that these fibers were rescued by utrophin and protected 
from damage (Figures 2.3e and 2.3f).  
Thus, expression of the PV transgene in slow dystrophin-deficient muscle fibers 
resulted in impaired activity of downstream targets for CaM-based signaling, including 









Figure 2.3: PV expression in WT and mdx soleus muscles leads to decreased utrophin 
expression 
QPCR of mRNA levels of utrophin (a) and utrophin-A (b) in soleus and EDL tissues of  WT, PV, 
mdx and mdx/PV mice. Relative quantities are normalized to 36B4, beta and gamma actin (n=4 
for soleus and n=3 for EDL). AU represents Arbitrary Units. (c-d) Representative immunoblot 
and quantification for total utrophin protein levels in the soleus muscle of WT, PV, mdx and 
mdx/PV mice. Relative quantities are normalized to α-tubulin (n=3; P<0.05). *compared to WT 
soleus; $compared to PV soleus, #compared to mdx soleus. Means ± SEM are shown. (e-f) IFs for 
utrophin co-staining with MyHC I (e) and MyHC IIa (f) in mdx and mdx/PV soleus muscles 
(n=3). Scale bars, 20µm. 
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2.5.4 Dystrophic slow fibers expressing PV exhibit more hallmarks of 
mdx cellular damage  
 
 Reduced utrophin expression in mdx mice has been correlated with augmented 
severity in dystrophic pathology [144, 146]. To determine whether impairment of Cn 
signaling and reduced utrophin expression have affected the pathological features in slow 
fibers of mdx/PV mice, we assessed several morphological indices in soleus muscles 
from mdx/PV mice. 
 H&E staining of muscle sections revealed an exacerbated appearance and 
extended infiltration in mdx/PV muscle fibers compared to mdx counterparts. The left 
column shows more central nucleation, whereas the right column shows more fibrosis and 
infiltrate in mdx/PV compared to mdx (Figure 2.4a). Quantification and measurement 
showed a ~ 20% increase in the percentage of fibers with central nucleation in mdx/PV 
compared to mdx soleus muscles (Figure 2.4b), indicating extensive cycles of 
regeneration and degeneration in those fibers. The latter suggests, once again, the role of 
the Cn pathway in the improvement and/or exacerbation of the dystrophic phenotype [98, 
106]. Additionally, healthy skeletal muscle exhibits relatively uniform size in individual 
muscle fibers [234]. Among the several pathological parameters, dystrophic muscle fibers 
display more variations in fiber size than normal muscles [234]. Quantitative evaluation 
of fiber size variability determined by the averaged standard deviation of the cross 
sectional areas of soleus muscles, revealed higher variability in mdx/PV compared to mdx 
(Figure 2.4b). This exacerbation is in agreement with our previous findings that 
impairment of the Cn pathway has a critical role in the pathological features of mdx 
muscle fibers [98, 106]. 
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 To test for membrane integrity that might have been affected by reduced utrophin 
expression, we injected mdx and mdx/PV mice with the small dye Evans Blue (EB) and 
monitored, using fluorescence microscopy, the uptake of the dye in myofibers (Figure 
2.4c). This dye is normally excluded from cytosolic regions of normal muscle fibers 
except if lesions take place in the sarcolemma [233]. Quantitative assessment of the 
average intensity of EB staining showed a significant increase in soleus muscles from 
mdx/PV compared to mdx mice (Figure 2.4d). These results add to the pathological 
features of mdx/PV soleus muscle fibers and suggest a correlation with reduced utrophin 
expression. 
Fast fibers are more susceptible than their slower counterparts to damage 
stimulated by forced lengthening contractions [243, 244], whereas slow muscle fibers in 
mdx mice are rescued by upregulation of utrophin [220]. Therefore, we hypothesized that 
slow muscle fibers of mdx/PV would be more sensitive than mdx slow muscle fibers. This 
was tested by measuring the percentage of slow fibers with central nucleation in soleus 
tissues stained with MyHC I in both mdx and mdx/PV mice (Figure 2.4e). Quantification 
revealed more central nucleation in MyHC I positive fibers of mdx/PV compared to mdx 





Figure 2.4: Dystrophic slow fibers expressing PV exhibit more hallmarks of mdx cellular 
damage 
(a) Representative photomicrographs of cross sections from mdx and mdx/PV muscles processed 
for hematoxylin and eosin staining. Scale bars, 50µm. (b) Quantitative evaluation of central 
nucleation and size variability. Values are normalized to mdx and then multiplied by 100 (n=4; 
*p<0.05). (c) Cross sectional views of Evans blue dye-positive regions of soleus muscles from 
mdx and mdx/PV mice intraperitoneally injected (images taken at 10X; scale bars, 100µm and 
40X; scale bars, 20µm). (d) Assesment of Evans blue dye staining in damaged regions of mdx 
and mdx/PV mice (n=3; *p<0.05). AU represents Arbitrary Units. (e-f) IFs for MyHC I showing 
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central nucleation in MyHC I +ve fibers of mdx and mdx/PV mice. Scale bars, 20µm. (n=4 for 
mdx and n=3 for mdx/PV; *P<0.05). Means ± SEM are shown. 
 
2.5.5 HSP70 expression does not change in soleus msucle of mdx/PV 
with reduction in utrophin level 
 
 Early studies done on human DMD tissues have shown elevated levels of HSP70,  
suggesting an autoprotective role for this protein [226]. Moreover, it has been recently 
demonstrated that pharmacological induction of HSP70 preserves muscle strength and 
contractile function in mdx mice. Yet, this amelioration is not accompanied by a 
significant increase in utrophin transcript levels in both diaphragm and TA muscles 
[150]. Therefore, we sought to investigate if HSP70 expression was changed in mdx/PV 
soleus muscles with reduced utrophin levels. Using immunoblotting analysis, HSP70 
protein levels did not change in soleus muscles between mdx and mdx/PV mice, 
suggesting that the expression of HSP70 and utrophin is not co-regulated (Figures 2.5a 
and 2.5b). In agreement, IFs on soleus muscles showed colocalization of HSP70 with 
MyHC I and utrophin positive fibers in mdx mice. HSP70 also was colocalized with 
MyHC I-positive fibers in mdx/PV soleus tissues. Nevertheless, both HSP70 and MyHC I 
positive fibers were not stained for utrophin. On the contrary, they showed more central 
nucleation when stained with Dapi (Figure 2.5c). 
2.5.6 RyR1 is significantly increased, while SERCA1 & 2 protein levels 
are not changed by PV expression in mdx soleus muscles 
 
 RyR is an intracellular Ca2+ release channel located at the SR membrane [245]. 
This receptor is activated when muscle fibers are excited via motor nerves that generate 
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an action potential, thus leading to the release of Ca2+ from the SR [217]. In addition, PV 
facilitates Ca2+ translocation from the myofibril to the SR in fast muscle fibers, whereas 
SR-Ca2+-ATPases (SERCA) enzymes regulate Ca2+ uptake into the SR [51]. 
Furthermore, the maximal activity of SERCA enzymes decreases with alterations in Ca2+ 
binding and ATP binding domains [151]. In addition, HSP70 binds SERCA and enhances 
its activity in cases of cellular stresses [151]. Thus, we next examined whether the 
expression of PV has affected RyR1 or SERCA1 or 2 expressions in mdx soleus muscles. 
 Being expressed predominantly in fast skeletal muscles, RyR1 transcript was 
significantly increased in PV soleus muscles compared to WT counterparts, suggesting a 
possible regulation of this protein with alterations in Ca2+ handling [214]. Our current 
findings, showed an increase in RyR1 protein level in PV compared to WT and in 
mdx/PV compared to mdx soleus muscles. However, SERCA1 (mostly expressed in fast 
fibers) and SERCA2 (mostly expressed in slow fibers) did not change between the 
corresponding groups (Figures 2.5d and 2.5e). Thus, higher levels of RyR1, without 
changes in SERCA isoforms suggest that the additional chelation of [Ca2+]i by PV led to 






Figure 2.5: Decreased utrophin expression in mdx/PV slow fibers appears independent of 
HSP70 and SERCA1 and 2 expressions but associated with higher fast RyR1 protein levels 
 (a-b) Representative immunoblots and quantification of HSP70 protein levels in mdx and 
mdx/PV soleus muscles (n=3). (c) IFs showing HSP70, MyHC I, MyHC IIa and utrophin 
expression in mdx and mdx/PV soleus muscles. Asterisks indicate fibers stained for both MyHC I 
and HSP70 (n=3). Scale bars, 20µm. (d-e) Representative immunoblots and quantification of 
RyR1, SERCA1 and SERCA2 protein levels in mdx and mdx/PV soleus muscles. Relative 
quantities are normalized to α-tubulin (n=4; P<0.05). *compared to WT; $compared to PV, 
#compared to mdx. Means ± SEM are shown.  
 
2.5.7 Transgenic models known to rescue [106, 193] or exacerbate [98] 
the dystrophic phenotype in mdx mice via utrophin regulation, display 
constant muscle HSP70 levels 
 
 We then wanted to investigate if HSP70 and utrophin proteins are regulated 
differently in other transgenic models. Thus, we studied HSP70 expression in mdx mice 
crossed with mice expressing an activated form of Cn (mdx/CnA*) where utrophin 
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expression is upregulated [106] and in mdx mice crossed with transgenic mice expressing 
CaMBP (mdx/CaMBP)  where utrophin expression is downregulated [98].  
 
Figure 2.6: Transgenic models known to rescue [106, 193] or exacerbate[98] the dystrophic 




(a,d) Representative immunoblots for utrophin and HSP70 proteins in the TA muscles of mdx and 
mdx/CnA* mice and in the soleus muscles of mdx and mdx/CaMBP mice. (b,e) Quantifications of 
utrophin protein levels. (c,f) Quantifications of HSP70 protein levels. Relative quantities are 
normalized to α-tubulin (n=3; P<0.05). *compared to mdx. Means ± SEM are shown.  
 
Immunoblotting analysis suggests that activation of Cn signaling in TA muscles 
of mdx/CnA* leads to increased utrophin but not HSP70 expressions supporting our 
previous results [98] (Figures 2.6a, 2.6b and 2.6c). Similarly, attenuation of Cn signaling 
in soleus muscles of mdx/CaMBP leads to reduced utrophin but not HSP70 expression 
[98] (Figures 2.6d, 2.6e and 2.6f). These results suggest, once again, that HSP70 is not 
regulated with changes in Cn signaling. 
To further support this observation, data from IFs in Lateral Gas (LG) tissues of 
both mdx and mdx/CnA* mice showed colocalization of HSP70 with MyHC I and MyHC 
IIa  but not with MyHC IIb muscles confirming our previous data [227]. Those MyHC 
IIb fibers were shown to be rescued by increased utrophin expression and reduced central 
nucleation accompanied by the expression of the CnA* transgene. Additionally, utrophin 
positive fibers were not necessarily stained for HSP70 in mdx/CnA*, suggesting that 
HSP70 is not affected with the regulation of the slow myofiber gene program 




Figure 2.7: HSP70 expression does not change in Lateral Gas muscles between mdx and 
mdx/CnA* mice   
IFs demonstrate  colocalization of HSP70 with MyHC I and MyHC IIa but not MyHC IIb fibers 
in mdx (a) and mdx/CnA* (b) Lateral Gas muscles. Asterisks indicate fibers positively stained for 












 Our lab previously has demonstrated the involvement of the Cn/NFAT signaling 
pathway in the regulation of utrophin-A expression in slow muscle fibers [98, 106]. 
Therefore, we and others illustrated the concept that strategies aimed at regulating the 
slower, high oxidative myofiber program in muscle could play a role in the treatment or 
exacerbation of DMD [98, 106, 224, 225]. In the current study, we attenuated Ca2+/CaM-
based signaling in dystrophin-deficient slow muscle fibers by crossbreeding mdx mice 
with transgenic mice expressing PV, which is normally expressed only in fast fibers 
[229]. This transgene is driven by the TnIs promoter and forced expressed in slow fibers, 
leading to attenuation of Cn activity [214]. Having done that, slow mdx fibers became 
more stressed and subject to deterioration. Unlike our previous approaches, the transgene 
in the present study causes alterations in [Ca2+]i kinetics in slow fibers which would 
interfere with Cn/NFAT signaling [214]. Indeed, expression of PV in mdx slow muscle 
fibers inhibited the latter pathway via reducing utrophin expression, decreased NFATc1 
nuclear localization and drastic increase in the hallmarks of mdx cellular damage. 
Attenuation of the Cn/NFAT pathway has a well-known effect on the downstream 
targets of Cn [98]. Herein, we observed reduced percentage of nuclear NFATc1 in PV 
compared to its WT soleus muscles and in mdx/PV compared to mdx soleus muscles 
possibly due to reduced Cn activity (Figure 2.1). Surprisingly, mdx soleus muscle showed 
also reduced NFATc1 nuclear localization compared to WT counterparts despite the 
increase in the [Ca2+]i levels in mdx mice. This increased [Ca
2+]i levels is due to that the 
total Ca2+ content in muscle biopsies from mdx mice is double that in muscle biopsies 
from WT mice, in addition to the increased [Ca2+]i influx through the cellular membrane 
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[246, 247]. Such an increase in [Ca2+]i should theoretically stimulate the Cn pathway and 
NFATc1 nuclear localization. However, altered [Ca2+]i levels also can affect other 
transcriptional factors such as the Mitogen Activated Protein Kinase (MAPK) family that 
consists of Janus-N-Terminal Kinase (JNK), leading to their activation [248]. The 
increased JNK activity observed in dystrophic muscles might result in increased 
interactions with NFATc1, causing its transport out of the nucleus [106, 114]. 
Furthermore, the reduced NFATc1 nuclear localization in mdx/PV soleus muscles could 
be explained in part via activation of the MAPK-JNK pathway and also via Ca2+ 
buffering caused by expression of the PV transgene. 
 Our previous findings did not show changes in fiber type conversion due to 
overexpression of PV [214]. Neither did our current study comparing mdx/PV to mdx 
mice. In 2003, it was suggested that PV would buffer additional Ca2+ in non-stressed 
fibers. It is also possible that the amplitude and duration of the Ca2+ transients are altered 
by PV through an unknown mechanism. Yet, there might be an alteration in contractile 
and biochemical characteristics in soleus muscles without any fiber type conversion 
[214]. We did not observe changes in MyHC I or IIa transcripts in mdx/PV compared to 
mdx soleus muscles (Figure 2.2). These results together with our previous ones, suggest a 
selective role for Ca2+-dependent transcriptional pathways in regulating muscle 
energetics but not all fiber type-related muscle characteristics [214]. It is also possible 
that complete transformation from slow to fast muscles, might require additional 
regulation of Ca2+ and perhaps other signaling pathways. 
 The involvement of Cn/NFAT signaling in regulating utrophin-A expression has 
previously been discussed [105, 249]. In addition to reduced NFATc1 nuclear 
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localization, the expression of PV in mdx slow muscles has caused reduction in utrophin 
and utrophin-A expression (Figure 2.3). The absence of a difference in utrophin 
expression between mdx and mdx/PV EDL muscle fibers, supports the fact that the 
transgene is solely expressed in slow muscle fibers. With respect to these findings, it is 
critical to mention that adult mdx fast muscles are more susceptible to the damage caused 
by forced lengthening contractions than are slow muscles [243]. Since this damage is 
rescued by upregulation of utrophin and due to that slow fibers are capable of expressing 
more utrophin, the latter fibers can overcome the pathological progression of the disease 
[105, 220, 242]. In the current study, IF co-staining of utrophin and MyHC I revealed 
positive utrophin staining in MyHC I fibers of mdx soleus muscle confirming the rescue 
provided by utrophin. However, and due to reduced utrophin staining in both MyHC I 
and IIa fibers of mdx/PV soleus muscles, this rescue was abolished in both slow and fast 
muscle fibers of dystrophic mice expressing the PV transgene (Figures 2.3e and 2.3f). 
Moreover, the increase in central nucleation and invasion of EBD staining in mdx/PV 
slow fibers compared to the rescued mdx counterparts support the fact that only fast fibers 
are sensitive to death in mdx mice and that the most exacerbated fibers were indeed those 
where the PV transgene was being expressed (Figure 2.4). Taken together, these results 
clearly show the detrimental effects of attenuating Cn activity in muscular dystrophy. 
 The pharmacological induction of HSP70, as well as its overexpression in 
mdx/utrophin-/- mice, have been shown recently to rescue the dystrophic phenotype 
[150]. Further, HSP70 can improve the function of SERCA enzymes in the removal of 
excess Ca2+ from the cytosol [150]. Nevertheless, our current results did not show 
significant changes in HSP70 and SERCA1 and 2 expressions between mdx and mdx/PV 
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slow fibers (Figure 2.5). In agreement, Gehrig et al., [150] also showed no differences in 
SERCA1 and 2 protein levels between 10 week old WT and mdx mice. In the same 
context, Chin et al., [214] showed no differences in the transcript level of SERCA2 
between WT and PV soleus muscles. Moreover, our IFs showed colocalization of HSP70 
with MyHC I positive fibers in both mdx and mdx/PV. Interestingly, utrophin negative 
fibers that were stained positive for HSP70 in mdx/PV soleus muscles, showed more 
central nucleation than utrophin and HSP70 positive fibers in mdx mice. These data 
indicate that utrophin but not HSP70 might have rescued those fibers. They further 
suggest that both HSP70 and SERCA proteins are not regulated via the Cn/NFAT 
pathway. 
 In addition to the PV model, other transgenic approaches in our study that 
manipulate the Cn/NFAT pathway showed that HSP70 expression was constant despite 
increased utrophin expression in mdx/CnA* mice and decreased utrophin levels in 
mdx/CaMBP mice (Figure 2.6). Accordingly, IFs revealed colocalization of HSP70 in 
MyHC I and IIa fibers and in utrophin positive fibers as well, but not in MyHC IIb fibers 
in mdx LG muscles. In mdx/CnA* mice, MyHC IIb fibers were rescued by increased 
expression of utrophin and decreased central nucleation compared to mdx. However, 
those rescued fibers were not positive for HSP70, suggesting once again, that HSP70 is 
not regulated via the Cn/NFAT pathway (Figure 2.7). In this context, HSP70 has been 
shown to prevent disuse muscle fiber atrophy via inhibition of Foxo3a, which in turn 
prevents the increase of atrogin-1 and Murf1 promoter activities [152]. In this case, 
rescuing muscular dystrophy by HSP70 might be correlated to the prevention of muscle 
atrophy via the Akt-growth pathway. HSP70 also inhibits Nuclear Factor-KB (NF-KB) 
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activity during muscle disuse but without affecting atrogin-1 and Murf1 promoter 
activities [152]. It also has been shown that the pharmacological blockade or genetic 
manipulations of the NF-KB pathway reduces inflammation and ameliorates muscular 
dystrophy [250, 251]. Therefore, another possibility for the regulation of HSP70 might be 
via the NF-KB pathway, which needs further investigation. 
 Simultaneously, RyR1, a marker of increased SR [Ca2+]i release, was significantly 
increased in PV compared to WT and in mdx/PV compared to mdx mice (Figure 2.5). 
Interestingly, Chin et al., [214] showed a significant increase in RyR1 transcript level in 
PV compared to WT soleus muscle. In our study, RyR1 expression did not change 
between WT and mdx soleus muscles. In agreement, no difference in RyR1 expression 
was shown between WT and mdx mice [252], suggesting that changes in Ca2+ 
homeostasis in mdx mice might not be due to changes in RyR1 expression but to other 
signaling molecules. In addition, the changes in RyR1, but not SERCA isoforms, suggest 
that the additional chelation of [Ca2+]i by PV led to a faster profile and produced a 
reciprocal effect to Cn in mdx slow fibers. The increase in RyR1 expression in PV and 
mdx/PV mice also suggests an activation of the Ca2+-sensitive RyR to uptake more Ca2+ 
from the SR to the cytoplasm.  
 Collectively, our data from the current study would be of great influence in 
studying the regulation of the Cn/NFAT pathway, promoting the slower, more oxidative 
myofiber gene program and eventually in the treatment of DMD. Further, this study 
increases the chances of understanding the physiological and pathological features of the 
disease. It also raises the possibility that HSP70 acts upon different mechanisms in the 
rescue of muscular dystrophy. 
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3.1 Background  
 
 In Chapter 3, we seek to understand the regulation of direct Calcineurin (Cn) 
modulators in different transgenic models in an mdx background. The transgenic models 
either stimulate or inhibit Cn activity and utrophin expression. The Cn modulators have a 
major feedback mechanism, which is essential for regulating Cn activity. Therefore, they 
may be of great value in the treatment of Duchenne Muscular Dystrophy (DMD) disease. 
Our preliminary results illustrate changes in the expression of these proteins suggesting a 
critical role in mdx mice, which will need further investigation. 
 The results of this chapter, once completed, could be submitted for publication to 
a scientific journal that publishes topics in chemistry, biology and/or genetics. Our work 
provides new insights into the regulation of Cn in mdx mice and unveils some facts about 
Cn modulators, which could be essential for future research. All these collectively, 











3.2 Abstract  
 
We have previously shown that dystrophic symptoms are ameliorated by 
stimulation of the Calcineurin/Nuclear Factor of Activated T cells (Cn/NFAT) pathway 
and an increase in utrophin-A expression. Further, we have shown exacerbation of the 
dystrophic phenotype upon impairment of Cn signaling and reduction in utrophin-A 
levels (Chakkalakal et al., 2004, 2006). Additionally, alterations in [Ca2+]i kinetics by 
forced expression of the fast protein Parvalbumin (PV) in slow fibers of crossbred mdx 
mice also exacerbates the dystrophic phenotype (Chapter 2). The direct Cn modulators 
were first identified in various types of cardiac diseases, where the majority provide 
cardio-protective effect. However, little is known about the role of these molecules in 
Duchenne Muscular Dystrophy (DMD). Therefore, we set out to determine the role of 
various Cn modulators in mdx mice, an animal model of DMD, particularly with respect 
to changes in the Cn/NFAT signaling pathway. Herein, we hypothesize that the 
expression of the Cn modulators is modified upon changing Cn activity and that the 
inhibition of these inhibitors, may be of therapeutic value since inhibiting the inhibitors 
will maintain effective Cn levels. Using qPCR and immunoblotting analyses, our results 
showed an upregulation in the mRNA level of RCAN1.4, whereas RCAN1, calsarcin-1 
and MLP protein levels did not change between mdx and mdx crossed with PV (mdx/PV) 
soleus muscles. On the contrary, the expression levels of RCAN1 did not change in mdx 
crossed with mice over expressing CnA (mdx/CnA*). However, calsarcin-2 protein level 
was significantly lower in mdx/CnA* compared to CnA* mice. These preliminary results 
confirm the dual regulation of RCAN and open discussions on the regulation and the 





 Duchenne Muscular Dystrophy (DMD) is a disease characterized by muscle 
wasting and early death and caused by the loss of the cytoskeletal protein dystrophin [94, 
95]. Although there has been limited success in the use of pharmacological drugs to treat 
DMD patients [193], stimulating the Cn pathway has shown positive effects in increasing 
the expression of the dystrophin-homologue protein utrophin-A [106, 224]. Utrophin-A 
relocalizes at the muscle sarcolemma in slow but not fast mdx muscle fibers, to 
compensate for the loss of dystrophin [98]. Such compensation rescues slow fibers, but 
leads to eventual death of their fast counterparts [98]. Therefore, targeting 
Calcineurin/Nuclear Factor of Activated T cells (Cn/NFAT) signaling may be a useful 
approach when considering an effective treatment for DMD [98, 106]. One of the 
possible concepts in targeting the Cn pathway involves regulation of a group of 
modulators, which directly regulate Cn activity. Being linked to cardiac hypertrophy, the 
direct Cn modulators have initially been identified to regulate diseases linked to Cn [4, 
184, 185]. They are well-characterized in heart diseases such as cardiac myopathy and 
heart hypertrophy [4, 184, 185]. In this context, overexpression of most of these 
regulators has been shown to provide cardio-protective effects [4, 185]. However, little is 
known about the role of these Cn regulators in the progression of neuromuscular diseases 
such as DMD. Such information may be useful in planning strategies for ameliorating the 
effects of the disease. 
 The Cn modulators are introduced as a replacement for the non specific 
pharmacological drugs that inhibit Cn but cause severe side effects [213]. Drugs such as 
Cyclosporin A (CsA) and FK506 inhibit the phosphatase activity of Cn in a unique 
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manner [253]. Cn dephosphorylates NFAT at its N-terminal regulatory domain [82]. 
There are multiple domains in NFAT, called "anchors", which are used for interaction 
with different sites on the phosphatase Cn. One important anchoring sequence lying in 
the N-terminal region of NFAT contains the consensus site "PXIXIT", in which X 
represents any amino acid. This sequence is sufficient for Cn-substrate docking [254]. 
While CsA binds to the cytosolic receptor protein cyclophilin, FK506 binds to FK506-
Binding Protein (FKBP) [255, 256]. Thus, the immunophilins cyclophilin and FKBP 
might either have a direct interaction with Cn or just serve in an allosteric manner to fix 
the drugs in a certain conformation that interact with Cn. Therefore, both drugs and 
immunophilins are necessary for significant inhibition of Cn [213]. However, these drugs 
are not specific for the immune system since they cause neurotoxicity and nephrotoxicity 
side effects [257]. Hence, the PXIXIT sequence required for any substrate to interact with 
Cn, has been utilized in the development of NFAT-specific inhibitors of Cn, which are 
direct Cn modulators or inhibitors. These modulators affect NFAT dephosphorylation 
solely without causing any side effects such as neurotoxicity or nephrotoxicity, as these 
novel inhibitors do not affect dephosphorylation of other substrates [213]. 
 The direct Cn inhibitors are classified into three major groups based on the way 
they affect Cn: inhibitors of Cn, dual regulators and Anchoring proteins. Inhibitors of Cn 
bind to and inhibit Cn activity, such as Calcineurin Inhibitor (CAIN/Cabin1). Dual 
regulators have both inhibitory and stimulatory effects, driven by a feedback mechanism 
such as Regulator of Calcineurin (RCAN) or called Modulatory Calcineurin-Interacting 
Protein (MCIP). Anchoring proteins tether Cn to other signaling proteins such as the Z-
line family of proteins "Calsarcins" (reviewed in [192]). 
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 CAIN/Cabin1 is a phospho-protein, discovered in a mouse T-cell cDNA library. It 
is highly expressed in the brain, and accumulates in the cytoplasm and the nucleus [182]. 
CAIN may serve in a negative regulatory loop. Thus, upon activation of Protein Kinase C 
(PKC), CAIN becomes hyperphosphorylated, which increases its affinity to Cn (reviewed 
in [192]). 
 The RCAN family is the only known family of Cn inhibitors that is conserved 
from yeast to humans. RCAN is known by its dual regulation of Cn, acting as an activator 
at low concentration and an inhibitor at high concentration [204, 258, 259]. Two splice 
variants of RCAN are identified: RCAN1.1 and RCAN1.4 [207]. Like CAIN, RCAN also 
serves as a feedback inhibitor of Cn. Upon activation of Cn signaling, the 
dephosphorylated NFAT binds to the putative NFAT binding site in RCAN1.4 promoter 
region and stimulates its expression. RCAN1.4 protein then binds and inactivates Cn 
[207, 258]. 
 Anchoring proteins include Muscle LIM Protein (MLP), calsarcin-1, which is 
expressed specifically in adult cardiac and slow-twitch skeletal muscles and calsarcin-2, 
which is expressed in fast-twitch skeletal muscles. These proteins also function as Cn 
modulators [194]. Calsarcins link Cn to α-actinin at the Z-line of cardiac and skeletal 
muscle, whereas MLP is tethered to calsarcin-1 and colocalizes with Cn at the Z-disc. 
Accordingly, both calsarcins and MLP inhibit Cn activity [184, 197]. 
 We set out to learn more about the Cn pathway by monitoring changes in the 
expression of Cn modulators in various mutant conditions. Thus, we decided to examine 
the expression of RCAN, calsarcins and MLP in different transgenic models in an mdx 
background. In a previous study, we showed that crossbreeding mdx mice with transgenic 
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mice expressing an activated form of Cn (CnA*) upregulates utrophin-A and improved 
the pathological symptoms of DMD [106]. In addition, crossbreeding mdx mice with 
transgenic mice expressing a small peptide inhibitor called Calmodulin-Binding Protein 
(CaMBP) leads to a reduction in the levels of utrophin-A and the transcript of slow 
myosin heavy chain I (MyHC I) [98]. Recently, we showed that alterations in [Ca2+]i 
kinetics by forced expression of the fast protein Parvalbumin (PV) in slow fibers of 
crossbred mdx mice, interfered with Cn/NFAT signaling via reduction in utrophin 
expression and exacerbation of the dystrophic phenotype (Chapter 2). Herein, we 
hypothesize that the expression of the Cn modulators would be modified in mdx mice 
expressing either the CnA* transgene (which stimulates Cn activity) or the PV transgene 
(which attenuates Cn activity). Understanding how these proteins are regulated may 
eventually help in maintaining Cn in an activated state. 
 Using quantitative real time PCR (qPCR) and immunoblotting analyses, our 
results showed an upregulation in the mRNA levels but no change in protein levels of 
RCAN1 in the soleus muscles of mdx/PV compared to mdx mice. Further, we showed 
calsarcin-1 mRNA levels to be increased in mdx/PV compared to Wild-Type (WT) mice, 
with no difference between mdx and mdx/PV mice at the transcript or protein level. In 
contrast, we saw no changes in the expression levels of RCAN1 in the Extensor 
Digitorum Longus (EDL) muscles of mdx/CnA* mice compared to mdx mice but a 
downregulation of calsarcin-2 mRNA level in EDL tissue of mdx/CnA* mice compared 
to those of CnA* mice. MLP protein level also showed a significant decrease in 
mdx/CnA* mice compared to WT mice. 
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 These preliminary results confirm the dual regulation of RCAN and raise 
questions about the role of these proteins in DMD. Further, understanding the different 
effectors that control various Cn regulators will possibly assist in controlling those 




 Animal care and experimental procedures were performed in accordance to the 
guidelines of the Canadian Council of Animal Care. Transgenic mice expressing either 
PV or CnA* proteins were generated [163, 214]. Female mdx mice were crossed with 
male PV or CnA* transgenic mice, resulting in pups having the dystrophic pathology. 
Male pups were selected for the experiments and the presence of the transgene in PV and 
mdx/PV mice was identified by PCR screening of genomic DNA extracted from tails 
using primers encoding PV-TnIs (Sigma Genosys). WT, PV, CnA*, mdx, mdx/PV and 
mdx/CnA* of 10-12 week old were utilized for all subsequent analyses. Details about 
mice genotyping techniques and the primers used are explained in Chapter 2 of this 
thesis. 
3.4.2 Muscle extraction and preservation 
 
 Mice were anesthetized by a mixture of 100 mg/ml ketamine hydrochloride 
(Bimeda-MTC Animal Health Inc.) and 20 mg/ml xylazine (Bayer HealthCare) in a 
volume ratio of 1.6:1. A dosage of 0.04 ml/30 g of body weight was administered 
intramuscularly to each mouse. Muscles were extracted and frozen directly in liquid 
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nitrogen for biochemical use. Samples were stored at -86ºC until used. Animals were 
euthanized after extraction using CO2 gas. 
3.4.3 RNA extraction and quantitative real time PCR (qPCR) 
 
 Soleus and EDL skeletal muscles were homogenized in a solution made up of 4 M 
guanidinium thiocyanate (Sigma Aldrich), 25 mM sodium citrate, 0.5% (v/v) N-
laurylsarcosine (Sigma Aldrich) and 0.1 M 2-mercaptoethanol (Bioshop), followed by 
addition of 0.2 M sodium acetate (pH 4.0) with vortexing, phenol (Sigma Aldrich) and 
chloroform:isoamyl alcohol with vortexing until the appearance of a white emulsion. 
Samples were cooled on ice for fifteen minutes, and then centrifuged at 10,000 x g for ten 
minutes at 4ºC. Afterwards, two volumes of 99% ethanol were added to the aqueous layer 
with vortexing and centrifugation again at 10,000 x g for ten minutes at 4ºC. The ethanol 
was decanted and the RNA was suspended in 200 μl of 70% ethanol and centrifuged at 
10,000 x g for ten minutes at 4ºC. The ethanol again was decanted and the RNA pellet 
was left to dry and re-suspended in 15 μl of RNAse free H2O (Bioshop) per 10 mg of 
tissue with subsequent vortexing and heating at 70ºC for 3 minutes. To test RNA 
integrity, the RNA concentration was determined using an Eppendorf Biophotometer 
(Eppendorf) at 260nm. Subsequently, 2 μg of RNA was mixed with a 2:1 
formamide:ethidium bromide, formaldehyde (Sigma Aldrich), 10X MOPS (pH 7.0) and 
bromophenol blue, heated at 65ºC for ten minutes and loaded on a 1.5% agarose gel 
containing 1X MOPS and formaldehyde. The three rRNA bands: 5S, 18S and 28S were 
visualized to indicate RNA integrity. 
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 The changes in abundance of RCAN1.4, calsarcin-1, calsarcin-2 and MLP were 
assessed using real time PCR. Briefly, 2 µg of freshly extracted RNA was reverse 
transcribed to cDNA using iScript reverse transcription supermix (Bio-Rad) and qPCR 
was performed, using gene specific primers together with appropriate reference genes for 
quantification (CFX96 Real-Time System, Bio-Rad). Relative quantities were then 
normalized by the Real-time System software to the average relative quantities of 36B4, 
beta actin, gamma actin and/or 28S rRNA housekeeping genes. All primer sequences are 
listed in Table 3.1. 
Table 3.1: Primers for quantitative real-time PCR 
Gene            Forward Primer  Reverse Primer                           Product 
                                                      Size(bp)           
RCAN1.4 5’-aaggaacctccagcttgggct-3’ 5’-ccctggtctcactttcgctg-3’          160 
Calsarcin-1 5’-gccaaaggggtgggtatct-3’ 5’-tgccctaagcagaccaacag-3’       156 
Calsarcin-2 5’-accgaggctccaagatgttc-3’ 5’-cagagccctgctgatgacg -3’       243 
MLP 5 '-gtcttcaccatgccaaac-3' 5'-agctttcctgcaggccatgc-3' 138 
28S 5’-ttgttgccatggtaatcctgctcagta-3’ 5’-tctgacttagaggcgttcagtcataatc-3’ 132 
36B4 5’-gctccaagcagatgcagca-3’ 5’-ccggatgtgaggcagcag-3’ 143 
β- actin 5’-ccagccatgtacgtagccatccag -3’ 5’-cacgcacgatttccctctcagctgt-3’ 244 
γ- actin 5’-acccaggcattgctgacaggatgc-3’ 5’-ccatctagaagcatttgcggtggacg-3’ 216 
 
3.4.4 Protein extraction and Immunoblotting  
 
 The expression levels of RCAN1, calsarcin-1, calsarcin-2 and MLP were 
measured by immunoblotting using extracts from soleus tissues of WT, PV, mdx and 
mdx/PV mice and EDL or Tibialis Anterior (TA) tissues of WT, CnA*, mdx and 
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mdx/CnA* mice. Relative protein levels were measured using commercially available 
primary antibodies and secondary antibodies coupled to horse radish peroxidase (HRP). 
Briefly, whole tissues were homogenized in 1X RIPA buffer solution (6 µl/mg tissue) 
consisting of 1X PBS, 1% Igepal, 0.5% Sodium Deoxycholate, 0.1% Sodium Dodecyl 
Sulfate (SDS), 0.001 M Sodium Orthovanadate, 0.01 M Sodium Fluoride, 0.01 mg/ml 
Aprotinin, 0.01 mg/ml Leupeptin and 1 mM Phenylmethanesulfonyl fluoride (PMSF). 
Homogenates were centrifuged at 15,000 x g for twenty minutes and the supernatant 
layers were collected and re-centrifuged. 
 Protein concentrations were measured using Quick Start Bradford dye reagent 
(Bio-Rad), followed by loading 40 µg of proteins with electrophoresis on 10% SDS-
PAGE at 120V and transfer at 30V for 90 minutes, using Borax (Bioshop), to a Polyvinyl 
difluoride (PVDF) membrane (Millipore) followed by blocking in 5% non-fat milk in 
0.1% Tween/Tris Buffered Saline (T/TBS) for one hour. Primary antibodies were 
incubated with the blot on a shaker at 4ºC overnight. The following primary antibodies 
and concentrations were used; RCAN1 (NBP1-46853, Novus Biologicals; 1:500), 
calsarcin-1 (rabbit polyclonal antibody; a gift from Drs. Norbert Frey and Derk Frank; 
1:2000), calsarcin-2 (13160-1-AP, Cedarlane; 1:1000) and MLP (10721-1-AP, 
Cedarlane; 1:1000). Membranes were washed with 0.1% T/TBS and incubated with 
secondary antibodies (Sigma Aldrich and Cell Signaling; 1:2000), coupled to HRP on a 
shaker at room temperature for one hour, followed by washing and developing with 
enhanced chemi-luminescence reagents (Millipore), using the Alpha Innotec FluorChem 
system (Cell Biosciences). Bands were then quantified and their intensities were 
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measured using the Alpha Innotec FluorChem software. Alpha tubulin (2125, Cell 
Signaling) was used as a loading control and groups were normalized to WT. 
3.4.5 Statistical analyses 
 
 Statistical analyses were performed using the SPSS software program version 
17.0. (IBM SPSS, Chicago, IL, USA). Results were expressed as means ± SEM. 
Statistical differences between individual groups (P<0.05) were analyzed using One Way 
Analysis of Variance (Anova) to test for differences among four groups of different 
phenotypes. Kruskal Wallis non-parametric test was used for the statistical analysis of the 
mRNA levels of RCAN in EDL samples of the PV models. Analyses for Chapter 3 are 
fully explained in Appendix II. 
3.5 Results 
3.5.1 RCAN1.4 and calsarcin-1 transcript levels are increased while MLP 
does not change in soleus muscle of mdx/PV  
 
The expression of the direct Cn modulators including RCAN1, calsarcins and 
MLP was assessed by generating mdx mice expressing a PV or an activated form of Cn 
(CnA*) transgene. PV is normally expressed only in fast fibers [229], but was driven by 
the fiber-specific TnIs promoter to express the transgene in slow fibers [214]. CnA* is a 
transgene driven by the fast muscle creatine kinase promoter [260].  
 Concurrent with the reduction in Cn activity and accompanied by the expression 
of PV [214], we showed previously a reduction in the expression of the NFAT down 
stream target, utrophin (Chapter 2). Being another NFAT target [207], RCAN was 
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hypothesized to be reduced with a reduction in Cn activity, but since RCAN1 also 
functions in a negative feedback loop to inhibit Cn activity [201, 202], we expected to see 
different results in its expression. Additionally, calsarcin-1 tethers Cn to α-actinin at the 
Z- line of cardiac and skeletal muscle cells, and inhibits Cn activity [184]. MLP as well, 
colocalizes with Cn at the sarcomeric Z-disc and probably affects Cn activity [197]. 
Besides Z-disc, MLP also is found in the cytoplasm and the nucleus [199, 200]. 
Moreover, multiple proteins might interact with MLP and influence its expression. Yet, it 
is still unclear if calsarcin and MLP work through a negative feedback loop as RCAN 
does. 
 To assess whether downregulation of the Cn signaling pathway, caused by 
overexpression of PV, affected Cn modulators expression, we sought to determine the 
transcript levels of RCAN1.4, calsarcin-1 and MLP in soleus muscles. Our qPCR results 
showed constant RCAN1.4 mRNA levels among WT, PV and mdx mice, but a significant 
increase in mdx/PV mice compared to the other three groups (Figure 3.1a), suggesting a 
possible feed back regulation of RCAN or interference with other transcription factors. 
Similarly, calsarcin-1 mRNA levels did not change within the soleus muscles of WT, PV 
and mdx mice but instead there was a significant increase in the mdx/PV mice compared 
to WT mice. A slight but insignificant increase in calsarcin-1 mRNA levels in the 
mdx/PV mice compared to the mdx mice also was seen (Figure 3.1b). In addition, MLP 
expression was constant in the groups tested (Figure 3.1c). In these experiments, the fast 
muscle, EDL, was used as a negative control since the PV transgene is solely expressed 
in slow muscle fibers [214], and thus should not affect the expression of the Cn 






Figure 3.1: RCAN1.4 and calsarcin-1 mRNA levels are increased in mdx/PV while MLP 
level does not change in soleus slow muscles 
(a) QPCR histograms showing mRNA levels of  RCAN1.4 in soleus muscles of WT, PV, mdx and 
mdx/PV mice. (b) QPCR histograms showing mRNA levels of calsarcin-1 in soleus muscles of 
WT, PV, mdx and mdx/PV mice. (c) QPCR histograms showing mRNA levels of MLP in soleus 
muscles of WT, PV, mdx and mdx/PV mice. Note that EDL is used as a negative control in these 
experiments. Relative quantities are normalized to 36B4, beta and gamma actin (n=4 for soleus 
and n=3 for EDL; P<0.05). AU represents Arbitrary Units. *compared to soleus WT, $compared 
to soleus PV, #compared to soleus mdx. Means ± SEM are shown. 
 
3.5.2 RCAN1, calsarcin-1 and MLP protein levels are not changed in the 
soleus muscle of mdx/PV 
 
 To examine the effect of the PV transgene on protein levels, we next asessed the 
levels of RCAN1, calsarcin-1 and MLP in soleus tissues of WT PV, mdx and mdx/PV 
mice. Unexpectedly, our immunoblotting experiments showed downregulation in 
RCAN1 protein levels in the soleus muscle of mdx/PV compared to mdx, with no changes 
in other phenotypes (Figures 3.2a and 3.2b). Although the latter effect is insignificant 
(P=0.15), it suggests that the mRNA and protein levels of RCAN1 are regulated 
independently. 
 Although there was a significant increase in calsarcin-1 mRNA levels in mdx/PV 
compared to WT, there was no change in calsarcin-1 protein levels among WT, PV, mdx 
and mdx/PV mice (Figures 3.2c and 3.2d), suggesting a possible post transcriptional 
modification of calsarcin-1. 
 In agreement with the calsarcin-1 expression results, MLP protein levels did not 
change among WT, PV, mdx and mdx/PV mice (Figures 3.2e and 3.2f). This might be 




Figure 3.2: RCAN1, calsarcin-1 and MLP protein levels are not changed in the soleus 
muscle of mdx/PV 
(a,c,e) Representative immunoblots for RCAN1, calsarcin-1 and MLP proteins in the soleus 
muscles of WT, PV, mdx and mdx/PV mice. (b,d,f) Quantifications of the immunoblots showing 
RCAN1, calsarcin-1 and MLP expression. Relative quantities are normalized to α-tubulin (n=3). 





3.5.3 RCAN1.4, calsarcin-2 and MLP transcript levels do not change in 
mdx and mdx/CnA* EDL fast muscles 
 
 Being linked to the fast muscle creatine kinase promoter, the transgene that 
overexpresses Cn is expressed in fast fibers causing stimulation of the slow myofiber 
gene program [260]. Accordingly, EDL fast muscle was used to test the trasncript levels 
of RCAN1.4, calsarcin-2 and MLP. Since Cn activity is stimulated with overexpression 
of CnA, we hypothesized an increase in RCAN1.4, calsarcin-2 and/or MLP mRNA levels 
in EDL tissues of CnA and mdx/CnA mice. 
 Our qPCR results showed constant RCAN1.4 and MLP mRNA levels between 
WT and CnA* EDL tissues. They both showed a tendency for a decrease in mdx and 
mdx/CnA* where Cn activity is high, but with no difference between mdx and mdx/CnA* 
mice (Figure 3.3a and Figure 3.3c). 
 In additon, calsarcin-2, which is expressed in fast-twitch skeletal muscles, 





Figure 3.3: RCAN1.4, calsarcin-2 and MLP mRNA levels do not show significant changes 
between mdx and mdx/CnA* mice 
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(a) QPCR histograms showing mRNA levels of RCAN1.4 in EDL muscles of WT, CnA*, mdx 
and mdx/CnA* mice. (b) QPCR histograms showing mRNA levels of calsarcin-2 in EDL 
muscles of WT, CnA*, mdx and mdx/CnA* mice. (c) QPCR histograms showing mRNA levels of 
MLP in EDL muscles of WT, CnA*, mdx and mdx/CnA* mice. AU represents Arbitrary Units. 
Relative quantities are normalized to 36B4 and 28S (n=3). Means ± SEM are shown. 
 
3.5.4 Calsarcin-2 and MLP protein levels are reduced while RCAN1 does 
not change in mdx/CnA* mice 
 
 To see the effect of the transgene on the translational level of the Cn modulators, 
we then examined the protein levels of RCAN1, calsarcin-2 and MLP in fast muscles of 
WT, CnA*, mdx and mdx/CnA* mice (EDL muscle was used for RCAN1 and calsarcin-2 
and TA muscle was used for MLP). 
 Our imunblotting results for RCAN1 expression showed similar levels in WT, 
CnA*, mdx and mdx/CnA* in agreement with the qPCR results (Figures 3.4a and 3.4b). 
In addition, the calsarcin-2 protein level was significantly reduced in mdx/CnA* mice 
compared to CnA* mice with a tendency for downregulation compared to mdx mice 
(P=0.1) (Figures 3.4c and 3.4d). Finally, MLP protein level was not changed between 
WT and CnA, or between mdx and mdx/CnA* muscle fibers. Yet, there was a significant 
decrease in MLP protein level in mdx/CnA* mice compared to WT and a tendency for 
downregulation in MLP protein level in mdx/CnA* mice compared to CnA* mice 
(P=0.06) (Figures 3.4e and 3.4f). These results were also unexpected, as we hypothesized 





Figure 3.4: RCAN1, calsarcin-2 and MLP protein levels in WT, CnA*, mdx and mdx/CnA* 
mice 
(a,c,e) Representative immunoblots for RCAN1, calsarcin-2 and MLP proteins in WT, CnA*, 
mdx and mdx/CnA* mice. (b,d,f) Quantification of the immunoblots showing RCAN1, calsarcin-
2 and MLP expression. Relative quantities are normalized to α-tubulin (n=3; P<0.05). *compared 









DMD, the most prevalent inherited neuromuscular disorder, is caused by the loss 
of the muscle sarcolemmal protein dystrophin, which is a 427 kDa cytoskeletal protein 
[95]. Utrophin, a neuromuscular junctional protein that shares a high degree of sequence 
identity with dystrophin, has been considered a strong candidate among therapeutic 
strategies for treating DMD [105]. Several studies have shown that upregulating 
utrophin-A at the muscle sarcolemma by stimulating the Cn/NFAT pathway, can 
compensate for the loss of dystrophin [105, 106]. Our lab previously has demonstrated 
the involvement of the Cn/NFAT signaling pathway in the regulation of utrophin-A 
expression in slow muscle fibers, and thus in the treatment of DMD [98, 106]. In 2003, 
our lab defined a new approach to knock down Ca2+/CaM-based signaling in slow muscle 
fibers by overexpressing the transgene PV [214]. 
 Recently, we crossbred mdx mice with transgenic mice expressing PV, which is 
normally expressed only in fast fibers [229]. This transgene is driven by the TnIs 
promoter, which leads to the force expression of PV in slow fibers leading to alterations 
in [Ca2+]i kinetics and attenuation of Cn activity [214]. Thus, we showed that 
overexpression of PV in mdx slow muscle fibers reduces utrophin expression and 
increases the hallmarks of mdx cellular damage accompanied with an increase in the 
severity of the dystrophic pathology (Chapter 2). To better understand utrophin 
regulation, we started looking at proteins, which might have a role in regulating Cn 
activity and thus utrophin expression. The direct Cn modulators have been identified in 
Cn related-diseases such as cardiac hypertrophy [4, 184, 185]. However, their role in 
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skeletal muscle diseases is still not clear. Consequently, we set out to determine the 
expression levels of the direct Cn modulators in DMD disease using different transgenic 
models crossed with mdx mice. 
 Our preliminary results showed a mixture of expected and unexpected findings, 
which might be correlated to different types of regulation of these proteins. These 
differences might be driven by changes in the Cn/NFAT pathway and the various 
phosphatases and kinases affecting it. For instance, RCAN1.4 mRNA levels were 
increased in the soleus muscle of mdx/PV mice compared to those of WT, PV and mdx 
mice (Figure 3.1). There was a tendency for downregulation in the RCAN1 protein level 
in mdx/PV mice compared to mdx mice (P=0.15) (Figure 3.2). In the fast EDL tissue, we 
did not find significant changes in RCAN1.4 mRNA and protein levels between mdx and 
mdx/CnA* mice (Figures 3.3 and 3.4). Therefore, there seems to be different regulation 
of RCAN1 expression upon changes in Cn activity driven by different transgenes. 
 RCAN is known to have a dual regulatory effect on Cn, thus acting as both an 
activator at low concentrations and an inhibitor at high concentrations [204, 258, 259]. 
The dual regulation of RCAN for Cn has been observed earlier by the Olson group while 
investigating the role of RCAN1 in cardiac hypertrophy. They have shown that deletion 
of the RCAN gene leads to a significant reduction in Cn activity, with similar levels of Cn 
expression in RCAN knockout (RCAN-/-) and WT mice [261]. Moreover, under 
conditions of high Cn activity, RCAN1 suppresses Cn signaling and exacerbates cardiac 
hypertrophy but not to the same extent as other transgenic models do [149, 261]. Not 
only in mice but also in other organisms such as yeast, the dual regulation exists, 
supporting our finding [258]. Furthermore, upon activation of Cn signaling, RCAN1.4 is 
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induced and then binds and inactivates Cn in a part of a feedback inhibition mechanism 
[207, 258]. This suggests that our results might be correlated to the time the expression of 
RCAN was measured. Thus measurement of RCAN could have been performed either 
during its induction or after being induced to go back and further inhibit Cn, as well as 
the expression of the downstream targets of NFAT including RCAN. In the future, it 
might be worth measuring RCAN expression in different time points; during 
development, in young and in adult mice. Additionally, the Olson group has shown no 
changes in Cn protein level in RCAN1-/- mice, but an increase in RCAN1 protein 
stability in the presence of Cn [261]. In our transgenic models in an mdx background, it 
would be interesting to look at RCAN1 protein stability bearing in mind the different 
kinases that might phosphorylate RCAN and affect its stability. One more thing that 
would be useful is to knockout the RCAN gene in mdx mice, with either impaired Cn 
activity such as mdx/PV or stimulated Cn activity such as mdx/CnA*. This will better 
underscore the role of RCAN in the Cn/NFAT pathway. 
 In this study, we observed an unexpected increase in calsarcin-1 mRNA levels 
with impairment of Cn activity in the soleus muscle of mdx/PV mice compared to WT 
but not to mdx mice (Figure 3.1). However, protein levels did not change in the same 
transgenic models (Figure 3.2). Moreover, the mRNA levels of calsarcin-2, the isoform 
that is expressed in fast-twitch muscles, was also unchanged between mdx and mdx/CnA* 
(Figure 3.3), whereas the protein level showed a significant reduction in mdx/CnA* 
compared to CnA* EDL tissues (Figure 3.4). So, what is controlling the expression of 
calsarcins and how do they exert their function on Cn? 
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 It has been shown that mice lacking the calsarcin-1 gene have normal hearts but 
increased NFAT activity [262]. Like the RCAN studies, mice lacking calsarcin-1 crossed 
with CnA* mice show an enhanced hypertrophic response [262]. Moreover, calsarcin-1 
is a known cardio-protective gene whose overexpression prevents Angiotensin II and 
Endothelin-1-induced hypertrophy in the heart [263]. However, does the same protection 
effect exist in skeletal muscles? If so, then the increase in calsarcin-1 transcript level that 
we saw in mdx/PV mice might be related to protection provided by calsarcin-1 in a failed 
attempt to rescue the dystrophic phenotype, as we did not see the same increase at the 
translational level. Additionally, calsarcin-1 is not restricted to the Z-disc, it also can 
shuttle to the nucleus [194]. Whether it interacts with NFAT in the nucleus is not yet 
established. Like RCAN1, calsarcin-1 could be phosphorylated, but the kinases 
responsible for this phosphorylation are still to be determined [264]. Further, Vondrisk's 
group has documented phosphorylation and post-translational processing of calsarcin-1 in 
the heart in a trial to establish growth-signaling mechanisms during heart diseases [265]. 
This regulation of calsarcin-1 is worth looking into in the future work. In regard to 
calsarcin-2, it has been shown, again by the Olson group, that calsarcin-2-/- mice exhibit 
improved running distances in exercise studies via the regulation of the Cn/NFAT 
pathway [184]. It is possible that calsarcin-2 was downregulated in our mdx/CnA* mice 
as a result of the improved performance carried out by stimulating the Cn/NFAT 
pathway. Yet, the latter needs further study. Thus, research on the role of calsarcins in the 
sarcomere function and their medical value particularly in DMD remains to be explored. 
 Finally yet importantly, we showed that there was no change in MLP expression 
in the soleus tissues of mdx/PV mice compared to mdx mice (Figures 3.1 and 3.2). 
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Nevertheless, we saw a down regulation in MLP protein levels in the TA tissues of 
mdx/CnA* compared to WT mice (Figure 3.4). As in RCAN1 and calsarcin-1, mice 
lacking MLP display hypertrophy and dilated cardiac myopathy, suggesting MLP 
negatively regulates skeletal and cardiac myofibers [196]. It was also shown that MLP-/- 
cardiomyocytes are not able to induce the Brain Natriuretic Peptide (BNP) when exposed 
to mechanical stimulation, where BNP together with the Atrial Natriuretic Peptide (ANP) 
decrease blood volume and thus lower systemic blood pressure [266]. These data suggest 
that MLP has a cardio-protective role. However, it is essential to figure out whether the 
decrease in the protein level that we detected in mdx/CnA* is related to Cn inhibition or 
considered as a negative reaction toward the protection provided by stimulating Cn in 
those mice. 
 One important Cn modulator whose role should not be ruled out is CAIN. The 
latter protein works in a negative regulatory loop. Thus, it becomes hyperphosphorylated 
upon activation of Protein Kinase C (PKC), which in turn affects Cn activity (reviewed in 
[192]). The importance of CAIN, has been well discussed in T-lymphocytes where CAIN 
could shuttle between the nucleus and the cytoplasm just like calsarcin-1 (Fan Pan and 
J.O.L, unpublished data). Further, CAIN contains a putative Cn-binding and Myocyte 
Enhancer Factor 2 (MEF2)-binding domain at its COOH terminus [182, 210, 212]. 
Knocking down these two binding domains in the C-terminus of CAIN, leads to 
upregulation of cytokines including interleukin-2 (IL-2) in response to stimulation by T-
cell receptor agonists, yet with no changes in Cn activity. This might be explained in part 
by the low sensitivity of the NFAT dephosphorylation assay, in which low differences are 
undetectable. It can also be explained by the nature of T-lymphocytes, where CAIN may 
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have other functions rather than Cn inhibition [192]. Additionally, there might be 
competition between CAIN and NFAT or other substrates of Cn [192]. Therefore, it is 
worth exploring the expression and binding of CAIN with other transcription factors like 
MEF2. This might help understanding how this protein works to inhibit and regulate Cn. 
 Together, RCAN1, calsarcins, MLP and CAIN are four examples of Cn-
interacting proteins which are quite important in regulating Cn and muscle diseases. 
Nevertheless, they require further studies on their regulation. It might be worthwhile to 
overexpress and/or knockdown the genes encoding these proteins in order to understand 
the importance of their roles in skeletal muscles particularly in certain types of muscle 
diseases such as muscle dystrophy. In case these proteins have only inhibitory effects on 
Cn, it would be interesting in the future to inhibit those inhibitors in order to maintain 
high but effective levels of Cn, which could stimulate utrophin expression in mdx mice 












Chapter 4 : The role of the NFATc2 transcription factor in 
Calcineurin-dependent cardiac hypertrophy in adult mice 
 
 


























4.1 Background  
 
 
 In Chapter 4, we are interested in investigating the role of the NFATc2 
transcription factor in the hearts of adult mice. A new manipulation in the 
Calcineurin/Nuclear Factor of Activated T cells (Cn/NFAT) pathway includes the 
knockout of the functional NFATc2 isoform in the heart. It has been demonstrated that 
young (1-2 month old) NFATc2-/- mice display a complete inhibition of forced 
hypertrophy and reduced fibrosis, suggesting a clear protection against pathological 
cardiac remodeling in the absence of NFATc2 [267]. However, we observed that adult 
(6-9 month old) NFATc2-/- mice were more susceptible to sudden death and had enlarged 
hearts when autopsied. Hence, we wanted to shed light on the role of the NFATc2 
transcription factor in Cn-mediated cardiac hypertrophy, in normotensive and 
Angiotensin II (Ang II)-stressed hearts. 
 The results of this chapter are to be submitted for publication to the Journal of 
Molecular and Cellular Cardiology. This journal publishes work advancing knowledge 
of the mechanisms responsible for both normal and diseased cardiovascular function. Our 
work emphasizes a hidden role of the NFATc2 transcription factor in the adult heart and 
the regulation of some genes that might have an essential role in cardiac hypertrophy. 
Patrick Sin-Chan has generated Figures 1-4 (Appendix IV). I added data to Figure 
4a and performed the calculations and analyses for Figures 4d-4f. Patrick has also 
interpreted the results of the mentioned Figures, which are part of his MSc thesis. Dr. 
Mathieu St-Louis carried out NFATc1 immunofluorescence in the 14 day Ang II 





Cardiac hypertrophy is an overall increase in heart mass without improved contractile 
function. In this abnormality, the heart can no longer supply adequate amounts of blood to 
meet the body’s hemodynamic demands, resulting in cardiac dilatation, decrease in 
contractile effectiveness, organ failure and death. The Ca2+-dependent phosphatase, 
Calcineurin (Cn) and its downstream target, the Nuclear Factor of Activated T cells 
(NFAT), are major intracellular modulators of cardiac hypertrophy. In young mice, the 
NFATc2 transcription factor has been identified as the major NFAT isoform responsible 
for Cn-mediated cardiac hypertrophy. Surprisingly, we observed that adult NFATc2 null 
(NFATc2-/-) mice were more prone to sudden death, suggesting that NFATc2 might be 
essential at later rather than earlier stages of life. Hence, we raised a question as to the 
role of NFATc2 in the hearts of adult mice. Our histological analysis showed that 
NFATc2-/- mice displayed left ventricular inner chamber dilatation, which might cause 
death to those mice. Nevertheless, Angiotensin II (Ang II)-stimulated cardiac growth for 
14 days displayed alterations of transcriptional mechanisms in NFATc2-/- mice but no 
changes in the damage hallmarks compared to their Wild-Type (NFATc2+/+) 
counterparts. Additionally, Ang II stimulation for 28 days showed more damage in the 
stressed hearts compared to normotensive ones, with no detectable changes between 
NFATc2+/+ and NFATc2-/- mice. Our data collectively suggest a cardio-protective role 
for NFATc2 in normotensive adult mice to maintain normal heart function and signaling. 
This protection is compromised when stressing the hearts for 14 and 28 days of Ang II 
stimulation. This study moves the discussion toward a better understanding of the role of 





 Cardiovascular disease represents one of the leading causes of death in the 
modern world. An abnormality associated with the majority of cardiovascular diseases is 
pathological cardiac hypertrophy in which hearts are subjected to increased workload and 
decreased contractile efficiency [268]. Individuals living with this disease have a greater 
susceptibility to cardiac arrhythmias, organ failure and sudden death [268]. Further, 
prolonged cardiac hypertrophy leads to heart failure in which the heart cannot supply the 
body with enough blood and can no longer sustain the increased workload required to 
meet the body’s hemodynamic demands as a healthy heart can, causing left ventricular 
dilatation. This enlargement of the left ventricle causes irregular heartbeats (arrhythmia), 
thinning of the myocardial walls and an overall decrease in heart contraction and function 
resulting in sudden death [269, 270]. The Ca2+/Calmodulin (CaM)-dependent 
phosphatase, Calcineurin (Cn) and its downstream transcriptional target, the Nuclear 
Factor of Activated T cells (NFAT), are major intracellular modulators of pathological 
cardiac hypertrophy [155, 271-273]. Of the five known NFAT isoforms, four (NFATc1, 
NFATc2, NFATc3, NFATc4) are regulated by Cn signaling and their presence has been 
detected in the heart [72, 274]. Cn dephosphorylates NFAT triggering its nuclear transit, 
where it interacts with other cardiac factors to activate the transcription of cardiac fetal 
genes including β-Myosin Heavy Chain (β-MyHC), Atrial Natriuretic Peptide (ANP) and 
Brain Natriuretic Peptide (BNP), thereby initiating the hypertrophic gene program [156]. 
In vivo and in vitro studies previously have demonstrated the effectiveness of Cn/NFAT 
signaling in the mediation of cardiac hypertrophy and heart failure [72, 149, 155, 275-
282]. Another well-characterized inducer of cardiac hypertrophy is the GATA4 
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transcription factor. Transgenic mice overexpressing GATA4 display increased heart 
sizes, cardiomyopathy and reactivation of the cardiac fetal genes [283]. In addition, 
GATA4 has been shown to cooperate with NFATc4 to synergistically activate the BNP 
promoter to induce cardiac hypertrophy [149]. 
 Genetic loss-of-function studies have identified that NFATc2 is the major NFAT 
isoform responsible for Cn-induced pathological cardiac hypertrophy. Thus, 1-2 month 
old NFATc2-/- mice display a complete inhibition of forced hypertrophy, decreased 
cardiac fetal gene expression, reduced fibrosis and restored contractile functions 
suggesting a clear protection against pathological cardiac remodeling [267]. However, we 
observed that 6-9 month NFATc2-/- mice are physically frailer in appearance, more 
susceptible to sudden death and have larger hearts upon autopsy. These observations 
suggest that in younger NFATc2-/- mice, other transcription factors may be compensating 
for the absence of functional NFATc2. Over time, these compensatory transcription 
factors might not be able to completely restore normal cardiomyocyte growth and 
function, predisposing these mice to heart failure. Having this difference between early 
findings on young mice and our observations on adult mice, we decided to examine the 
role of NFATc2 transcription factor in the hearts of adult mice in normotensive and 
Angiotensin II (Ang II)-stimulated hearts for 14 and 28 days. Ang II performs a 
physiologic stimulus, which promotes myocyte growth and cardiac hypertrophy [267]. 
 Our results on normotensive adult NFATc2-/- mice showed a similar Heart 
Weight-to-Body Weight (HW/BW) ratio as NFATc2+/+ mice. However, NFATc2-/- mice 
displayed left ventricular inner chamber dilatation and thinning of the right ventricular 
wall, which might be correlated with heart failure. We also demonstrated that NFATc2-/- 
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mice have increased GATA4 expression and both NFATc1 and GATA4 nuclear 
translocation, suggesting a compensatory mechanism induced by these factors for the loss 
of NFATc2 in an attempt to rescue cardiomyocyte growth. Moreover, when inducing 
cardiac hypertrophy using Ang II implantation for 14 days, we observed that the overall 
heart morphology of Ang II-stimulated NFATc2-/- mice was similar to those of 
NFATc2+/+ mice. We also showed that the expression of cardiac fetal genes may be 
regulated by separate mechanisms, since the change in their expression did not show the 
same pattern. However, the mRNA levels of the cardio-protective genes calsarcin-1, the 
beta 1 isoform of Calcineurin A (CnAβ1) and the Activating Transcription Factor 4 
(ATF4), were either reduced or unchanged in the stimulated NFATc2-/- hearts compared 
to their NFATc2+/+ counterparts. The protein levels of phospho-Akt (pAkt) (Ser473), 
phospho-Foxo3a (pFoxo3a) (Ser253) and CnAβ were unchanged in the 14 day Ang II-
stimulated NFATc2-/- mice compared to their NFATc2+/+ counterparts. Additionally, 
Haematoxylin and Eosin (H&E), picrosirius red, CD45 and the fibroblast markers Alpha 
Smooth Muscle Actin (α-SMA) and Vimentin did not show any differences between the 
14 day stimulated NFATc2-/- mice and their NFATc2+/+ counterparts. Comparable to the 
14 day stimulation, the 28 day Ang II-stimulated NFATc2+/+ and NFATc2-/- hearts were 
both overstressed showing the same degree of damage, collagen infiltrate and fibrosis. 
 Our results collectively, suggest that the NFATc2 transcription factor does not 
cause pathological cardiac hypertrophy in normotensive hearts. On the contrary, it might 
have a protective role in maintaining normal heart function and regulating growth-
mediated biochemical signaling. In addition, upon stressing the hearts with Ang II, the 
loss of NFATc2 does not confer any protection against damage and failure since both 
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stimulated NFATc2-/- and NFATc2+/+ hearts show similar degree of inflammation and 
fibrosis. In all cases, we propose that normal Cn/NFAT signaling is required for proper 
heart function. Simultaneously, abnormalities driven by Ang II are able to induce changes 
in this signaling pathway, thereby produce an exacerbated pathological situation. 
4.4 Methods 
4.4.1 Mouse model, breeding and maintenance 
 
 Transgenic NFATc2 null (NFATc2-/-) mice were generously provided by Drs. 
Grace Pavlath (Emory University) and Laurie Glimcher (Harvard University). As a result 
of NFATc2 gene disruption, a loss of function mutation is produced as previously 
described [284]. Breeding of heterozygous (NFATc2+/-) or homozygous (NFATc2-/-) 
mice yielded a second generation NFATc2-/- mice. For the experimental design, 
NFATc2-/- mice were age and sex-matched with Wild-Type (NFATc2+/+) counterparts, 
which were purchased from (Charles River Laboratories) or generated from breeding. All 
mice were housed under standard environmental conditions (20-22ºC) and provided with 
standard rodent food and tap water. Mice between 6 and 9 months of age were used for 
all subsequent analyses. Animal care and experimental procedures were performed in 
accordance to the guidelines of the Canadian Council of Animal Care. 
 4.4.2 Mice genotyping 
 
 DNA from mouse tails was amplified by adding 2 μl of DNA to 1X Taq buffer 
with KCl (Fermentas), 2 mM MgCl2 (Fermentas), 0.2 mM dNTP (Invitrogen), 0.5 mM 
primers (Sigma Aldrich) and 20 U Taq DNA polymerase (Fermentas), yielding a final 
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volume of 20 μl. The following primers were used 5' -gcaagcctcagtgacaaagtatccacttca-3', 
5'-ccacgagctgcccatggtggagagacaaga-3' and 5'-agcgttggctacccgtgatattgctgaaga-3'. Cycling 
conditions were as follows: 1) initial denaturation at 95ºC for five minute, 2) denaturation 
at 94ºC for one minute, 3) primer annealing at 60 ºC for one minute, extension at 72ºC 
for one minute, 4) repeat steps 2 and 3 for 36 cycles, 5) final extension at 72ºC for ten 
minutes. PCR products were loaded on a 1.5% agarose gel stained with ethidium bromide 
and resolved, after electrophoresis, under UV irradiation using the Alpha Innotec 
FluorChem system (Cell Biosciences). 
4.4.3 Muscle extraction and preservation 
 
 Prior to muscle extraction, mice were anesthetized by an intramuscular injection 
of a 1.6:1 volume ratio mixture of 100 mg/ml ketamine hydrochloride (Bimeda-MTC 
Animal Health Inc.) and 20 mg/ml xylazine (Bayer Health Care). A dosage of 0.04 ml/30 
g of body weight was administered to each mouse. Animals were euthanized after 
extraction using CO2 gas. Hearts for biochemical use were extracted and frozen directly 
in liquid nitrogen. For histology, the hearts were stimulated with an equal volume of 5% 
gelatin (Sigma Aldrich) in each ventricle, embedded with Tissue-Tek Optimum Cutting 
Temperature compound (Fisher Scientific) and frozen in a pool of melting isopentene 
cooled in liquid nitrogen. All samples were stored at -86ºC until used.  
4.4.4 RNA extraction and semi-quantitative RT-PCR 
 
 Mouse hearts were homogenized in a solution made up of guanidinium 
thiocyanate (Sigma Aldrich), 25 mM sodium citrate, 0.5% (v/v) N-laurylsarcosine 
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(Sigma Aldrich) and 0.1 M 2-mercaptoethanol (Bioshop), followed by addition of 0.2 M 
sodium acetate (pH 4.0) with vortexing, phenol (Sigma Aldrich) and chloroform:isoamyl 
alcohol with vortexing until the appearance of a white emulsion. Samples were cooled on 
ice for fifteen minutes, and then centrifuged at 10,000 x g for ten minutes at 4ºC. 
Afterwards, two volumes of 99% ethanol were added to the aqueous layer with vortexing 
and centrifugation again at 10,000 x g for ten minutes at 4ºC. The ethanol was decanted 
and the RNA was suspended in 200 μl of 70% ethanol and centrifuged at 10,000 x g for 
ten minutes at 4ºC. The ethanol again was decanted and the RNA pellet was left to dry 
and re-suspended in 15 μl of RNAse free H2O (Bioshop) per 10 mg of tissue with 
subsequent vortexing and heating at 70ºC for 3 minutes. To test RNA integrity, the RNA 
concentration was determined using an Eppendorf Biophotometer (Eppendorf) at 260nm. 
Subsequently, 2 μg of RNA was mixed with a 2:1 formamide:ethidium bromide, 
formaldehyde (Sigma Aldrich), 10X MOPS (pH 7.0) and bromophenol blue, heated at 
65ºC for ten minutes and loaded on a 1.5% agarose gel containing 1X MOPS and 
formaldehyde. The three rRNA bands: 5S, 18S and 28S were visualized to verify RNA 
integrity. 
 RT-PCR was performed by combining 2 μg of RNA and ultrapure water, to a 
final volume of 10 μl. The final volume of the RT mixture was 40 µl, and consisted of 
0.625 μM random primer hexamers (Invitrogen), 1X RT-buffer (Ambion), 0.5 μM dNTP 
(Invitrogen), 40 U of RNase Inhibitor (Ambion) and 100 U of MMLV-RT (Ambion). The 
RT-PCR program (fifteen minutes at 20ºC, one hour at 37ºC, and ten minutes at 65 º C) 
was performed using an MJ Research PTC-100 thermalcycler. As a negative control, RT 
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samples were duplicated in the absence of MMLV-RT. The cDNA was stored at -20ºC 
until used.  
 The cDNA was amplified by adding 2.5 μl of cDNA to 1X Taq buffer with KCl 
(Fermentas), 1.5 mM MgCl2 (Fermentas), 0.1 mM dNTP (Invitrogen), 0.2 mM primers 
(Sigma Aldrich) and 0.5 μl Taq DNA polymerase (Fermentas), yielding a final volume of 
50 μl. Cycling conditions were as follows: 1) initial denaturation at 94ºC for one minute, 
2) denaturation at 94ºC for one minute, 3) primer annealing at 55 ºC for one minute and 
extension at 72ºC for one minute, 4) repeat steps 2 and 3 for X number of cycles, 6) final 
extension at 72ºC for ten minutes, using an MJ Research PTC-100 thermalcycler. PCR 
products were loaded on a 1.5% agarose gel stained with ethidium bromide and resolved 
under UV irradiation using the Alpha Innotec FluorChem system (Cell Biosciences) after 
electrophoresis. The primer sequences used for semi-quantitative RT-PCR are listed in 
Table 4.1. 
Table 4.1: Primers for semi-quantitative PCR 
Gene Forward Primer         Reverse Primer     Product 
Size (bp) 








NFATc2 5’-tctgctgttctcatggatgccc-3’ 5’-ggatgcagtcacagggatgct-3’ 
5’-ggcagatgtaactgctgggt-3’ NFATc3 5’-cgatctgctcaagaactccc-3’ 
NFATc4 5’-ctgaggatcgaggtacagcc-3’ 5’-ttgttctctgggagcaaggt -3’ 
28S 5’-ttgttgccatggtaatcctgctcagta-3’ 5’-tctgacttagaggcgttcagtcataatc-3’ 
β-MHC 5’-gccaacaccaacctgtccaagttc-3’ 5’-tgcaaaggctccaggtctgagggc-3’ 
ANP 5’-ttggcttccaggccataattg-3’ 5’-aagagggcagatctatcgga-3’ 
BNP 5’-atggatctcctgaaggtgct-3’ 5’-tcttgtgcccaaagcagctt-3’ 
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4.4.5 Real time quantitative-PCR (qPCR) 
 
 Changes in gene expression for calsarcin-1, CnAβ1, ATF4, Foxo3a and myostatin 
were assessed by qPCR. Briefly, 2 µg of freshly extracted heart RNA was reverse 
transcribed to cDNA using iScript reverse transcription supermix (Bio-Rad) and qPCR 
was performed using gene-specific primers together with appropriate reference genes for 
quantification (CFX96 Real-Time System, Bio-Rad). Relative quantities then were 
normalized by the Real-time System software to the relative quantities of Hypoxanthine-
guanine Phospho-Ribosyl Transferase (HPRT), 60S Ribosomal Protein L13 (RPL13) 
and/or TATA-Binding Protein (TBP) housekeeping genes. The primer sequences used for 
qPCR are listed in Table 4.2. 
Table 4.2: Primers for quantitative real-time PCR 
Gene      Forward Primer Reverse Primer                        Product 
                                                  Size(bp) 
Calsarcin-1 5’-gccaaaggggtgggtatct-3’ 5’-tgccctaagcagaccaacag-3’      156 
CnAβ1 5’-agaaggtgaagaccagt-3’ 5’-agcaagttgcataacatcatt-3’       144 
5’-gtctgagggggctccttatt-3’         121 ATF4 5’-atgctctgtttcgaatgga-3’ 
Foxo3a 5’-caaagcagaccctcaaactga-3’ 5’-caaaggtgtcaagctgtaaacgg-3’  102 
MSTN 5’-taaccttcccaggaccagga-3’ 5’-cactctccagagcagtaatt-3’         223 
RPL13 5’-aaggtggtggtcgtacgctgtg-3’ 5’-gcgccagaaaatgcggctgg-3’      153 
HPRT 5’-ccagcgtcgtgattagcgatgatg-3’ 5’-gagcaagtctttcagtcctgtcc-3’    135 





4.4.6 Protein extraction and Immunoblotting  
 
 Briefly, whole hearts were homogenized in 1X RIPA buffer solution (6 µl/mg 
tissue) consisting of 1X PBS, 1% Igepal, 0.5% Sodium Deoxycholate, 0.1% Sodium 
Dodecyl Sulfate (SDS), 0.001 M Sodium Orthovanadate, 0.01 M Sodium Fluoride, 0.01 
mg/ml Aprotinin, 0.01 mg/ml Leupeptin and 1 mM Phenylmethanesulfonyl fluoride 
(PMSF). Homogenates were centrifuged at 15,000 x g for twenty minutes and the 
supernatant layers were collected and re-centrifuged. Protein concentrations were 
measured using Quick Start Bradford dye reagent (Bio-Rad) and extracts were stored at -
86ºC until used. For nuclear-cytosolic protein extraction, fractionation into cytoplasmic 
and nuclear proteins was performed using the NE-PER® Nuclear and Cytoplasmic 
Extraction Kit (Pierce Biotechnology) according to the manufacturer’s protocol. 
 Between 50-100 μg of protein were loaded on an SDS polyacrylamide gel 
consisting of a 5% w/v stacking gel composed of 3.9% acrylamide (Sigma Aldrich), 
0.125 M Tris (pH 6.8), 0.1% SDS, 0.06% ammonium persulfate and 0.14% 
Tetramethylethylenediamine (TEMED) (Bioshop), and a 10% w/v separating gel 
composed of 9.9% acrylamide, 0.375 M Tris (pH 8.8), 0.1% SDS, 0.06% ammonium 
persulfate and 0.25% TEMED. Samples were electrophoresed at 120V until the protein 
sizes of interest were visibly separated using the Amersham Full-Range Rainbow 
Molecular Weight Markers (GE Healthcare Bio-Sciences Corp). Proteins were 
transferred to a PVDF membrane (Millipore) at 30V for 90 minutes using Borax 
(Bioshop), followed by blocking in 5% non-fat milk or bovine serum albumin in 0.1% 
Tween/Tris Buffered Saline (T/TBS) for one hour. Primary antibodies to GATA4 
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(1:1000; sc-25310, Santa Cruz), α-tubulin (1:2000; 2125, Cell Signaling), Histone H3 
(1:1000; 9715, Cell Signaling), GAPDH (1:2000; ab9484, Abcam), pAkt (Ser473) 
(1:1000; 9271, Cell Signaling), total Akt (1:1000; 610861, BD Biosciences), Alpha 
smooth muscle actin (1:1000; ab5694, Abcam), pFoxo3a (Ser 253) (1:500; sc-101683, 
Santa Cruz), total Foxo3a (1:500; sc-11351, Santa Cruz), CnAβ (1:1000; ADI-SPA-610, 
Enzo Life Sciences), Vimentin (1:500; C0390, Assay BioTech) and calsarcin-1 (1:2000; 
rabbit polyclonal antibody; a gift from Drs. Norbert Frey and Derk Frank) were added to 
membranes based on the manufacturer’s recommendation and incubated on a shaker at 
4ºC overnight. The following day, membranes were washed three times with 0.1% T/TBS 
and incubated with secondary antibodies (1:2000, Sigma Aldrich and Cell Signaling) 
coupled to horse radish peroxidase (HRP) for one hour. Membranes were washed three 
times with 0.1% T/TBS and developed with enhanced chemi-luminescence reagents 
(Millipore) using the Alpha Innotec FluorChem system. 
4.4.7 Angiotensin II infusion 
 
 Alzet 2002 micro-osmotic pumps (Alzet) were placed through a small dorsal 
incision in the skin between the scapulae in 6-9 month old female mice anesthetized as 
described above. Pumps were filled with Ang II (Sigma Aldrich), administered in a 
dosage of 432 μg·kg-1·day-1 in 150 mM NaCl-0.01N acetic acid. Ang II was continuously 
stimulated into mice for a period of 14 days. The hearts were then extracted as described 
earlier. For the 28 day stimulated hearts, the incision was opened and the pump was 




4.4.8 Histology, Staining and Microscopy 
 
 Hearts embedded in Optimum Cutting Temperature were transversally sectioned 
in 10 μm cuts, using a Leica CM3060S cryostat (Leica Microsystems Inc.) and collected 
on Superfrost Plus microslides (VWR).  
 For H&E, samples were incubated in 0.5% Harris haematoxylin (Sigma Aldrich) 
for five minutes, rinsed with water, quickly immersed in 1% HCl/70% ethanol solution, 
rinsed with water, incubated in 1% eosin (Fisher Scientific) for three minutes and rinsed 
with water. Slides were subsequently incubated in 70%, 80% and 90% ethanol solution 
for two minutes each and immersed in xylene (Fisher Scientific) for thirty seconds. Slides 
were air dried and mounted in Permount (Fisher Scientific). Images were captured on a 
Nikon SMZ1500 stereomicroscope or Zeiss microscope. 
 Picrosirius red staining for collagen infiltrate was performed using the picrosirius 
red kit (Polysciences, Inc.) as follows: hearts from the normotensive and Ang II 
stimulated mice were transversally sectioned in 10 μm cuts. Slides were fixed in 4% 
paraformaldehyde (PFA) for 30 minutes, followed by washing with distilled water and 
incubation in 20% of the stock solution A (Phosphomolybdic acid hydrate) for 5 minutes. 
Slides then were rinsed in distilled water and further incubated in 20% of the stock 
solution B (Trinitrophenol) for 30 minutes. This was followed by rinsing with distilled 
water and incubation in 20% of the stock solution C (Hydrogen chloride) for 2 minutes. 
Slides were finally dehydrated in 70% ethanol for 30 seconds, cleared with xylene for 
fifteen seconds, air dried and mounted in Permount. Images were visualized and captured 
using a microdissection microscope (Applied Biosystems). 
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 For immunofluorescence (IF), samples were fixed in 2% PFA and washed with 
1X PBS three times for five minutes. Tissues were blocked and permeabilized with 2% 
goat serum (Sigma Aldrich) and 0.2% Triton X-100 (Sigma Aldrich) for one hour. 
Samples were incubated overnight at 4ºC with primary antibodies; 1:50 NFATc1 (sc-
13033), 1:25 NFATc2 (sc-13034), 1:25 NFATc3(sc-8321), 1:50 NFATc4 (sc-13036) 
(Santa Cruz), 1:50 CD45 (05-1413, Millipore), 1:50 α-SMA (ab5694, Abcam) or 1:50 
Vimentin (C0390, Assay BioTech) in 1X PBS containing 1% goat serum and 0.05% 
Triton X-100. The following day, samples were washed three times with 1X PBS and 
incubated with 1:100 Alexa Fluor® 488 Goat Anti-mouse IgG (A-11001) (Invitrogen) for 
mouse primary antibodies or 1:100 Alexa Fluor® 546 Goat Anti-rabbit IgG (A-11010) 
(Invitrogen) for rabbit primary antibodies in 1X PBS, containing 1% goat serum and 
0.05% Triton X-100 for one hour at room temperature. Slides were washed five times 
with 1X PBS, dried and mounted with Vectashield with 4',6-diamidino-2-phenylindole 
(Dapi) (Vector Laboratories Inc.). Images were captured at 40X magnification using a 
Zeiss Axioplan fluorescence microscope mounted with a Lumenera Infinity 3-1C1.4 
camera (Ottawa, ON, Canada). Negative control slides without primary antibodies 
revealed the absence of background staining at the acquisition time used. Colocalization 
analysis was performed using ImagePro Plus version 6.2 software (Olympus, Markham, 
ON, Canada).  
4.4.9 Statistical analyses 
 
 The levels of cDNA and protein expression were quantified by measuring the 
density of the band of interest with respect to a control using the Alpha Innotec 
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FluorChem system. Differences between experimental groups were evaluated for 
statistical significance using One Way Analysis of Variance (ANOVA) with necessary 
Post-Hoc tests. Student's t test was used for comparing two groups with one variable. 
Values were considered to be statistically significant if P<0.05. Analyses for Chapter 4 
are fully explained in Appendix III. 
4.5 Results 
4.5.1 Characterization of heart phenotype in NFATc2-/- mice 
 
 NFATc2-/- mice were generated by substituting the NFATc2 N-terminal DNA 
binding domain of the NFAT Rel Homology Domain (RHD) with a neomycin cassette, 
using homologous recombination [284]. The genotypes of experimental mice were 
validated by amplifying DNA isolated from tails by PCR (Appendix IV; Figure 1a). 
Normotensive hearts of NFATc2-/- mice displayed a comparable overall gross 
morphology (Appendix IV; Figure 1b) and a similar relative HW/BW ratio compared to 
NFATc2+/+ mice (Appendix IV; Figure 1c). 
We monitored changes in the sizes of heart ventricles and myocardial wall 
thickness, well-characterized markers of heart disease and failure (Appendix IV; Figure 
1d). The ratio of the left ventricular chamber inner diameter to total heart diameter 
showed that the left ventricular chamber of NFATc2-/- mice was approximately 28% 
more dilated than NFATc2+/+ hearts (Appendix IV; Figure 1e). Additionally, the right 
ventricular wall was approximately 25% thinner than in NFATc2+/+ hearts. However, the 
latter effect was not significant (Appendix IV; Figure 1f). The changes in both ventricular 
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dilatation and thickness of the myocardial wall suggest that adult NFATc2-/- mice might 
be more susceptible to heart failure and sudden death. 
4.5.2 NFATc1 has increased nuclear localization in the hearts of NFATc2-
/- mice 
 
 To monitor the ability of NFATc1, NFATc3 and NFATc4 to compensate for the 
absence of functional NFATc2 at the mRNA level, semi-quantitative RT-PCR was 
conducted on RNA isolated from experimental hearts. Although mRNA transcript levels 
showed no differences between NFATc2+/+ and NFATc2-/- hearts (Appendix IV; Figure 
2a), IFs showed that NFATc1 had a significantly higher nuclear presence, whereas 
NFATc3 and NFATc4 were unchanged in the hearts of NFATc2-/- compared to 
NFATc2+/+ mice (Appendix IV; Figures 2b and 2c). This suggests that NFATc1 may 
have increased nuclear translocation in order to potentially compensate for the absence of 
the non-functional NFATc2 in the adult hearts. 
4.5.3 The GATA4 transcription factor has a higher protein expression 
and nuclear transit in the NFATc2-/- compared to NFATc2+/+ hearts  
 
 GATA4 transcription factor is one of the most well-characterized proteins 
required for cardiac morphogenesis and a marker of adult cardiac failure [285]. It has 
been demonstrated that GATA4 can interact with NFATc4 to synergistically activate the 
transcription of genes leading to cardiac growth and eventually heart failure [149].  
Although GATA4 was not altered in the hearts of adult NFATc2-/- mice at the transcript 
level (data not shown), it was significantly upregulated at the protein level (Appendix IV; 
Figures 3a and 3b), suggesting that the synthesis of GATA4 protein was increased maybe 
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to compensate for the loss of a functional DNA binding domain in the NFATc2 protein. 
To determine whether there also was increased nuclear transit of GATA4 in the hearts of 
adult NFATc2-/- mice, we fractionated the hearts into cytoplasmic and nuclear protein 
extracts and used Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) as a cytosolic 
loading control and Histone H3 as a nuclear loading control (Appendix IV; Figure 3c). 
Results showed that GATA4 expression was comparable in the cytoplasmic fraction of 
NFATc2+/+ and NFATc2-/- hearts, whereas GATA4 was significantly upregulated in the 
nuclear fraction of NFATc2-/- hearts, compared to the NFATc2+/+ counterparts 
(Appendix IV; Figures 3d and 3e). Thus, as a molecular partner of NFATc2, GATA4 had 
an increased expression as well as increased nuclear transit in the absence of functional 
NFATc2. 
4.5.4 The 14 day Ang II-stimulated NFATc2-/- mice have morphological 
and anatomical markers of heart failure comparable to NFATc2+/+ 
counterparts 
 
 Because normotensive adult NFATc2-/- mice displayed both physiological and 
biochemical alterations indicative of heart failure, we induced acute cardiac hypertrophy 
in those mice using Ang II administration for 14 days. We hypothesized that imposing 
further strain on NFATc2-/- mice by using a functional overload, the hearts of these mice 
would display a more severe pathological state. Ang II-mediated cardiac hypertrophy was 
validated by a 20% increased HW/BW ratio in both stimulated NFATc2+/+ and NFATc2-
/- hearts compared to their normotensive counterparts (Appendix IV; Figure 4a). When 
comparing the left ventricular inner chamber diameter and thickness of the right 
ventricular wall in Ang II-stimulated NFATc2+/+ and NFATc2-/- mice, we visually 
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observed some differences (Appendix IV; Figure 4b). Yet, there was no significant 
change in the left ventricular chamber inner wall diameter or the right ventricular wall 
diameter between stimulated NFATc2+/+ and NFATc2-/- hearts (data not shown), 
implying that imposed acute pharmacological stress on these mice might have caused 
some but not major changes. 
 In addition, we saw alterations in the expression of the cardiac fetal genes, β-
MyHC, ANP and BNP (Appendix IV; Figure 4c). The reactivation of the cardiac fetal 
genes is another hallmark feature of hearts undergoing pathophysiological hypertrophy 
and damage [156]. We showed that of all fetal genes tested, only the β-MyHC gene was 
increased in expression, whereas ANP and BNP did not change between Ang II-induced 
NFATc2-/- and their NFATc2+/+ counterparts (Appendix IV; Figures 4d, 4e and 4f). 
4.5.5 The 14 day Ang II-stimulated NFATc2-/- mice display altered 
cardio-protective gene expressions 
 
 In addition to cardiac fetal genes, we monitored gene expression of regulators of 
cardiac growth following 14 days of Ang II-induced hypertrophy in NFATc2-/- mice. 
Based on our previous findings on normotensive NFATc2-/- mice that had altered cardiac 
fetal gene expression, we predicted that genes with a cardio-protective function would be 
downregulated, whereas genes involved in heart failure and damage would be increased 
in expression. Interestingly, we observed that genes with cardio-protective roles; 
calsarcin-1 and CnAβ1, were significantly increased in Ang II-stimulated NFATc2+/+ 
mice compared to NFATc2+/+ counterparts. However, calsarcin-1 was unchanged and 
CnAβ1 was reduced in Ang II-stimulated NFATc2-/- mice compared to their NFATc2+/+ 
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counterparts (Figures 4.1a and 4.1b). In agreement with this observation, ATF4, a 
downstream target of the mammalian Target Of Rapamycin (mTORC1) and a potential 
mediator of the cardio-protective effect produced by CnAβ1 [64, 175, 180, 181], had a 
tendency for an increase (P=0.09) in stimulated NFATc2+/+ compared to normotensive 
NFATc2+/+ mice. However, this increase was lost in stimulated NFATc2-/- hearts (Figure 
4.1c). 
 Additionally, the expression levels of genes with known roles in cardiac damage 
and atrophy were measured [174, 286-289]. Foxo3a was upregulated in stimulated 
NFATc2-/- mice compared to normotensive NFATc2-/- mice, whereas myostatin was 





Figure 4.1: The 14 day Ang II-stimulated NFATc2-/- mice display less protective properties  
QPCR showing changes in relative mRNA expression levels of calsarcin-1 (a), CnAβ1 (b), ATF4 
(c), Foxo3a (d) and myostatin (MSTN) (e) in normotensive as well as in the hearts of Ang II- 
stimulated NFATc2+/+ and NFATc2-/- mice. Relative quantities are normalized to HPRT, TBP 
and/or RPL13 (n=3 for calsarcin-1, CnAβ1 and Foxo3a and n=4 for ATF4 and MSTN; P<0.05). 
AU represents Arbitrary Units. *compared to normotensive NFATc2+/+, $compared to stimulated 




4.5.6 The 14 day Ang II-stimulated hearts show similar signs of damage 
as normotensive hearts   
 
 In order to determine if changes in the expression of cardiac fetal genes driven by 
Ang II stimulation had generated any damage hallmarks in the hearts of NFATc2-/- mice, 
we next assessed various pathological indices. Picrosirius red, a strong anionic dye, was 
introduced to substitute for Acid Fuchsin in Van Gieson's trichrome method. This dye 
specifically stains collagen by direct interaction between the basic groups in collagen and 
sulphonic acid groups of sirius red [290]. Accordingly, H&E and picrosirius red staining 
did not show differences in visual morphological abnormalities between stimulated and 
normotensive NFATc2-/- hearts (Figure 4.2a). 
 CD45, also called Leukocyte common antigen, is a high molecular weight 
transmembrane glycoprotein, which is expressed in nucleated hematopoietic cells [291, 
292]. CD45 is a member of the protein tyrosine phosphatase family, which is an essential 
regulator of T- and B-cell antigen receptor signaling and functions by activating various 
kinases required for antigen receptor signaling [292]. This protein is considered a 
valuable marker to identify cells of leukocyte origin as well as to distinguish naive from 
memory T-cells that are induced during inflammatory responses [293, 294]. Thus to 
investigate the presence of inflammation due to 14 day Ang II stimulation, we stained for 
CD45. Both stimulated NFATc2+/+ and NFATc2-/- showed a similar staining for this 
marker (Figure 4.2a). 
 To detect and examine the presence of fibrosis in NFATc2-/- mice, we used two 
markers: α-SMA, a marker of fibrosis and smooth muscle differentiation, is a protein 
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synthesized from the myofibroblasts at the site of injury during wound healing [295]. 
Vimentin is the most frequent occurring intermediate filament in fibroblasts and thus a 
reliable fibroblast marker [296]. Both α-SMA and Vimentin showed similar staining in 
normotensive NFATc2-/-, stimulated NFATc2+/+ and stimulated NFATc2-/- hearts 
(Figure 4.2a). 
 We previously saw an increased NFATc1 nuclear localization in the hearts of 
normotensive NFATc2-/- mice, which might be correlated to the ability of NFATc1 to 
compensate for the absence of NFATc2 (Appendix IV; Figure 2c). In agreement with this, 
IFs showed that NFATc1 had a tendency for a higher nuclear presence in the hearts of the 
14 day stimulated NFATc2-/- mice compared to the 14 day stimulated NFATc2+/+ mice 





Figure 4.2: The 14 day Ang II-stimulated hearts do not show differential signs of damage 
from normotensive hearts 
(a) H&E, picrosirius red staining and IFs for CD45, α-SMA and Vimentin in the hearts of 
normotensive and stimulated NFATc2+/+ and NFATc2-/- mice (n=3). Arrows indicate positive 
staining. Scale bars; 50µm for (H&E), 10µm for (Picrosirius red), 20µm for (CD45 and 
Vimentin) and 100µm for (α-SMA). (b) Representative photomicrographs depicting nuclear 
localization of NFATc1 isoform in the heart. Arrows indicate nuclei positively stained for 
NFATc1. Scale bars, 20µm. (c) Quantification of the percentage of myonuclei stained for 
NFATc1 in normotensive NFATc2-/- compared to normotensive NFATc2+/+ hearts (n=3; 
P<0.05). *compared to normotensive NFATc2+/+, $compared to stimulated NFATc2+/+. Means 
± SEM are shown. 
 
4.5.7 Phospho-Akt, α-SMA, phospho-Foxo3a and Vimentin protein levels 
do not change in the 14 day Ang II-stimulated NFATc2-/- mice 
 
 We next investigated whether pathways regulating protein translation were 
affected in Ang II-stimulated NFATc2-/- mice. The Insulin Growth Factor-I/Akt (IGF-
1/Akt) signaling pathway is one of the most studied growth pathways involved in 
promoting both gene transcription and protein translation, as well as in inhibiting the 
activation of pathways resulting in protein degradation [178, 179]. We thus speculated 
that the expression of activated Akt would also be downregulated in Ang II-stimulated 
NFATc2-/- mice. Our results showed an upregulation of pAkt (Ser473) in the stimulated 
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NFATc2+/+ hearts compared to normotensive NFATc2+/+ hearts, but no change in the 
stimulated NFATc2-/- hearts compared to their NFATc2+/+ counterparts (Figures 4.3a 
and 4.3c). Although two bands were visible when probing for total Akt, the lower band 
was deemed unspecific in mice using alkaline phosphatase treatment and Western blots 
on rat muscles (data not shown). In addition, pFoxo (Ser253), which is inhibited by the 
active form of Akt [174], was also unchanged with Ang II stimulation in both phenotypes 
(Figures 4.3b and 4.3e) 
 We also examined the protein levels of α-SMA, Vimentin and CnAβ (Figure 4.3). 
Here, we showed a slight but not significant increase in the expression of α-SMA in both 
stimulated NFATc2+/+ and NFATc2-/- hearts compared to normotensive ones. 
Nevertheless, there was no difference between NFATc2+/+ and NFATc2-/- mice (Figures 
4.3a and 4.3d). Likewise, there was no difference in the expression of Vimentin (Figures 
4.3b and 4.3f). Unlike qPCR results, our immunoblotting did not show a difference in 
CnAβ expression between stimulated NFATc2-/- and NFATc2+/+ hearts but a significant 
decrease in stimulated NFATc2-/- hearts compared to their normotensive NFATc2-/- 
counterparts (Figures 4.3b and 4.3g).  
 Since the changes in signaling observed in normotensive NFATc2-/- mice were 
compromised after 14 days Ang II stimulation, we decided to carry out 28 days Ang II 






Figure 4.3: PAkt (Ser473), α-SMA, pFoxo3a (Ser253), Vimentin and CnAβ expression levels 
in the 14 day Ang II-stimulated mice 
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(a) Representative immunoblots for pAkt (Ser473), total Akt and α-SMA. (b) Representative 
immunoblots for pFoxo3a (Ser253), total Foxo3a, Vimentin and CnAβ. (c-g) Quantifications of 
the immunoblots normalized to α-tubulin expression (n=4; P<0.05). *compared to normotensive 
NFATc2+/+, $compared to stimulated NFATc2+/+, #compared to normotensive NFATc2-/-. 
Means ± SEM are shown.  
 
4.5.8 The 28 day Ang II-stimulated NFATc2-/- hearts have similar 
features as their NFATc2+/+ counterparts 
 
 The same collagen infiltrate, inflammatory and fibroblast markers used for the 14 
day Ang II-stimulated hearts were used for the 28 day stimulated hearts. Thus, heart cross 
sections were stained for H&E, picrosirius red, CD45 and α-SMA (Figure 4.4a). Similar 
to the 14 day stimulation, we did not observe differences in those markers among the 
tested groups. However, picrosirius red in the stimulated hearts showed increased 
collagen infiltrate. 
 Additionally, we wanted to see if the prolonged Ang II stimulation has affected 
the Akt pathway. Immunoblotting for pAkt (Ser473) showed no changes in expression 
despite a slight increase in both stimulated NFATc2+/+ and NFATc2-/- hearts (Figures 
4.4b and 4.4d). In agreement with this finding, pFoxo3a (Ser253), was also unchanged 
with Ang II stimulation for 28 days in both phenotypes (Figures 4.4b and 4.4e). 
 We next set out to monitor the expression of the fibroblast markers Vimentin and 
α-SMA (Figures 4.4b and 4.4c). Both targets did not show any differences in expression 
between stimulated NFATc2-/- and stimulated NFATc2+/+ hearts (Figures 4.4f and 4.4g). 
Interestingly, α-SMA was significantly higher in stimulated NFATc2+/+ and NFATc2-/- 
compared to normotensive ones (Figure 4.4g). 
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 In addition, we tested the expression of the cardio-protective genes calsarcin-1 
and CnAβ (Figure 4.4c). Interestingly calsarcin-1 was lower, whereas CnAβ was not 







Figure 4.4: Absence of signaling changes between the hearts of the 28 day Ang II-stimulated 
NFATc2-/- mice and their NFATc2+/+ counterparts 
(a) H&E, picrosirius red staining and IFs for CD45 and α-SMA demonstrate similar staining in 
the hearts of stimulated NFATc2-/- mice compared to NFATc2+/+ mice (n=3). Arrows indicate 
positive staining. Scale bars; 50µm for (H&E), 10µm for (Picrosirius red), 20µm for (CD45) and 
100µm for (α-SMA). (b-c) Representative immunoblots for pAkt (Ser473), total Akt, pFoxo3a 
(Ser253), total Foxo3a, Vimentin, α-SMA, Calsarcin-1 and CnAβ expressions. (d-i) 
Quantifications of the immunoblots normalized to α-tubulin expression (n=3; P<0.05). 








 During the initial phase of our study, we observed that adult 6-9 month old 
NFATc2-/- mice were susceptible to sudden death and had enlarged hearts when 
autopsied. However, it has been demonstrated that 1-2 month old NFATc2-/- mice display 
a complete inhibition of forced hypertrophy, decreased cardiac fetal gene expression and 
reduced fibrosis, suggesting a clear protection against pathological cardiac remodeling in 
the absence of the NFATc2 [267]. Hence, we wanted to shed light on the role of NFATc2 
transcription factor in Cn-mediated cardiac hypertrophy taking into consideration the age 
differences between our mice and the mice in the earlier study. 
 Although the hearts of 6-9 month old NFATc2-/- mice shared an overall similar 
gross morphology and HW/BW ratio as age and sex-matched NFATc2+/+ mice, only 
normotensive NFATc2-/- mice displayed a more dilated left ventricular chamber inner 
diameter and a thinner right ventricle wall, which are characteristics of compromised 
cardiac contractility and eventual heart failure (Appendix IV; Figure 1). In this case, the 
heart cannot supply the body with enough blood causing left ventricular enlargement and 
sudden death. Previous work has demonstrated that hearts of 1-2 month old NFATc2-/- 
mice display no significant change in left ventricular internal diameter and contractility of 
the left ventricle compared to NFATc2+/+ mice [267], which correlates with our findings 
in adult stimulated mice. 
  NFATc2 has been shown to be the major isoform responsible for cardiac 
hypertrophy [267], but other transcription factors are possibly compensating for its loss, 
raising questions about the cardio-protective role of NFATc2 at later stages of life. 
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Because no compensation by NFATc1, NFATc3 and NFATc4 was detected at the 
transcript level for the absence of functional NFATc2, we decided to monitor NFAT 
cellular localization. As transcription factors, NFAT proteins become active after being 
dephosphorylated by Cn, which enables nuclear translocation leading to increased 
expression of the cardiac fetal genes. Our IFs indicate that the nuclear translocation of 
NFATc1 was significantly higher in the normotensive hearts of NFATc2-/- mice, whereas 
nuclear NFATc3 and NFATc4 levels were unchanged (Appendix IV; Figure 2). Thus, 
NFATc1 may be compensating for NFATc2 in an attempt to increase growth-mediated 
transcription. 
 Dunn et al., [297] have shown that Cn-mediated dephosphorylation of NFATc1 is 
correlated with increased muscle usage. They showed that normal weight-bearing soleus 
and functional overload-induced plantaris muscles express more dephosphorylated 
NFATc1. In addition, Shen et al., [298] have demonstrated that NFATc1 has a higher 
cytoplasmic to nuclear shuttling rate in resting skeletal muscle cells compared to other 
NFAT proteins, which suggests that Cn/NFAT has a higher basal activity than other 
NFAT isoforms. In addition, the role of the NFATc1 transcription factor in heart function 
remains poorly understood since NFATc1-/- mice are embryonic lethal, whereas other 
NFAT knockout mice remain viable [299]. This suggests that NFATc1 is likely an 
important factor for physiological heart growth, which may explain why NFATc1 is the 
only isoform that compensates for the genetic loss of NFATc2 function in the heart. 
Nevertheless, NFATc1 might not be able to fully restore proper cardiomyocyte growth, 
function and size because NFATc2-/- mice display changes in the ventricles, which are 
characteristic of heart failure. 
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 NFAT transcription factors can interact with molecular partners in the nucleus to 
re-activate cardiac fetal genes in response to hypertrophic stimuli leading to heart failure 
[79, 92, 149, 300]. Our results showed that nuclear protein expression of GATA4 is 
significantly elevated in both whole homogenate and fractionated hearts of NFATc2-/- 
mice (Appendix IV; Figure 3). As a well-characterized marker of cardiac hypertrophy, 
such an increased level of GATA4 protein might be a strong indicator of a diseased, 
overly stressed and most likely failed heart. Both in vitro and in vivo overexpression of 
GATA4 is necessary and sufficient to induce morphological, functional, molecular and 
structural changes resulting in cardiomyocyte remodeling and failure [283, 301, 302]. 
The significant increase in GATA4 protein expression and nuclear import in NFATc2-/- 
mice suggests that GATA4 is compensating for the absence of functional NFATc2. 
Similar to NFATc1, GATA4 may be attempting to promote transcriptional growth in the 
hearts of NFATc2-/- mice, but cannot completely compensate for the lack of NFATc2, 
causing these hearts to fail in adulthood. 
 Because some changes in signaling were minimal or absent in normotensive 
hearts, we stimulated cardiac hypertrophy in mice using Ang II for 14 and 28 days. As 
observed in normotensive hearts, the HW/BW ratio of 6 month old 14 day Ang II-
stimulated NFATc2-/- mice was similar to that of Ang II-stimulated NFATc2+/+ mice, 
but it was higher in stimulated hearts compared to normotensive ones, suggesting a 
preserved ability of these hearts to develop hypertrophy due to induced stress (Appendix 
IV; Figure 4a). These results differ from previous work showing that 1-2 month old Ang 
II-stimulated NFATc2-/- mice display a HW/BW ratio that is significantly lower than 
NFATc2+/+ counterparts [267]. The latter suggests that there could be a difference 
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between young and adult mice in the role of NFATc2 in the heart, and this interesting 
possibility should be confirmed by future studies with direct side-by-side comparison of 
the two age groups. 
 We initially expected that the transcript expression of β-MyHC, ANP and BNP 
would be increased in Ang II-stimulated adult NFATc2-/- mice, which would suggest that 
these mice are more vulnerable to cardiac disease. Although we observed increased β-
MyHC expression, ANP and BNP expression did not change in Ang II-stimulated 
NFATc2-/- mice compared to their NFATc2+/+ counterparts (Appendix IV; Figures 4c-
4f). As a major structural protein in the myocardial sarcomeric contractile unit, β-MyHC 
is thought to be a more representative indirect marker of pathological cardiac hypertrophy 
and failure [303]. Abraham et al., [303] found that β-MyHC transcript expression 
incrementally declines when patients having idiopathic dilated cardiomyopathy are 
treated with β-blockers, whereas ANP expression decreases in both placebo and β-
blocker treated groups. This indicates that ANP responds non-specifically to the method 
of treatment and that the regulation of other cardiac fetal genes might be controlled by a 
separate mechanism from that of the cardiac MyHC isoforms. In addition, it seems that 
once hearts are hypertrophied with Ang II, changes in contractile protein expression take 
place causing these hearts to fail.  
 As a known negative regulator of Cn signaling in the heart, in vitro and in vivo 
work has shown that overexpression of calsarcin-1 attenuates Ang II-mediated cardiac 
hypertrophy [263]. In NFATc2+/+ mice, calsarcin-1 was increased in expression 
following stimulation as an initial cellular reaction to increased load and as a rescue 
response. However, it was not changed in Ang II-stimulated NFATc2-/- mice compared 
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to stimulated NFATc2+/+ mice, indicating decreased protective properties in NFATc2- 
deficient hearts (Figure 4.1a). Moreover, calsarcin-1 protein level was downregulated in 
the 28 day Ang II-stimulated mice compared to normotensive hearts, suggesting the 
absence of cardio-protection (Figure 4.4h). Whether NFATc2 has a role in regulating 
calsarcin-1 gene expression as a manner for preventing heart failure remains unclear. 
 Recent studies have demonstrated that mice overexpressing cardiac CnAβ1 are not 
subject to hypertrophy, but rather display a cardio-protective function through activation 
of the Akt and Serum and Glucocorticoid-regulated Kinase (SGK) pathway [65]. In our 
study, CnAβ1 expression was increased following 14 day Ang II treatment in NFATc2+/+ 
mice, suggesting that its expression is activated as a protective measure in response to 
induced stress. In contrast, CnAβ1 expression was decreased in stimulated NFATc2-/- 
mice, which indicates that additional exerted stress by Ang II treatment may have caused 
those hearts to pass a critical stage for recovery and to lose the cardio-protective 
functions of CnAβ1 (Figure 4.1b). It is noteworthy that the change in CnAβ expression 
between stimulated NFATc2-/- and NFATc2+/+ mice was restricted to the transcript, but 
not protein level suggesting a possible post-transcriptional modification of CnAβ in the 
hearts of NFATc2-/- mice (Figures 4.3g and 4.4i).  
  Further, ATF4 activates an amino acid biosynthesis program and mediates the 
cardio-protective effect produced by CnAβ1 [65, 180, 181]. Here, ATF4 worked in 
concert with CnAβ1, and showed a tendency for upregulation in the stimulated 
NFATc2+/+ mice perhaps to produce a protective effect. However, it was unchanged in 
the stimulated NFATc2-/- compared to normotensive ones, suggesting once more the loss 
of protection after Ang II stimulation (Figure 4.1c). 
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 Foxo factors are the downstream targets of pAkt which represses Foxo 
transcription and thus inhibits protein degradation [174]. All members of the Foxo family 
except Foxo6 are essential for cardiac function [304]. Akt phosphorylates Foxo3a at 
Ser253, which masks its nuclear localization sequence, leading to its export from the 
nucleus to the cytoplasm [305, 306]. Thus, Akt signaling is a major regulator of Foxo 
activity. In this context, we showed an upregulation of  Foxo3a only at the transcript level 
in the stimulated NFATc2-/- mice compared to normotensive NFATc2-/- mice but with no 
significant difference compared to stimulated NFATc2+/+ mice, suggesting a possible 
shift toward protein degradation in the knockout stressed hearts (Figure 4.1d).  
 The exact role of myostatin in the heart is still being established and several 
studies have reported an elevated myostatin expression in mammalian models of heart 
failure [286-289]. Heineke et al., [307] showed that the heart can actively secrete 
myostatin to skeletal muscles to induce cachexia in an endocrine manner and that the 
genetic deletion of myostatin in the heart inhibits skeletal muscle wasting. Another report 
has shown that myostatin inhibition could contribute to repairing damaged cardiac 
muscle fibers by increasing contractility and Ca2+ influx into cardiomyocytes, both of 
which are features of physiological cardiac hypertrophy [308]. Furthermore, myostatin 
plasma levels correlate with biomarkers of heart failure severity [288]. In agreement with 
Foxo3a expression levels, we showed that myostatin is significantly upregulated in the 
hearts of stimulated NFATc2-/- mice, which signifies that these mice have a greater 
susceptibility to heart failure (Figure 4.1e). The collective findings that CnAβ1 is 
lowered, and that myostatin and Foxo3a are elevated in the hearts of Ang II-treated 
NFATc2-/- mice, suggest that these hearts may have passed a critical stage of heart failure 
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severity in which rescue is not feasible. These results also suggest that induced cardiac 
hypertrophy causes a shift in gene expression profiles toward a more damaged status. 
 Additionally, both the 14 and 28 day stimulated hearts from NFATc2+/+ and 
NFATc2-/- mice did not show variations in any of the damage markers used in this study, 
suggesting that NFATc2 is neither protecting nor exacerbating the hearts of adult mice 
exposed to pathological stress (Figures 4.2a and 4.4a). 
 Upon imitating cardiac workload by Ang II stimulation, we observed that 
activated pAkt (Ser473) was higher in the hearts of the 14 day Ang II-stimulated 
NFATc2+/+ mice than in normotensive mice supporting previous findings [309]. This 
observation suggests that the upregulation of pAkt expression in the stimulated 
NFATc2+/+ was an attempt to overcome the stress produced by Ang II. However, this 
attempt did not work with the stimulated NFATc2-/- hearts since the expression of pAkt 
was unchanged in the hearts of the 14 day Ang II-stimulated NFATc2-/- mice, which 
suggests an inactivation of translational-mediated cardiac growth in NFATc2-/- mice 
(Figure 4.3c). After 28 days of Ang II stimulation no change was observed, suggesting an 
inactivation of the Akt growth pathway due to Ang II stimulation as opposed to the loss 
of NFATc2 (Figure 4.4d). 
 The knockdown of α-SMA in embryonic stem cells using RNA interference has 
been shown to affect cardiac differentiation [310]. In addition, it has been shown that α-
SMA is expressed during pressure-overload hypertrophy [311]. Another study has found 
an absence of α-SMA in cardiomyocytes during various pathological situations [312]. We 
showed a non-significant increase in the expression of α-SMA in the 14 day stimulated 
NFATc2+/+ and NFATc2-/- hearts compared to their normotensive controls, without any 
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difference between the stimulated hearts (Figure 4.3d). In the 28 day Ang II-stimulated 
hearts, there was a significant increase in α-SMA in the stimulated hearts compared to the 
normotensive ones, which is most likely due to prolonged Ang II stimulation (Figure 
4.4g). 
 Vimentin also has been used as a reliable fibroblast marker in many recent studies 
to identify cardiac myofibroblasts [313, 314]. Vimentin expression was unchanged 
among the tested groups in both the 14 and 28 day Ang II-stimulated hearts (Figures 4.3f 
and 4.4f). This indicates that prolonged Ang II stimulation does not affect the expression 
of Vimentin, which was not the case for α-SMA expression in the 28 day Ang II-
stimulated hearts.  
 Our work provides evidence that Cn/NFAT signaling has a crucial role in the 
normal function of the adult heart, contrary to the general theory which postulates that Cn 
signaling is responsible for cardiac disorders, heart failure and sudden death. 
Physiological and biochemical signaling alterations in the hearts of NFATc2-/- mice 
indicate that these mice are susceptible to disease, which provides further insights toward 
understanding the importance of the Cn/NFATc2 pathway in the adult heart. Bourajjaj et 
al., [267] provided additional evidence that the absence of NFATc2 produces clear 
protection against cardiac hypertrophy in young mice. Our study showed that NFATc2 
might produce cardio-protection in adult non-stressed hearts. However, this protection 
was minimized after stressing the hearts for 14 days and completely lost after 28 days of 
Ang II-stimulation. Nevertheless, the loss of NFATc2 isoform neither exacerbated the 
response of the hearts of adult mice nor prevented hypertrophy. 
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 Moreover, NFATc1 nuclear localization was significantly higher in normotensive 
NFATc2-/- mice compared to normotensive NFATc2+/+ mice (Appendix IV; Figure 2c), 
and nuclear localization had a tendency to increase (P=0.05) in the hearts of 14 day 
stimulated NFATc2-/- mice compared to their NFATc2+/+ counterparts (Figure 4.6c). 
Thus, our results from this study implicate a compensation for loss of NFATc2 by the 
NFATc1 isoform. Another explanation might be related to the fact that stressing the 
hearts for 14 or even 28 days with a potent drug like Ang II, might have caused a level of 
damage which masked any difference between NFATc2-/- and NFATc2+/+ mice, as those 
hearts have reached a damaged point which could not be exceeded. Over time, changes in 
growth-mediated signaling may predispose these mice to eventual heart deterioration and 
overt heart failure due to Ang II-mediated stress rather than through loss of the NFATc2 
isoform. Therefore, there is still much to be explored about this branch of Cn-mediated 
cardiac hypertrophy. 
 Bourajjaj et al., [267] proposed that because the hearts of young 1-2 month old 
NFATc2-/- or NFATc3-/- mice are either totally or partially impaired in their ability to 
grow in response to Cn-mediated hypertrophy, a combined NFATc2c3-/- mouse would 
display more complete inhibition to hypertrophy. Whether similar effects would be seen 
in adult NFATc3-/-, remains to be elucidated. Additionally, there are many signaling 
effectors that can regulate both physiological and pathophysiological cardiac growth and 
it is difficult to identify which other pathways could be activated or inactivated in the 
NFATc2-/- mouse model. An interesting pathway to investigate in NFATc2-/- mice would 
be that involving the Ca2+/CaM dependent Kinases (CaMK). It is likely that a disruption 
of Cn/NFATc2 signaling may be compensated by a parallel branch of the Ca2+/CaM 
140 
 
pathway. Transgenic mice overexpressing CaMK II in the heart are subject to cardiac 
hypertrophy, which is likely caused by increased nuclear export and dissociation of class 
II Histone Deacetylases (HDAC) from the DNA, allowing the Myocyte Enhancer Factor 
2 (MEF2) and other transcription factors to bind DNA more readily to compensate for the 
absence of NFATc2 [171, 285, 315, 316]. 
 All these data collectively will help explain the role of NFATc2 in Cn-mediated 
cardiac hypertrophy in normal hearts and following biochemical stress, which leads to 









































 The Ca2+/calmodulin-dependent phosphatase, Calcineurin (Cn) and its 
downstream transcriptional target, the Nuclear Factor of Activated T cells (NFAT) play a 
major role in controlling a variety of muscle diseases. Strategies that aim to control the 
amount of Cn may be of great value in identifying novel pharmacological targets for the 
treatment of muscle disorders. This research provides new insights into understanding 
different mechanisms by which Cn regulates and affects muscle diseases. The 
involvement of the Cn/NFAT pathway in Duchenne Muscular Dystrophy (DMD) has 
been thoroughly discussed in previous studies. These studies manipulated the activity of 
Cn, using several transgenic models that target either Cn or calmodulin [98, 106]. 
However, the study presented here is the first that shows manipulation of Ca2+ kinetics 
and the effect of such manipulation on Cn activity as well as on the expression of 
important genes such as utrophin. We provide information about the expression of other 
proteins including the Heat Shock Protein 70 (HSP70) in mdx and mdx crossbreeds. This 
protein recently has been shown to be involved in ameliorating the symptoms of DMD in 
the absence of utrophin [150]. Our results show no correlation between utrophin and 
HSP70 suggesting that the two proteins are regulated by different mechanisms. This 
looks exciting, as it shows the possibility that other pathways are involved in the 
regulation of DMD. Thus, targeting more than one pathway might be a more effective 
countermeasure for treating muscle dystrophy. Additionally, understanding the roles of 
various Cn modulators will help to clarify what is still unknown about this disease. 
Figure 5.1 illustrates the three transgenes used in this thesis and shows the effect of the 
PV transgene on the Cn/NFAT pathway. It also shows that HSP70 does not work through 




Figure 5.1: Schematic diagram showing the three transgenes used to manipulate the 
Cn/NFAT pathway and showing the effect of HSP70 on DMD 
 
 In addition, our research provides evidence that normal Cn/NFAT signaling has a 
crucial role in the function of the adult heart. Thus, it is not the high Cn activity that 
causes deterioration in cardiac hypertrophy, but the inability to adapt to and utilize high 
Cn levels. In accordance, we provide new insights toward understanding the importance 
of the Cn/NFAT pathway in the adult heart. Interestingly, our study might help in 


























 As it is one of the crucial Ca2+ signaling pathways involved in muscle diseases, it 
is important to continue research involving the Cn/NFAT pathway. This will lead to a 
better understanding of the regulation of Cn and its modulators in muscle disorders. In 
this manuscript-based thesis, we dealt with two important muscle diseases: Duchenne 
muscular dystrophy and cardiac hypertrophy, in which Cn and its effectors play a major 
role in their progression. The results of the second chapter (First manuscript): "Distinct 
calcineurin-related transgenic approaches rescue or exacerbate the dystrophic phenotype 
in fibers from crossbred mdx mice despite constant HSP70 expression" are completed and 
ready for submission to one of the most effective journals in the field such as The FASEB 
Journal, which has many contributions to health. As our results showed that utrophin-A 
and HSP70 are regulated by different mechanisms, I believe the next manuscript should 
involve research on the pathways that might be regulating HSP70 as well as other HSP 
isoforms, which also might have roles in muscle dystrophy. Suggestions for such 
pathways are included in the discussion of Chapter 2 in this thesis. 
 Similarly, the results of the fourth chapter (Third manuscript): "The role of 
NFATc2 transcription factor in Calcineurin-dependent cardiac hypertrophy in adult mice" 
are completed and ready for submission to one of the important cardiology journals such 
as the Journal of Molecular and Cellular Cardiology. Since our work investigates the 
role of the NFATc2 transcription factor and since little is known about the role of 
NFATc3 in the heart, it would be interesting for the next manuscript to involve research 
on the role of the double knockout model NFATc2c3-/- in the hearts of adult mice. In our 
laboratory, we already have this model and mice are being bred continuously. 
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 The third chapter of this thesis (Second manuscript): "Direct calcineurin 
modulators regulate calcineurin/NFAT signaling in mdx crossbreeds" is a manuscript in 
preparation, which needs a lot of work to be finalized for publication. Our preliminary 
results confirm the dual regulation of RCAN for Cn, which was observed earlier by the 
Olson group while they investigated the role of RCAN1 in cardiac hypertrophy [261]. 
However, RCAN could be phosphorylated by different kinases, which might affect its 
stability. Therefore, it would be interesting to explore those kinases and study how 
phosphorylation affects both the expression and stability of RCAN. Since our results 
might be correlated to the time the expression of RCAN was measured, as mentioned in 
the discussion of Chapter 3, it might be worth measuring RCAN expression in different 
time points; during development, in young and in adult mice. Additionally, the knockout 
of the RCAN gene in mdx mice, with either impaired Cn activity such as mdx/PV or 
stimulated Cn activity such as mdx/CnA*, might better reveal the role of RCAN in the 
Cn/NFAT pathway. 
 Similar to RCAN, mice lacking calsarcin-1 crossed with CnA* mice show an 
enhanced hypertrophic response [262], suggesting a cardio-protective role for calsarcin-1. 
Since calsarcins can shuttle to the nucleus [194], investigating whether they interact with 
NFAT in the nucleus might explain the current results. Moreover, Vondrisk's group has 
documented phosphorylation and post-translational processing of calsarcin-1 during heart 
diseases [265], which is worth looking into in the future. 
 Since MLP is suggested to negatively regulate skeletal and cardiac myofiber 
responses [196], it is thus essential to study the proteins that possibly interact and affect 
MLP. In this context, it is noteworthy that the fast muscle EDL was used in the qPCR 
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reactions of MLP in WT, CnA*, mdx and mdx/CnA* mice, whereas the fast muscle TA 
was used for the immunoblotting reactions in the same mice. Therefore, it would be 
important to replicate those experiments using the same type of muscle, in case there is 
any discrepancy between EDL and TA tissues.  
 Finally, it has been shown that CAIN works in a negative regulatory loop and 
becomes hyperphosphorylated upon activation of PKC, which in turn affects Cn activity 
(reviewed in [192]). Further, it was suggested that CAIN competes with NFAT or other 
substrates of Cn [192]. Therefore, it is worth studying the expression and binding of 
CAIN with other transcription factors. This might help in understanding how this protein 
works to inhibit and regulate Cn. 
 As discussed earlier in Chapter 3, research is continuing to overexpress and/or 
knockdown the genes encoding Cn modulators in order to understand their roles in 
muscle diseases particularly in muscle dystrophy. The objective of this research would be 
of great value to show the importance of inhibiting Cn modulators that inhibit Cn 
activity. Consequently, inhibiting the inhibitors will maintain effective Cn levels, which 
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Appendix I: Chapter 2- Statistical Analyses 
 
QPCR 
1) MyHC I in PV models: 
t-Test: Two-Sample Assuming Equal Variances 






Mean 4.347084 3.560541 
Variance 9.187562 11.06789 
Observations 4 4 
Pooled Variance 10.12773 
 Hypothesized Mean 
Difference 0 
 df 6 
 t Stat 0.349528 
 P(T<=t) one-tail 0.369317 
 t Critical one-tail 1.94318 
 P(T<=t) two-tail 0.738634 





2) MyHC IIa in PV models: 
t-Test: Two-Sample Assuming Equal Variances 
   




Mean 2.7895737 1.7791748 
Variance 2.542547 0.3444196 
Observations 4 4 




df 6  
t Stat 1.189329  
P(T<=t) one-tail 0.1396188  
t Critical one-tail 1.9431803  
P(T<=t) two-tail 0.2792377  
t Critical two-tail 2.4469118   
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WT Sol 4 5.7668 2.08676 1.04338 2.4463 9.0873 3.48 8.10 
PV Sol 4 1.5737 .44372 .22186 .8676 2.2798 1.00 2.03 
mdx Sol 4 10.9832 5.36512 2.68256 2.4461 19.5202 3.68 16.03 
mdx/PV Sol 4 3.5978 2.42721 1.21360 -.2644 7.4601 1.29 6.98 
WT EDL 3 1.7236 .62987 .36365 .1589 3.2883 1.00 2.15 
PV EDL 3 4.3659 .70876 .40920 2.6052 6.1266 3.80 5.16 
mdx EDL 3 3.0469 .62411 .36033 1.4965 4.5972 2.36 3.59 
mdx/PV EDL 3 3.6411 2.40612 1.38918 -2.3361 9.6182 1.24 6.05 
Total 28 4.5007 3.72985 .70487 3.0544 5.9469 1.00 16.03 
 
 
Test of Homogeneity of Variances 
Utrophin 
Levene Statistic df1 df2 Sig. 





 Sum of Squares df Mean Square F Sig. 
Between Groups 243.780 7 34.826 5.283 .002 
Within Groups 131.838 20 6.592   









Dependent Variable: Utrophin 
(I) Genotype (J) Genotype Mean 
Difference (I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT Sol 
PV Sol 4.19311* 1.81547 .032 .4061 7.9801 
mdx Sol -5.21634* 1.81547 .009 -9.0033 -1.4293 
mdx/PV Sol 2.16898 1.81547 .246 -1.6180 5.9560 
WT EDL 4.04320 1.96094 .052 -.0472 8.1336 
PV EDL 1.40093 1.96094 .483 -2.6895 5.4914 
mdx EDL 2.71996 1.96094 .181 -1.3705 6.8104 
mdx/PV EDL 2.12574 1.96094 .291 -1.9647 6.2162 
PV Sol 
WT Sol -4.19311* 1.81547 .032 -7.9801 -.4061 
mdx Sol -9.40945* 1.81547 .000 -13.1965 -5.6224 
mdx/PV Sol -2.02413 1.81547 .278 -5.8111 1.7629 
WT EDL -.14992 1.96094 .940 -4.2404 3.9405 
PV EDL -2.79219 1.96094 .170 -6.8826 1.2983 
mdx EDL -1.47315 1.96094 .461 -5.5636 2.6173 
mdx/PV EDL -2.06737 1.96094 .304 -6.1578 2.0231 
mdx Sol 
WT Sol 5.21634* 1.81547 .009 1.4293 9.0033 
PV Sol 9.40945* 1.81547 .000 5.6224 13.1965 
mdx/PV Sol 7.38532* 1.81547 .001 3.5983 11.1723 
WT EDL 9.25953* 1.96094 .000 5.1691 13.3500 
PV EDL 6.61726* 1.96094 .003 2.5268 10.7077 
mdx EDL 7.93630* 1.96094 .001 3.8459 12.0267 
mdx/PV EDL 7.34208* 1.96094 .001 3.2516 11.4325 
mdx/PV Sol 
WT Sol -2.16898 1.81547 .246 -5.9560 1.6180 
PV Sol 2.02413 1.81547 .278 -1.7629 5.8111 
mdx Sol -7.38532* 1.81547 .001 -11.1723 -3.5983 
WT EDL 1.87421 1.96094 .351 -2.2162 5.9647 
PV EDL -.76806 1.96094 .699 -4.8585 3.3224 
mdx EDL .55098 1.96094 .782 -3.5395 4.6414 
mdx/PV EDL -.04324 1.96094 .983 -4.1337 4.0472 
 
WT EDL 
WT Sol -4.04320 1.96094 .052 -8.1336 .0472 
PV Sol .14992 1.96094 .940 -3.9405 4.2404 
mdx Sol -9.25953* 1.96094 .000 -13.3500 -5.1691 
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mdx/PV Sol -1.87421 1.96094 .351 -5.9647 2.2162 
PV EDL -2.64227 2.09633 .222 -7.0151 1.7306 
mdx EDL -1.32323 2.09633 .535 -5.6961 3.0496 
mdx/PV EDL -1.91745 2.09633 .371 -6.2903 2.4554 
PV EDL 
WT Sol -1.40093 1.96094 .483 -5.4914 2.6895 
PV Sol 2.79219 1.96094 .170 -1.2983 6.8826 
mdx Sol -6.61726* 1.96094 .003 -10.7077 -2.5268 
mdx/PV Sol .76806 1.96094 .699 -3.3224 4.8585 
WT EDL 2.64227 2.09633 .222 -1.7306 7.0151 
mdx EDL 1.31904 2.09633 .536 -3.0538 5.6919 
mdx/PV EDL .72482 2.09633 .733 -3.6480 5.0977 
mdx EDL 
WT Sol -2.71996 1.96094 .181 -6.8104 1.3705 
PV Sol 1.47315 1.96094 .461 -2.6173 5.5636 
mdx Sol -7.93630* 1.96094 .001 -12.0267 -3.8459 
mdx/PV Sol -.55098 1.96094 .782 -4.6414 3.5395 
WT EDL 1.32323 2.09633 .535 -3.0496 5.6961 
PV EDL -1.31904 2.09633 .536 -5.6919 3.0538 
mdx/PV EDL -.59422 2.09633 .780 -4.9671 3.7786 
mdx/PV EDL 
WT Sol -2.12574 1.96094 .291 -6.2162 1.9647 
PV Sol 2.06737 1.96094 .304 -2.0231 6.1578 
mdx Sol -7.34208* 1.96094 .001 -11.4325 -3.2516 
mdx/PV Sol .04324 1.96094 .983 -4.0472 4.1337 
WT EDL 1.91745 2.09633 .371 -2.4554 6.2903 
PV EDL -.72482 2.09633 .733 -5.0977 3.6480 
mdx EDL .59422 2.09633 .780 -3.7786 4.9671 
*. The mean difference is significant at the 0.05 level. 
Note: WT soleus and WT EDL were compared using student-t-test as done earlier [242]. 
t-Test: Two-Sample Assuming Equal Variances 






 Mean 5.766813 1.72362 
 Variance 4.354566 0.39673 




Pooled Variance 2.771431 
  Hypothesized Mean 
Difference 0 
  df 5 
  t Stat 3.179904 
  P(T<=t) one-tail 0.01227 
  t Critical one-tail 2.015048 
  P(T<=t) two-tail 0.024541 
  t Critical two-tail 2.570582   
  
4) Utrophin-A levels in PV models: 
Descriptives 
Utrophin-A 











WT Sol 4 6.3575 1.17266 .58633 4.4916 8.2235 5.03 7.39 
PV Sol 4 3.4053 2.77895 1.38947 -1.0166 7.8272 1.00 7.41 
mdx Sol 4 65.7969 57.17105 28.58553 -25.1750 156.7688 8.80 125.92 
mdx/PV Sol 4 8.9390 3.45650 1.72825 3.4389 14.4390 4.81 12.70 
WT EDL 3 1.5327 .69911 .40363 -.2040 3.2694 1.00 2.32 
PV EDL 3 3.1684 .67708 .39091 1.4865 4.8504 2.71 3.95 
mdx EDL 3 3.5022 .76854 .44371 1.5930 5.4113 2.83 4.34 
mdx/PV EDL 3 4.3730 2.17575 1.25617 -1.0318 9.7779 2.18 6.53 
Total 28 13.4187 29.06918 5.49356 2.1469 24.6906 1.00 125.92 
 
Test of Homogeneity of Variances 
Utrophin-A 
Levene Statistic df1 df2 Sig. 




 Sum of Squares df Mean Square F Sig. 
Between Groups 12934.202 7 1847.743 3.740 .009 
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Within Groups 9881.266 20 494.063   




Dependent Variable: Utrophin-A 
(I) Genotype (J) Genotype Mean 
Difference (I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT Sol 
PV Sol 2.95221 15.71724 .853 -29.8334 35.7378 
mdx Sol -59.43936* 15.71724 .001 -92.2249 -26.6538 
mdx/PV Sol -2.58144 15.71724 .871 -35.3670 30.2041 
WT EDL 4.82484 16.97656 .779 -30.5876 40.2373 
PV EDL 3.18910 16.97656 .853 -32.2234 38.6016 
mdx EDL 2.85537 16.97656 .868 -32.5571 38.2678 
mdx/PV EDL 1.98450 16.97656 .908 -33.4280 37.3970 
PV Sol 
WT Sol -2.95221 15.71724 .853 -35.7378 29.8334 
mdx Sol -62.39157* 15.71724 .001 -95.1772 -29.6060 
mdx/PV Sol -5.53365 15.71724 .728 -38.3192 27.2519 
WT EDL 1.87263 16.97656 .913 -33.5399 37.2851 
PV EDL .23689 16.97656 .989 -35.1756 35.6494 
mdx EDL -.09684 16.97656 .996 -35.5093 35.3156 
mdx/PV EDL -.96771 16.97656 .955 -36.3802 34.4448 
mdx Sol 
WT Sol 59.43936* 15.71724 .001 26.6538 92.2249 
PV Sol 62.39157* 15.71724 .001 29.6060 95.1772 
mdx/PV Sol 56.85792* 15.71724 .002 24.0723 89.6435 
WT EDL 64.26420* 16.97656 .001 28.8517 99.6767 
PV EDL 62.62846* 16.97656 .001 27.2160 98.0409 
mdx EDL 62.29472* 16.97656 .002 26.8822 97.7072 
mdx/PV EDL 61.42386* 16.97656 .002 26.0114 96.8363 
mdx/PV Sol 
WT Sol 2.58144 15.71724 .871 -30.2041 35.3670 
PV Sol 5.53365 15.71724 .728 -27.2519 38.3192 
mdx Sol -56.85792* 15.71724 .002 -89.6435 -24.0723 
WT EDL 7.40628 16.97656 .667 -28.0062 42.8188 
PV EDL 5.77054 16.97656 .737 -29.6419 41.1830 
mdx EDL 5.43681 16.97656 .752 -29.9757 40.8493 
mdx/PV EDL 4.56594 16.97656 .791 -30.8465 39.9784 
WT EDL 
WT Sol -4.82484 16.97656 .779 -40.2373 30.5876 
PV Sol -1.87263 16.97656 .913 -37.2851 33.5399 
mdx Sol -64.26420* 16.97656 .001 -99.6767 -28.8517 
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mdx/PV Sol -7.40628 16.97656 .667 -42.8188 28.0062 
PV EDL -1.63574 18.14871 .929 -39.4933 36.2218 
mdx EDL -1.96948 18.14871 .915 -39.8270 35.8881 
mdx/PV EDL -2.84034 18.14871 .877 -40.6979 35.0172 
PV EDL 
WT Sol -3.18910 16.97656 .853 -38.6016 32.2234 
PV Sol -.23689 16.97656 .989 -35.6494 35.1756 
mdx Sol -62.62846* 16.97656 .001 -98.0409 -27.2160 
mdx/PV Sol -5.77054 16.97656 .737 -41.1830 29.6419 
WT EDL 1.63574 18.14871 .929 -36.2218 39.4933 
mdx EDL -.33374 18.14871 .986 -38.1913 37.5238 
mdx/PV EDL -1.20460 18.14871 .948 -39.0621 36.6529 
mdx EDL 
WT Sol -2.85537 16.97656 .868 -38.2678 32.5571 
PV Sol .09684 16.97656 .996 -35.3156 35.5093 
mdx Sol -62.29472* 16.97656 .002 -97.7072 -26.8822 
mdx/PV Sol -5.43681 16.97656 .752 -40.8493 29.9757 
WT EDL 1.96948 18.14871 .915 -35.8881 39.8270 
PV EDL .33374 18.14871 .986 -37.5238 38.1913 
mdx/PV EDL -.87086 18.14871 .962 -38.7284 36.9867 
mdx/PV EDL 
WT Sol -1.98450 16.97656 .908 -37.3970 33.4280 
PV Sol .96771 16.97656 .955 -34.4448 36.3802 
mdx Sol -61.42386* 16.97656 .002 -96.8363 -26.0114 
mdx/PV Sol -4.56594 16.97656 .791 -39.9784 30.8465 
WT EDL 2.84034 18.14871 .877 -35.0172 40.6979 
PV EDL 1.20460 18.14871 .948 -36.6529 39.0621 
mdx EDL .87086 18.14871 .962 -36.9867 38.7284 
*. The mean difference is significant at the 0.05 level. 
 
Note: WT soleus and WT EDL were compared using student-t-test 
t-Test: Two-Sample Assuming Equal Variances 






  Mean 6.357532 1.53269 
  Variance 1.375136 0.488754 
  Observations 4 3 
  Pooled Variance 1.020583 
   Hypothesized Mean 
Difference 0 
   df 5 
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t Stat 6.253174 
   P(T<=t) one-tail 0.000767 
   t Critical one-tail 2.015048 
   P(T<=t) two-tail 0.001533 
   t Critical two-tail 2.570582   
   
 Immunoblotting 
 








95% Confidence Interval for 
Mean 
Minimum Maximum 
Lower Bound Upper Bound 
WT 3 .8433 .27140 .15669 .1691 1.5175 .53 1.00 
PV 3 .4938 .02136 .01233 .4407 .5468 .48 .52 
mdx 3 1.5498 .48699 .28116 .3400 2.7595 .99 1.88 
mdx/PV 3 .8590 .09638 .05564 .6196 1.0984 .75 .92 
Total 12 .9365 .46724 .13488 .6396 1.2333 .48 1.88 
 
 
Test of Homogeneity of Variances 
Utrophin 
Levene Statistic df1 df2 Sig. 





 Sum of Squares df Mean Square F Sig. 
Between Groups 1.760 3 .587 7.322 .011 
Within Groups .641 8 .080   







Dependent Variable: Utrophin 
(I) Genotype (J) Genotype Mean 
Difference (I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT 
PV .34955 .23114 .169 -.1835 .8826 
Mdx -.70645* .23114 .016 -1.2395 -.1734 
mdx/PV -.01572 .23114 .947 -.5487 .5173 
PV 
WT -.34955 .23114 .169 -.8826 .1835 
Mdx -1.05600* .23114 .002 -1.5890 -.5230 
mdx/PV -.36528 .23114 .153 -.8983 .1677 
mdx 
WT .70645* .23114 .016 .1734 1.2395 
PV 1.05600* .23114 .002 .5230 1.5890 
mdx/PV .69072* .23114 .017 .1577 1.2237 
mdx/PV 
WT .01572 .23114 .947 -.5173 .5487 
PV .36528 .23114 .153 -.1677 .8983 
Mdx -.69072* .23114 .017 -1.2237 -.1577 
*. The mean difference is significant at the 0.05 level. 
 
 








95% Confidence Interval for 
Mean 
Minimum Maximum 
Lower Bound Upper Bound 
WT 3 1.0361 .06257 .03612 .8807 1.1915 1.00 1.11 
PV 3 .5058 .42134 .24326 -.5409 1.5524 .26 .99 
mdx 3 .8315 .77486 .44737 -1.0934 2.7564 .37 1.73 
mdx/PV 3 1.1735 .51492 .29729 -.1056 2.4527 .59 1.57 







Test of Homogeneity of Variances 
HSP70 
Levene Statistic df1 df2 Sig. 





 Sum of Squares df Mean Square F Sig. 
Between Groups .758 3 .253 .966 .455 
Within Groups 2.094 8 .262   




Dependent Variable: HSP70 
(I) Genotype (J) Genotype Mean 
Difference (I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT 
PV .53034 .41773 .240 -.4330 1.4936 
mdx .20463 .41773 .637 -.7587 1.1679 
mdx/PV -.13741 .41773 .751 -1.1007 .8259 
PV 
WT -.53034 .41773 .240 -1.4936 .4330 
mdx -.32572 .41773 .458 -1.2890 .6376 
mdx/PV -.66775 .41773 .149 -1.6310 .2955 
mdx 
WT -.20463 .41773 .637 -1.1679 .7587 
PV .32572 .41773 .458 -.6376 1.2890 
mdx/PV -.34204 .41773 .437 -1.3053 .6213 
mdx/PV 
WT .13741 .41773 .751 -.8259 1.1007 
PV .66775 .41773 .149 -.2955 1.6310 
mdx .34204 .41773 .437 -.6213 1.3053 
 
3) RyR1 levels in PV models: 
Note: Multiple student t-tests were performed for RyR1, which is 565 kDa in size since PV, mdx 
and mdx/PV were normalized to WT in each set. Thus, the loading control tubulin (52 kDa) of 




t-Test: Two-Sample Assuming Equal Variances 






Mean 1 2.077784 
Variance 0 0.487075 
Observations 4 4 
Pooled Variance 0.243537 
 Hypothesized Mean 
Difference 0 
 df 6 
 t Stat -3.08862 
 P(T<=t) one-tail 0.010713 
 t Critical one-tail 1.94318 
 P(T<=t) two-tail 0.021426 
 t Critical two-tail 2.446912   
 
t-Test: Two-Sample Assuming Equal Variances 






Mean 2.077784 0.766988 
Variance 0.487075 0.146738 
Observations 4 4 
Pooled Variance 0.316907 
 Hypothesized Mean 
Difference 0 
 df 6 
 t Stat 3.292945 
 P(T<=t) one-tail 0.008276 
 t Critical one-tail 1.94318 
 P(T<=t) two-tail 0.016553 
 t Critical two-tail 2.446912   
 
t-Test: Two-Sample Assuming Equal Variances 






Mean 0.766988 2.258649 
Variance 0.146738 1.388342 
Observations 4 4 






 Df 6 
 t Stat -2.40788 
 P(T<=t) one-tail 0.026363 
 t Critical one-tail 1.94318 
 P(T<=t) two-tail 0.052726 
 t Critical two-tail 2.446912   
 








95% Confidence Interval for 
Mean 
Minimum Maximum 
Lower Bound Upper Bound 
WT 4 .9873 .02531 .01266 .9471 1.0276 .95 1.00 
PV 4 .8079 .11643 .05821 .6226 .9931 .66 .93 
mdx 4 .9195 .18680 .09340 .6223 1.2168 .81 1.20 
mdx/PV 4 .7451 .35198 .17599 .1851 1.3052 .42 1.15 
Total 16 .8650 .20996 .05249 .7531 .9768 .42 1.20 
 
 
Test of Homogeneity of Variances 
SERCA1 
Levene Statistic df1 df2 Sig. 




 Sum of Squares df Mean Square F Sig. 
Between Groups .142 3 .047 1.097 .388 
Within Groups .519 12 .043   








Dependent Variable: SERCA1 
(I) Genotype (J) Genotype Mean 
Difference (I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT 
PV .17948 .14705 .246 -.1409 .4999 
mdx .06782 .14705 .653 -.2526 .3882 
mdx/PV .24221 .14705 .125 -.0782 .5626 
PV 
WT -.17948 .14705 .246 -.4999 .1409 
mdx -.11165 .14705 .462 -.4320 .2087 
mdx/PV .06273 .14705 .677 -.2577 .3831 
mdx 
WT -.06782 .14705 .653 -.3882 .2526 
PV .11165 .14705 .462 -.2087 .4320 
mdx/PV .17438 .14705 .259 -.1460 .4948 
mdx/PV 
WT -.24221 .14705 .125 -.5626 .0782 
PV -.06273 .14705 .677 -.3831 .2577 
mdx -.17438 .14705 .259 -.4948 .1460 
 
 








95% Confidence Interval for 
Mean 
Minimum Maximum 
Lower Bound Upper Bound 
WT 4 1.2974 .38869 .19434 .6790 1.9159 1.00 1.82 
PV 4 1.2902 .40498 .20249 .6458 1.9346 .86 1.69 
mdx 4 .7905 .04704 .02352 .7156 .8653 .74 .84 
mdx/PV 4 .9930 .48135 .24067 .2271 1.7589 .62 1.70 
Total 16 1.0928 .39797 .09949 .8807 1.3048 .62 1.82 
 
Test of Homogeneity of Variances 
SERCA2 
Levene Statistic df1 df2 Sig. 






 Sum of Squares df Mean Square F Sig. 
Between Groups .729 3 .243 1.770 .206 
Within Groups 1.647 12 .137   




Dependent Variable: SERCA2 
(I) Genotype (J) Genotype Mean 
Difference (I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT 
PV .00726 .26196 .978 -.5635 .5780 
mdx .50695 .26196 .077 -.0638 1.0777 
mdx/PV .30444 .26196 .268 -.2663 .8752 
PV 
WT -.00726 .26196 .978 -.5780 .5635 
mdx .49969 .26196 .081 -.0711 1.0705 
mdx/PV .29718 .26196 .279 -.2736 .8679 
mdx 
WT -.50695 .26196 .077 -1.0777 .0638 
PV -.49969 .26196 .081 -1.0705 .0711 
mdx/PV -.20251 .26196 .454 -.7733 .3683 
mdx/PV 
WT -.30444 .26196 .268 -.8752 .2663 
PV -.29718 .26196 .279 -.8679 .2736 
mdx .20251 .26196 .454 -.3683 .7733 
 
6) Total utrophin levels in CnA* models: 
t-Test: Two-Sample Assuming Equal Variances 






Mean 0.842697 1.636483 
Variance 0.081017 0.138693 
Observations 3 3 
Pooled Variance 0.109855 
 Hypothesized Mean 
Difference 0 
 df 4 




P(T<=t) one-tail 0.021339 
 t Critical one-tail 2.131847 
 P(T<=t) two-tail 0.042678 
 t Critical two-tail 2.776445   
 
7) HSP70 levels in CnA* models: 
t-Test: Two-Sample Assuming Equal Variances 






Mean 0.833651 0.870902 
Variance 0.042237 0.04419 
Observations 3 3 
Pooled Variance 0.043213 
 Hypothesized Mean 
Difference 0 
 Df 4 
 t Stat -0.21947 
 P(T<=t) one-tail 0.418514 
 t Critical one-tail 2.131847 
 P(T<=t) two-tail 0.837028 
 t Critical two-tail 2.776445   
 
8) Total utrophin levels in CaMBP models: 
Note: The four sets of utrophin were done on separate gels. CaMBP, mdx and mdx/CaMBP were 
normalized to WT in each set and WT was standardized to 1. 
t-Test: Two-Sample Assuming Equal Variances 






Mean 1 0.374818 
Variance 0 0.064136 
Observations 3 3 
Pooled Variance 0.032068 
 Hypothesized Mean 
Difference 0 
 Df 4 
 t Stat 4.275776 
 P(T<=t) one-tail 0.006445 




P(T<=t) two-tail 0.012891 
 t Critical two-tail 2.776445   
 
9) HSP70 levels in CaMBP models: 
t-Test: Two-Sample Assuming Equal Variances 






Mean 0.998953 0.755409 
Variance 0.078827 0.192775 
Observations 3 3 
Pooled Variance 0.135801 
 Hypothesized Mean 
Difference 0 
 Df 4 
 t Stat 0.809416 
 P(T<=t) one-tail 0.231837 
 t Critical one-tail 2.131847 
 P(T<=t) two-tail 0.463674 
 t Critical two-tail 2.776445   
Histology 
1) NFATc1 nuclear localization in PV models: 
 
Descriptives 
NFATc1 nuclear localization 





Interval for Mean 
Minimum Maximum 
Lower Bound Upper 
Bound 
WT 3 32.5795 7.23009 4.17429 14.6189 50.5400 24.24 36.99 
PV 3 9.9939 .84413 .48736 7.8970 12.0908 9.02 10.53 
mdx 3 16.2044 1.40801 .81292 12.7067 19.7021 14.91 17.70 
mdx/PV 3 5.5476 1.86867 1.07888 .9055 10.1896 3.39 6.63 







Test of Homogeneity of Variances 
NFATc1 nuclear localization 
Levene Statistic df1 df2 Sig. 




NFATc1 nuclear localization 
 Sum of Squares df Mean Square F Sig. 
Between Groups 1260.662 3 420.221 28.752 .000 
Within Groups 116.922 8 14.615   




Dependent Variable: NFATc1 nuclear localization 
(I) Genotype (J) Genotype Mean 
Difference (I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT 
PV 22.58558* 3.12146 .000 15.3875 29.7837 
mdx 16.37510* 3.12146 .001 9.1770 23.5732 
mdx/PV 27.03189* 3.12146 .000 19.8338 34.2300 
PV 
WT -22.58558* 3.12146 .000 -29.7837 -15.3875 
mdx -6.21047 3.12146 .082 -13.4086 .9876 
mdx/PV 4.44632 3.12146 .192 -2.7518 11.6444 
mdx 
WT -16.37510* 3.12146 .001 -23.5732 -9.1770 
PV 6.21047 3.12146 .082 -.9876 13.4086 
mdx/PV 10.65679* 3.12146 .009 3.4587 17.8549 
mdx/PV 
WT -27.03189* 3.12146 .000 -34.2300 -19.8338 
PV -4.44632 3.12146 .192 -11.6444 2.7518 
mdx -10.65679* 3.12146 .009 -17.8549 -3.4587 
*. The mean difference is significant at the 0.05 level. 
 
2) Fiber-type proportions in PV models: 




t-Test: Two-Sample Assuming Equal Variances 
(MyHC I) 






Mean 41.04335 44.20607 
Variance 221.0337 50.77086 
Observations 4 4 
Pooled Variance 135.9023 
 Hypothesized Mean 
Difference 0 
 Df 6 
 t Stat -0.38367 
 P(T<=t) one-tail 0.357224 
 t Critical one-tail 1.94318 
 P(T<=t) two-tail 0.714448 
 t Critical two-tail 2.446912   
 
t-Test: Two-Sample Assuming Equal Variances 
(MyHC IIa) 






Mean 50.24074 48.83463 
Variance 282.5569 32.8443 
Observations 4 4 
Pooled Variance 157.7006 
 Hypothesized Mean 
Difference 0 
 Df 6 
 t Stat 0.15835 
 P(T<=t) one-tail 0.439688 
 t Critical one-tail 1.94318 
 P(T<=t) two-tail 0.879376 
 t Critical two-tail 2.446912   
 
t-Test: Two-Sample Assuming Equal Variances 
(MyHC I/IIa co-expression) 






Mean 5.861323 3.74982 
Variance 2.881379 4.278988 
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Observations 4 4 
Pooled Variance 3.580183 
 Hypothesized Mean 
Difference 0 
 df 6 
 t Stat 1.578171 
 P(T<=t) one-tail 0.082801 
 t Critical one-tail 1.94318 
 P(T<=t) two-tail 0.165603 
 t Critical two-tail 2.446912   
 
3) H&E central nucleation in PV models: 
t-Test: Two-Sample Assuming Equal Variances 






Mean 100 120.1314 
Variance 0 15.93319 
Observations 4 4 
Pooled Variance 7.966596 
 Hypothesized Mean 
Difference 0 
 df 6 
 t Stat -10.0868 
 P(T<=t) one-tail 2.76E-05 
 t Critical one-tail 1.94318 
 P(T<=t) two-tail 5.51E-05 
 t Critical two-tail 2.446912   
 
4) H&E size variability in PV models: 
t-Test: Two-Sample Assuming Equal Variances 






Mean 100 144.0923 
Variance 0 757.4866 
Observations 4 4 
Pooled Variance 378.7433 
 Hypothesized Mean 
Difference 0 




t Stat -3.2041 
 P(T<=t) one-tail 0.009252 
 t Critical one-tail 1.943181 
 P(T<=t) two-tail 0.018504 
 t Critical two-tail 2.446914   
 
5) Evan's blue intensity in PV models: 
t-Test: Two-Sample Assuming Equal Variances 






Mean 20.72271 75.96756 
Variance 112.6333 752.357 
Observations 3 3 
Pooled Variance 432.4952 
 Hypothesized Mean 
Difference 0 
 Df 4 
 t Stat -3.25347 
 P(T<=t) one-tail 0.015637 
 t Critical one-tail 2.131847 
 P(T<=t) two-tail 0.031273 
 t Critical two-tail 2.776445   
 















mdx-TypeI +ve 4 10.4374 2.67827 1.33913 6.1757 14.6991 6.47 12.30 
mdx/PV-Type I +ve 3 32.8799 8.14085 4.70012 12.6569 53.1029 25.00 41.26 
mdx-Type I -ve 4 37.6226 9.35807 4.67904 22.7319 52.5134 25.18 47.06 
mdx/PV-Type I -ve 3 43.9219 8.89645 5.13637 21.8219 66.0219 34.27 51.79 





Test of Homogeneity of Variances 
Central nucleation 
Levene Statistic df1 df2 Sig. 




 Sum of Squares df Mean Square F Sig. 
Between Groups 2369.042 3 789.681 13.732 .001 
Within Groups 575.080 10 57.508   





Dependent Variable: Central nucleation 










mdx-Type I +ve 
mdx/PV-Type I +ve -22.44251* 5.79192 .003 -35.3477 -9.5373 
mdx-Type I -ve -27.18525* 5.36228 .000 -39.1331 -15.2373 
mdx/PV-Type I -ve -33.48452* 5.79192 .000 -46.3897 -20.5793 
mdx/PV-Type I +ve 
mdx-TypeI +ve 22.44251* 5.79192 .003 9.5373 35.3477 
mdx-Type I -ve -4.74274 5.79192 .432 -17.6479 8.1625 
mdx/PV-Type I -ve -11.04201 6.19182 .105 -24.8383 2.7542 
mdx-Type I -ve 
mdx-TypeI +ve 27.18525* 5.36228 .000 15.2373 39.1331 
mdx/PV-Type I +ve 4.74274 5.79192 .432 -8.1625 17.6479 
mdx/PV-Type I -ve -6.29927 5.79192 .302 -19.2045 6.6059 
mdx/PV-Type I -ve 
mdx-TypeI +ve 33.48452* 5.79192 .000 20.5793 46.3897 
mdx/PV-Type I +ve 11.04201 6.19182 .105 -2.7542 24.8383 
mdx-Type I -ve 6.29927 5.79192 .302 -6.6059 19.2045 






Appendix II: Chapter 3- Statistical Analyses 
 
QPCR 








95% Confidence Interval for 
Mean 
Minimum Maximum 
Lower Bound Upper Bound 
WT 4 1.3785 .37520 .18760 .7815 1.9755 1.00 1.87 
PV 4 3.5689 1.02850 .51425 1.9323 5.2055 2.57 4.87 
mdx 4 3.4565 1.58098 .79049 .9408 5.9722 1.99 5.25 
mdx/PV 4 6.9215 3.32524 1.66262 1.6303 12.2127 4.10 11.74 
Total 16 3.8314 2.67540 .66885 2.4057 5.2570 1.00 11.74 
 
Test of Homogeneity of Variances 
RCAN1.4 
Levene Statistic df1 df2 Sig. 




 Sum of Squares df Mean Square F Sig. 
Between Groups 63.100 3 21.033 5.702 .012 
Within Groups 44.266 12 3.689   




Dependent Variable: RCAN1.4 
(I) Genotype (J) Genotype Mean 
Difference (I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT 
PV -2.19041 1.35809 .133 -5.1494 .7686 
mdx -2.07802 1.35809 .152 -5.0371 .8810 




WT 2.19041 1.35809 .133 -.7686 5.1494 
mdx .11238 1.35809 .935 -2.8466 3.0714 
mdx/PV -3.35263* 1.35809 .030 -6.3117 -.3936 
mdx 
WT 2.07802 1.35809 .152 -.8810 5.0371 
PV -.11238 1.35809 .935 -3.0714 2.8466 
mdx/PV -3.46501* 1.35809 .025 -6.4240 -.5060 
mdx/PV 
WT 5.54303* 1.35809 .002 2.5840 8.5021 
PV 3.35263* 1.35809 .030 .3936 6.3117 
mdx 3.46501* 1.35809 .025 .5060 6.4240 
*. The mean difference is significant at the 0.05 level. 
2) RCAN1.4 levels in EDL muscles of PV models: Kriskal Wallis non-parametric test: 
 
 N Mean Std. 
Deviation 
WT 3 3.2623 .87256 
PV 3 1.4077 .50373 
mdx 3 5.7770 1.93515 
mdx/PV 3 4.3927 2.80839 





























WT 4 4.3679 3.89354 1.94677 -1.8276 10.5634 1.00 9.98 
PV 4 8.8391 4.17848 2.08924 2.1902 15.4880 5.80 15.02 
mdx 4 28.7825 26.67746 13.33873 -13.6673 71.2323 3.92 51.88 
mdx/PV 4 35.3554 21.32983 10.66492 1.4149 69.2959 10.92 58.22 
Total 16 19.3362 20.52341 5.13085 8.4001 30.2724 1.00 58.22 
 
Test of Homogeneity of Variances 
Calsarcin-1 
Levene Statistic df1 df2 Sig. 




 Sum of Squares df Mean Square F Sig. 
Between Groups 2720.352 3 906.784 3.024 .071 
Within Groups 3597.804 12 299.817   




















PV -4.47127 12.24371 .721 -31.1480 22.2055 
mdx -24.41467 12.24371 .069 -51.0914 2.2621 
mdx/PV -30.98756* 12.24371 .026 -57.6643 -4.3108 
PV 
WT 4.47127 12.24371 .721 -22.2055 31.1480 
mdx -19.94340 12.24371 .129 -46.6202 6.7334 




WT 24.41467 12.24371 .069 -2.2621 51.0914 
PV 19.94340 12.24371 .129 -6.7334 46.6202 
mdx/PV -6.57289 12.24371 .601 -33.2496 20.1039 
mdx/PV 
WT 30.98756* 12.24371 .026 4.3108 57.6643 
PV 26.51629 12.24371 .051 -.1605 53.1930 
mdx 6.57289 12.24371 .601 -20.1039 33.2496 
*. The mean difference is significant at the 0.05 level. 
 








95% Confidence Interval for 
Mean 
Minimum Maximum 
Lower Bound Upper Bound 
WT 3 3.8617 3.48453 2.01180 -4.7943 12.5178 1.00 7.74 
PV 3 2.6053 1.22637 .70805 -.4412 5.6518 1.86 4.02 
mdx 3 8.6736 9.70529 5.60335 -15.4357 32.7829 2.76 19.87 
mdx/PV 3 6.5238 5.56433 3.21256 -7.2988 20.3463 2.24 12.81 
Total 12 5.4161 5.59274 1.61448 1.8626 8.9696 1.00 19.87 
 
Test of Homogeneity of Variances 
Calsarcin-1 
Levene Statistic df1 df2 Sig. 




 Sum of Squares df Mean Square F Sig. 
Between Groups 66.465 3 22.155 .638 .611 
Within Groups 277.601 8 34.700   
























PV 1.25641 4.80972 .801 -9.8348 12.3476 
mdx -4.81190 4.80972 .346 -15.9031 6.2793 
mdx/PV -2.66205 4.80972 .595 -13.7533 8.4292 
PV 
WT -1.25641 4.80972 .801 -12.3476 9.8348 
mdx -6.06831 4.80972 .243 -17.1595 5.0229 
mdx/PV -3.91845 4.80972 .439 -15.0097 7.1728 
mdx 
WT 4.81190 4.80972 .346 -6.2793 15.9031 
PV 6.06831 4.80972 .243 -5.0229 17.1595 
mdx/PV 2.14985 4.80972 .667 -8.9414 13.2411 
mdx/PV 
WT 2.66205 4.80972 .595 -8.4292 13.7533 
PV 3.91845 4.80972 .439 -7.1728 15.0097 
mdx -2.14985 4.80972 .667 -13.2411 8.9414 
 








95% Confidence Interval for 
Mean 
Minimum Maximum 
Lower Bound Upper Bound 
WT 4 8.5681 3.16846 1.58423 3.5264 13.6098 5.84 12.26 
PV 4 11.2472 2.85125 1.42563 6.7102 15.7842 7.96 14.88 
mdx 4 6.5623 4.81832 2.40916 -1.1047 14.2293 1.00 12.61 
mdx/PV 4 6.6709 4.21651 2.10825 -.0385 13.3803 1.98 11.49 
Total 16 8.2621 3.95975 .98994 6.1521 10.3721 1.00 14.88 
 
Test of Homogeneity of Variances 
MLP 
Levene Statistic df1 df2 Sig. 







 Sum of Squares df Mean Square F Sig. 
Between Groups 57.703 3 19.234 1.300 .319 
Within Groups 177.492 12 14.791   





















PV -2.67910 2.71946 .344 -8.6043 3.2461 
mdx 2.00580 2.71946 .475 -3.9194 7.9310 
mdx/PV 1.89722 2.71946 .499 -4.0280 7.8224 
PV 
WT 2.67910 2.71946 .344 -3.2461 8.6043 
mdx 4.68490 2.71946 .111 -1.2403 10.6101 
mdx/PV 4.57632 2.71946 .118 -1.3489 10.5015 
mdx 
WT -2.00580 2.71946 .475 -7.9310 3.9194 
PV -4.68490 2.71946 .111 -10.6101 1.2403 
mdx/PV -.10857 2.71946 .969 -6.0338 5.8166 
mdx/PV 
WT -1.89722 2.71946 .499 -7.8224 4.0280 
PV -4.57632 2.71946 .118 -10.5015 1.3489 
mdx .10857 2.71946 .969 -5.8166 6.0338 
 








95% Confidence Interval for 
Mean 
Minimum Maximum 
Lower Bound Upper Bound 
WT 3 2.0069 .99790 .57614 -.4720 4.4858 1.25 3.14 
PV 3 1.9808 1.01490 .58595 -.5403 4.5020 1.00 3.03 
mdx 3 5.4481 2.35989 1.36248 -.4142 11.3104 3.52 8.08 
195 
 
mdx/PV 3 2.9308 2.71433 1.56712 -3.8120 9.6736 1.20 6.06 
Total 12 3.0917 2.21345 .63897 1.6853 4.4980 1.00 8.08 
 
Test of Homogeneity of Variances 
MLP 
Levene Statistic df1 df2 Sig. 




 Sum of Squares df Mean Square F Sig. 
Between Groups 23.968 3 7.989 2.136 .174 
Within Groups 29.925 8 3.741   
Total 53.893 11    
 
Multiple Comparisons 

















PV .02605 1.57916 .987 -3.6155 3.6676 
mdx -3.44122 1.57916 .061 -7.0828 .2003 
mdx/PV -.92394 1.57916 .575 -4.5655 2.7176 
PV 
WT -.02605 1.57916 .987 -3.6676 3.6155 
mdx -3.46727 1.57916 .059 -7.1088 .1743 
mdx/PV -.94999 1.57916 .564 -4.5915 2.6916 
mdx 
WT 3.44122 1.57916 .061 -.2003 7.0828 
PV 3.46727 1.57916 .059 -.1743 7.1088 
mdx/PV 2.51728 1.57916 .150 -1.1243 6.1588 
mdx/PV 
WT .92394 1.57916 .575 -2.7176 4.5655 
PV .94999 1.57916 .564 -2.6916 4.5915 
mdx -2.51728 1.57916 .150 -6.1588 1.1243 
 


















WT 3 6.7756 4.19668 2.42295 -3.6496 17.2007 3.59 11.53 
CnA 3 7.3028 4.81259 2.77855 -4.6523 19.2579 4.42 12.86 
Mdx 3 2.1684 1.01298 .58484 -.3479 4.6848 1.00 2.80 
mdx/CnA 3 2.3387 .66428 .38352 .6885 3.9888 1.65 2.98 
Total 12 4.6464 3.73738 1.07889 2.2717 7.0210 1.00 12.86 
 
Test of Homogeneity of Variances 
RCAN1.4 
Levene Statistic df1 df2 Sig. 




 Sum of Squares df Mean Square F Sig. 
Between Groups 69.167 3 23.056 2.183 .168 
Within Groups 84.481 8 10.560   




















CnA -.52724 2.65332 .847 -6.6458 5.5913 
mdx 4.60711 2.65332 .121 -1.5115 10.7257 
mdx/CnA 4.43689 2.65332 .133 -1.6817 10.5555 
CnA 
WT .52724 2.65332 .847 -5.5913 6.6458 
mdx 5.13435 2.65332 .089 -.9842 11.2529 
mdx/CnA 4.96413 2.65332 .098 -1.1544 11.0827 
Mdx 
WT -4.60711 2.65332 .121 -10.7257 1.5115 
CnA -5.13435 2.65332 .089 -11.2529 .9842 
197 
 
mdx/CnA -.17022 2.65332 .950 -6.2888 5.9483 
mdx/CnA 
WT -4.43689 2.65332 .133 -10.5555 1.6817 
CnA -4.96413 2.65332 .098 -11.0827 1.1544 
mdx .17022 2.65332 .950 -5.9483 6.2888 
 
 















WT 3 5.4847 .28371 .16380 4.7799 6.1895 5.16 5.65 
CnA 3 7.2099 2.65420 1.53240 .6165 13.8033 4.18 9.12 
Mdx 3 6.3149 1.97651 1.14114 1.4050 11.2248 5.09 8.59 
mdx/CnA 3 4.0088 3.67884 2.12398 -5.1299 13.1475 1.00 8.11 
Total 12 5.7546 2.44557 .70598 4.2007 7.3084 1.00 9.12 
 
Test of Homogeneity of Variances 
Calsarcin-2 
Levene Statistic df1 df2 Sig. 




 Sum of Squares df Mean Square F Sig. 
Between Groups 16.658 3 5.553 .904 .481 
Within Groups 49.131 8 6.141   


























CnA -1.72522 2.02343 .419 -6.3913 2.9408 
mdx -.83020 2.02343 .692 -5.4962 3.8358 
mdx/CnA 1.47590 2.02343 .487 -3.1901 6.1419 
CnA 
WT 1.72522 2.02343 .419 -2.9408 6.3913 
mdx .89502 2.02343 .670 -3.7710 5.5611 
mdx/CnA 3.20112 2.02343 .152 -1.4649 7.8672 
Mdx 
WT .83020 2.02343 .692 -3.8358 5.4962 
CnA -.89502 2.02343 .670 -5.5611 3.7710 
mdx/CnA 2.30610 2.02343 .287 -2.3599 6.9721 
mdx/CnA 
WT -1.47590 2.02343 .487 -6.1419 3.1901 
CnA -3.20112 2.02343 .152 -7.8672 1.4649 
mdx -2.30610 2.02343 .287 -6.9721 2.3599 
 















WT 3 7.1036 5.04364 2.91195 -5.4255 19.6327 2.83 12.67 
CnA 3 8.5211 6.04437 3.48972 -6.4939 23.5362 2.91 14.92 
Mdx 3 1.6426 .37522 .21663 .7105 2.5747 1.28 2.03 
mdx/CnA 3 3.0761 2.35078 1.35722 -2.7635 8.9158 1.00 5.63 
Total 12 5.0859 4.57841 1.32167 2.1769 7.9948 1.00 14.92 
 
Test of Homogeneity of Variances 
MLP 
Levene Statistic df1 df2 Sig. 






 Sum of Squares df Mean Square F Sig. 
Between Groups 95.301 3 31.767 1.879 .212 
Within Groups 135.279 8 16.910   




















CnA -1.41753 3.35757 .684 -9.1601 6.3250 
mdx 5.46094 3.35757 .143 -2.2816 13.2035 
mdx/CnA 4.02746 3.35757 .265 -3.7151 11.7700 
CnA 
WT 1.41753 3.35757 .684 -6.3250 9.1601 
mdx 6.87847 3.35757 .075 -.8641 14.6210 
mdx/CnA 5.44499 3.35757 .144 -2.2976 13.1876 
Mdx 
WT -5.46094 3.35757 .143 -13.2035 2.2816 
CnA -6.87847 3.35757 .075 -14.6210 .8641 
mdx/CnA -1.43347 3.35757 .681 -9.1760 6.3091 
mdx/CnA 
WT -4.02746 3.35757 .265 -11.7700 3.7151 
CnA -5.44499 3.35757 .144 -13.1876 2.2976 












95% Confidence Interval for 
Mean 
Minimum Maximum 
Lower Bound Upper Bound 
200 
 
WT 3 1.0531 .09205 .05314 .8245 1.2818 1.00 1.16 
PV 3 1.2222 .64067 .36989 -.3693 2.8138 .81 1.96 
Mdx 3 1.4098 .29933 .17282 .6662 2.1534 1.22 1.76 
mdx/PV 3 .9412 .13483 .07784 .6063 1.2761 .80 1.07 
Total 12 1.1566 .36056 .10408 .9275 1.3857 .80 1.96 
 
 
Test of Homogeneity of Variances 
RCAN1 
Levene Statistic df1 df2 Sig. 




 Sum of Squares df Mean Square F Sig. 
Between Groups .377 3 .126 .953 .460 
Within Groups 1.053 8 .132   
Total 1.430 11    
 
Multiple Comparisons 

















PV -.16911 .29629 .584 -.8523 .5141 
mdx -.35667 .29629 .263 -1.0399 .3266 
mdx/PV .11195 .29629 .715 -.5713 .7952 
PV 
WT .16911 .29629 .584 -.5141 .8523 
mdx -.18756 .29629 .544 -.8708 .4957 
mdx/PV .28106 .29629 .371 -.4022 .9643 
Mdx 
WT .35667 .29629 .263 -.3266 1.0399 
PV .18756 .29629 .544 -.4957 .8708 
mdx/PV .46862 .29629 .152 -.2146 1.1519 
mdx/PV 
WT -.11195 .29629 .715 -.7952 .5713 
PV -.28106 .29629 .371 -.9643 .4022 












95% Confidence Interval for 
Mean 
Minimum Maximum 
Lower Bound Upper Bound 
WT 3 .8144 .32140 .18556 .0160 1.6128 .44 1.00 
PV 3 .6534 .25840 .14919 .0115 1.2953 .43 .94 
Mdx 3 .4972 .20399 .11777 -.0095 1.0039 .36 .73 
mdx/PV 3 .5588 .05656 .03265 .4183 .6993 .51 .62 
Total 12 .6310 .23384 .06751 .4824 .7795 .36 1.00 
 
Test of Homogeneity of Variances 
Calsarcin-1 
Levene Statistic df1 df2 Sig. 





 Sum of Squares df Mean Square F Sig. 
Between Groups .172 3 .057 1.066 .416 
Within Groups .430 8 .054   
Total .602 11    
 
Multiple Comparisons 

















PV .16105 .18924 .419 -.2753 .5974 
mdx .31722 .18924 .132 -.1192 .7536 
mdx/PV .25560 .18924 .214 -.1808 .6920 
PV 
WT -.16105 .18924 .419 -.5974 .2753 
mdx .15617 .18924 .433 -.2802 .5926 




WT -.31722 .18924 .132 -.7536 .1192 
PV -.15617 .18924 .433 -.5926 .2802 
mdx/PV -.06162 .18924 .753 -.4980 .3748 
mdx/PV 
WT -.25560 .18924 .214 -.6920 .1808 
PV -.09455 .18924 .631 -.5309 .3418 
mdx .06162 .18924 .753 -.3748 .4980 
 








95% Confidence Interval for 
Mean 
Minimum Maximum 
Lower Bound Upper Bound 
WT 3 .7881 .36708 .21193 -.1238 1.6999 .36 1.00 
PV 3 .6549 .16122 .09308 .2544 1.0554 .47 .75 
Mdx 3 .7028 .35915 .20736 -.1894 1.5950 .33 1.05 
mdx/PV 3 .6885 .45505 .26272 -.4419 1.8189 .17 1.00 
Total 12 .7086 .30489 .08801 .5148 .9023 .17 1.05 
 
Test of Homogeneity of Variances 
MLP 
Levene Statistic df1 df2 Sig. 




 Sum of Squares df Mean Square F Sig. 
Between Groups .029 3 .010 .078 .970 
Within Groups .994 8 .124   


























PV .13318 .28775 .656 -.5304 .7967 
mdx .08526 .28775 .775 -.5783 .7488 
mdx/PV .09958 .28775 .738 -.5640 .7631 
PV 
WT -.13318 .28775 .656 -.7967 .5304 
mdx -.04791 .28775 .872 -.7115 .6156 
mdx/PV -.03359 .28775 .910 -.6971 .6300 
Mdx 
WT -.08526 .28775 .775 -.7488 .5783 
PV .04791 .28775 .872 -.6156 .7115 
mdx/PV .01432 .28775 .962 -.6492 .6779 
mdx/PV 
WT -.09958 .28775 .738 -.7631 .5640 
PV .03359 .28775 .910 -.6300 .6971 
mdx -.01432 .28775 .962 -.6779 .6492 
 















WT 3 1.0690 .11956 .06903 .7720 1.3660 1.00 1.21 
CnA 3 1.4339 .69304 .40013 -.2877 3.1555 .76 2.14 
mdx 3 1.0275 .53294 .30769 -.2965 2.3514 .60 1.62 
mdx/CnA 3 .7691 .24667 .14241 .1564 1.3819 .59 1.05 
Total 12 1.0749 .46251 .13351 .7810 1.3687 .59 2.14 
 
Test of Homogeneity of Variances 
RCAN1 
Levene Statistic df1 df2 Sig. 






 Sum of Squares df Mean Square F Sig. 
Between Groups .674 3 .225 1.071 .414 
Within Groups 1.679 8 .210   




















CnA -.36490 .37405 .358 -1.2275 .4977 
mdx .04158 .37405 .914 -.8210 .9041 
mdx/CnA .29992 .37405 .446 -.5626 1.1625 
CnA 
WT .36490 .37405 .358 -.4977 1.2275 
mdx .40647 .37405 .309 -.4561 1.2690 
mdx/CnA .66481 .37405 .113 -.1977 1.5274 
mdx 
WT -.04158 .37405 .914 -.9041 .8210 
CnA -.40647 .37405 .309 -1.2690 .4561 
mdx/CnA .25834 .37405 .509 -.6042 1.1209 
mdx/CnA 
WT -.29992 .37405 .446 -1.1625 .5626 
CnA -.66481 .37405 .113 -1.5274 .1977 
mdx -.25834 .37405 .509 -1.1209 .6042 
 















WT 3 1.1512 .26183 .15117 .5007 1.8016 1.00 1.45 
CnA 3 1.4186 .16594 .09581 1.0064 1.8308 1.25 1.58 
205 
 
mdx 3 1.2481 .24137 .13936 .6485 1.8477 1.06 1.52 
mdx/CnA 3 .9326 .13565 .07832 .5957 1.2696 .81 1.08 
Total 12 1.1876 .25505 .07363 1.0256 1.3497 .81 1.58 
 
 
Test of Homogeneity of Variances 
Calsarcin-2 
Levene Statistic df1 df2 Sig. 




 Sum of Squares df Mean Square F Sig. 
Between Groups .370 3 .123 2.856 .105 
Within Groups .346 8 .043   
Total .716 11    
 
Multiple Comparisons 
















CnA -.26742 .16968 .154 -.6587 .1239 
mdx -.09692 .16968 .584 -.4882 .2944 
mdx/CnA .21853 .16968 .234 -.1728 .6098 
CnA 
WT .26742 .16968 .154 -.1239 .6587 
mdx .17050 .16968 .344 -.2208 .5618 
mdx/CnA .48595* .16968 .021 .0947 .8772 
mdx 
WT .09692 .16968 .584 -.2944 .4882 
CnA -.17050 .16968 .344 -.5618 .2208 
mdx/CnA .31545 .16968 .100 -.0758 .7067 
mdx/CnA 
WT -.21853 .16968 .234 -.6098 .1728 
CnA -.48595* .16968 .021 -.8772 -.0947 
mdx -.31545 .16968 .100 -.7067 .0758 
*. The mean difference is significant at the 0.05 level 
















WT 3 1.2190 .37931 .21899 .2767 2.1612 1.00 1.66 
CnA 3 1.1699 .36113 .20850 .2728 2.0670 .90 1.58 
mdx 3 .7720 .02296 .01326 .7150 .8290 .75 .79 
mdx/CnA 3 .7076 .01391 .00803 .6731 .7422 .69 .72 
Total 12 .9671 .32751 .09454 .7590 1.1752 .69 1.66 
 
Test of Homogeneity of Variances 
MLP 
Levene Statistic df1 df2 Sig. 





 Sum of Squares df Mean Square F Sig. 
Between Groups .630 3 .210 3.054 .092 
Within Groups .550 8 .069   
Total 1.180 11    
 
Multiple Comparisons 
















CnA .04912 .21409 .824 -.4446 .5428 
mdx .44699 .21409 .070 -.0467 .9407 
mdx/CnA .51136* .21409 .044 .0177 1.0051 
CnA 
WT -.04912 .21409 .824 -.5428 .4446 
mdx .39787 .21409 .100 -.0958 .8916 
mdx/CnA .46224 .21409 .063 -.0314 .9559 
mdx WT -.44699 .21409 .070 -.9407 .0467 
207 
 
CnA -.39787 .21409 .100 -.8916 .0958 
mdx/CnA .06437 .21409 .771 -.4293 .5581 
mdx/CnA 
WT -.51136* .21409 .044 -1.0051 -.0177 
CnA -.46224 .21409 .063 -.9559 .0314 
mdx -.06437 .21409 .771 -.5581 .4293 















































WT -VE 3 .4679 .16859 .09734 .0491 .8867 .34 .66 
WT +VE 14 days 3 .8566 .16214 .09361 .4538 1.2594 .67 .96 
KO -VE 3 .3856 .11942 .06894 .0889 .6822 .26 .49 
KO +VE 14 days 3 1.2670 .17642 .10186 .8288 1.7053 1.13 1.46 
Total 12 .7443 .38998 .11258 .4965 .9921 .26 1.46 
 
 
Test of Homogeneity of Variances 
β-MyHC 
Levene Statistic df1 df2 Sig. 





 Sum of Squares df Mean Square F Sig. 
Between Groups 1.473 3 .491 19.617 .000 
Within Groups .200 8 .025   








Dependent Variable: β-MyHC  
(I) Genotype (J) Genotype Mean 
Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT -VE 
WT +VE 14 days -.38868* .12916 .017 -.6865 -.0908 
KO -VE .08237 .12916 .541 -.2155 .3802 
KO +VE 14 days -.79908* .12916 .000 -1.0969 -.5012 
WT +VE 14 days 
WT -VE .38868* .12916 .017 .0908 .6865 
KO -VE .47105* .12916 .007 .1732 .7689 
KO +VE 14 days -.41040* .12916 .013 -.7083 -.1126 
KO -VE 
WT -VE -.08237 .12916 .541 -.3802 .2155 
WT +VE 14 days -.47105* .12916 .007 -.7689 -.1732 
KO +VE 14 days -.88146* .12916 .000 -1.1793 -.5836 
KO +VE 14 days 
WT -VE .79908* .12916 .000 .5012 1.0969 
WT +VE 14 days .41040* .12916 .013 .1126 .7083 
KO -VE .88146* .12916 .000 .5836 1.1793 
*. The mean difference is significant at the 0.05 level. 
 















WT -VE 3 .2186 .04780 .02760 .0999 .3374 .16 .25 
WT +VE 14 days 3 .4755 .08816 .05090 .2564 .6945 .38 .55 
KO -VE 3 .2643 .09525 .05499 .0277 .5009 .16 .34 
KO +VE 14 days 3 .5260 .01685 .00973 .4841 .5678 .51 .54 






Test of Homogeneity of Variances 
ANP 
Levene Statistic df1 df2 Sig. 




 Sum of Squares df Mean Square F Sig. 
Between Groups .209 3 .070 14.325 .001 
Within Groups .039 8 .005   




Dependent Variable: ANP  
(I) Genotype (J) Genotype Mean 
Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT -VE 
WT +VE 14 days -.25685* .05688 .002 -.3880 -.1257 
KO -VE -.04567 .05688 .445 -.1768 .0855 
KO +VE 14 days -.30734* .05688 .001 -.4385 -.1762 
WT +VE 14 days 
WT -VE .25685* .05688 .002 .1257 .3880 
KO -VE .21118* .05688 .006 .0800 .3424 
KO +VE 14 days -.05049 .05688 .401 -.1817 .0807 
KO -VE 
WT -VE .04567 .05688 .445 -.0855 .1768 
WT +VE 14 days -.21118* .05688 .006 -.3424 -.0800 
KO +VE 14 days -.26167* .05688 .002 -.3928 -.1305 
KO +VE 14 days 
WT -VE .30734* .05688 .001 .1762 .4385 
WT +VE 14 days .05049 .05688 .401 -.0807 .1817 
KO -VE .26167* .05688 .002 .1305 .3928 
*. The mean difference is significant at the 0.05 level. 
 
 


















WT -VE 3 .0808 .03937 .02273 -.0170 .1786 .04 .12 
WT +VE 14 days 3 .2160 .00928 .00536 .1930 .2391 .21 .23 
KO -VE 3 .1319 .04276 .02469 .0257 .2381 .10 .18 
KO +VE 14 days 3 .1715 .02038 .01177 .1209 .2221 .15 .19 
Total 12 .1500 .05845 .01687 .1129 .1872 .04 .23 
 
Test of Homogeneity of Variances 
BNP 
Levene Statistic df1 df2 Sig. 





 Sum of Squares df Mean Square F Sig. 
Between Groups .030 3 .010 10.251 .004 
Within Groups .008 8 .001   




Dependent Variable: BNP  
(I) Genotype (J) Genotype Mean 
Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT -VE 
WT +VE 14 days -.13524* .02543 .001 -.1939 -.0766 
KO -VE -.05108 .02543 .079 -.1097 .0076 
KO +VE 14 days -.09071* .02543 .007 -.1493 -.0321 
WT +VE 14 days 
WT -VE .13524* .02543 .001 .0766 .1939 
KO -VE .08416* .02543 .011 .0255 .1428 




WT -VE .05108 .02543 .079 -.0076 .1097 
WT +VE 14 days -.08416* .02543 .011 -.1428 -.0255 
KO +VE 14 days -.03962 .02543 .158 -.0983 .0190 
KO +VE 14 days 
WT -VE .09071* .02543 .007 .0321 .1493 
WT +VE 14 days -.04454 .02543 .118 -.1032 .0141 
KO -VE .03962 .02543 .158 -.0190 .0983 
*. The mean difference is significant at the 0.05 level. 
QPCR 
 















WT -VE 3 1.5822 .63267 .36527 .0105 3.1538 1.00 2.26 
WT +VE 14 days 3 5.7069 .70142 .40497 3.9645 7.4493 4.90 6.12 
KO -VE 3 2.4209 1.30922 .75588 -.8314 5.6732 1.24 3.83 
KO +VE 14 days 3 4.8697 2.62680 1.51658 -1.6556 11.3951 1.88 6.80 
Total 12 3.6449 2.20594 .63680 2.2433 5.0465 1.00 6.80 
 
Test of Homogeneity of Variances 
Calsarcin-1 
Levene Statistic df1 df2 Sig. 




 Sum of Squares df Mean Square F Sig. 
Between Groups 34.515 3 11.505 4.841 .033 
Within Groups 19.013 8 2.377   







Dependent Variable: Calsarcin-1  
(I) Genotype (J) Genotype Mean 
Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT -VE 
WT +VE 14 days -4.12470* 1.25873 .011 -7.0273 -1.2221 
KO -VE -.83868 1.25873 .524 -3.7413 2.0640 
KO +VE 14 days -3.28755* 1.25873 .031 -6.1902 -.3849 
WT +VE 14 days 
WT -VE 4.12470* 1.25873 .011 1.2221 7.0273 
KO -VE 3.28602* 1.25873 .031 .3834 6.1887 
KO +VE 14 days .83715 1.25873 .525 -2.0655 3.7398 
KO -VE 
WT -VE .83868 1.25873 .524 -2.0640 3.7413 
WT +VE 14 days -3.28602* 1.25873 .031 -6.1887 -.3834 
KO +VE 14 days -2.44886 1.25873 .088 -5.3515 .4538 
KO +VE 14 days 
WT -VE 3.28755* 1.25873 .031 .3849 6.1902 
WT +VE 14 days -.83715 1.25873 .525 -3.7398 2.0655 
KO -VE 2.44886 1.25873 .088 -.4538 5.3515 
*. The mean difference is significant at the 0.05 level. 
 















WT -VE 3 2.4564 1.14438 .66071 -.3864 5.2992 1.37 3.65 
WT +VE 14 days 3 4.1993 .19155 .11059 3.7235 4.6752 4.00 4.38 
KO -VE 3 2.5813 .99899 .57677 .0997 5.0630 1.90 3.73 
KO +VE 14 days 3 2.0881 1.14892 .66333 -.7660 4.9422 1.00 3.29 






Test of Homogeneity of Variances 
CnAβ1 
Levene Statistic df1 df2 Sig. 




 Sum of Squares df Mean Square F Sig. 
Between Groups 7.881 3 2.627 2.868 .104 
Within Groups 7.329 8 .916   
Total 15.209 11    
 
Multiple Comparisons 
Dependent Variable: CnAβ1 
(I) Genotype (J) Genotype Mean 
Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT -VE 
WT +VE 14 days -1.74294 .78148 .056 -3.5450 .0592 
KO -VE -.12494 .78148 .877 -1.9270 1.6772 
KO +VE 14 days .36830 .78148 .650 -1.4338 2.1704 
WT +VE 14 days 
WT -VE 1.74294 .78148 .056 -.0592 3.5450 
KO -VE 1.61800 .78148 .072 -.1841 3.4201 
KO +VE 14 days 2.11124* .78148 .027 .3091 3.9133 
KO -VE 
WT -VE .12494 .78148 .877 -1.6772 1.9270 
WT +VE 14 days -1.61800 .78148 .072 -3.4201 .1841 
KO +VE 14 days .49324 .78148 .546 -1.3089 2.2953 
KO +VE 14 days 
WT -VE -.36830 .78148 .650 -2.1704 1.4338 
WT +VE 14 days -2.11124* .78148 .027 -3.9133 -.3091 
KO -VE -.49324 .78148 .546 -2.2953 1.3089 
*. The mean difference is significant at the 0.05 level. 
 




















WT -VE 4 5.9883 4.75434 2.37717 -1.5769 13.5535 1.00 12.44 
WT +VE 14 days 4 14.4966 8.35622 4.17811 1.2000 27.7933 5.18 24.43 
KO -VE 4 8.1644 4.08719 2.04359 1.6608 14.6681 3.44 12.80 
KO +VE 14 days 4 12.1799 7.90211 3.95106 -.3941 24.7540 3.51 21.67 
Total 16 10.2073 6.79112 1.69778 6.5886 13.8260 1.00 24.43 
 
Test of Homogeneity of Variances 
ATF4 
Levene Statistic df1 df2 Sig. 




 Sum of Squares df Mean Square F Sig. 
Between Groups 177.053 3 59.018 1.376 .297 
Within Groups 514.736 12 42.895   
Total 691.789 15    
 
Multiple Comparisons 
Dependent Variable: ATF4  
(I) Genotype (J) Genotype Mean 
Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT -VE 
WT +VE 14 days -8.50837 4.63113 .091 -18.5987 1.5820 
KO -VE -2.17616 4.63113 .647 -12.2665 7.9142 
KO +VE 14 days -6.19166 4.63113 .206 -16.2820 3.8987 
WT +VE 14 days 
WT -VE 8.50837 4.63113 .091 -1.5820 18.5987 
KO -VE 6.33221 4.63113 .197 -3.7581 16.4226 
KO +VE 14 days 2.31671 4.63113 .626 -7.7737 12.4071 
KO -VE 
WT -VE 2.17616 4.63113 .647 -7.9142 12.2665 
WT +VE 14 days -6.33221 4.63113 .197 -16.4226 3.7581 
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KO +VE 14 days -4.01550 4.63113 .403 -14.1059 6.0749 
KO +VE 14 days 
WT -VE 6.19166 4.63113 .206 -3.8987 16.2820 
WT +VE 14 days -2.31671 4.63113 .626 -12.4071 7.7737 
KO -VE 4.01550 4.63113 .403 -6.0749 14.1059 
 















WT -VE 3 1.3641 .40548 .23410 .3569 2.3714 1.00 1.80 
WT +VE 14 days 3 1.9699 .54447 .31435 .6174 3.3225 1.64 2.60 
KO -VE 3 1.5112 .13952 .08055 1.1646 1.8578 1.42 1.67 
KO +VE 14 days 3 2.6801 .96190 .55535 .2906 5.0696 1.65 3.55 
Total 12 1.8813 .73623 .21253 1.4135 2.3491 1.00 3.55 
 
Test of Homogeneity of Variances 
Foxo3a 
Levene Statistic df1 df2 Sig. 




 Sum of Squares df Mean Square F Sig. 
Between Groups 3.151 3 1.050 2.989 .096 
Within Groups 2.811 8 .351   










Dependent Variable: Foxo3a  
(I) Genotype (J) Genotype Mean 
Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT -VE 
WT +VE 14 days -.60580 .48401 .246 -1.7219 .5103 
KO -VE -.14703 .48401 .769 -1.2631 .9691 
KO +VE 14 days -1.31596* .48401 .026 -2.4321 -.1998 
WT +VE 14 days 
WT -VE .60580 .48401 .246 -.5103 1.7219 
KO -VE .45877 .48401 .371 -.6573 1.5749 
KO +VE 14 days -.71016 .48401 .180 -1.8263 .4060 
KO -VE 
WT -VE .14703 .48401 .769 -.9691 1.2631 
WT +VE 14 days -.45877 .48401 .371 -1.5749 .6573 
KO +VE 14 days -1.16893* .48401 .042 -2.2851 -.0528 
KO +VE 14 days 
WT -VE 1.31596* .48401 .026 .1998 2.4321 
WT +VE 14 days .71016 .48401 .180 -.4060 1.8263 
KO -VE 1.16893* .48401 .042 .0528 2.2851 
*. The mean difference is significant at the 0.05 level. 
 















WT -VE 4 5.9163 4.89668 2.44834 -1.8754 13.7080 1.19 12.37 
WT +VE 14 days 4 3.6115 1.95252 .97626 .5046 6.7184 1.59 5.96 
KO -VE 4 9.2726 9.43216 4.71608 -5.7361 24.2813 1.00 22.63 
KO +VE 14 days 4 43.2075 39.99396 19.99698 -20.4318 106.8468 5.93 99.95 






Test of Homogeneity of Variances 
Myostatin 
Levene Statistic df1 df2 Sig. 




 Sum of Squares df Mean Square F Sig. 
Between Groups 4158.677 3 1386.226 3.231 .061 
Within Groups 5148.818 12 429.068   
Total 9307.495 15    
 
Multiple Comparisons 
Dependent Variable: Myostatin  
(I) Genotype (J) Genotype Mean 
Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT -VE 
WT +VE 14 days 2.30486 14.64698 .878 -29.6082 34.2179 
KO -VE -3.35627 14.64698 .823 -35.2693 28.5568 
KO +VE 14 days -37.29116* 14.64698 .026 -69.2042 -5.3781 
WT +VE 14 days 
WT -VE -2.30486 14.64698 .878 -34.2179 29.6082 
KO -VE -5.66113 14.64698 .706 -37.5742 26.2519 
KO +VE 14 days -39.59602* 14.64698 .019 -71.5090 -7.6830 
KO -VE 
WT -VE 3.35627 14.64698 .823 -28.5568 35.2693 
WT +VE 14 days 5.66113 14.64698 .706 -26.2519 37.5742 
KO +VE 14 days -33.93489* 14.64698 .039 -65.8479 -2.0219 
KO +VE 14 days 
WT -VE 37.29116* 14.64698 .026 5.3781 69.2042 
WT +VE 14 days 39.59602* 14.64698 .019 7.6830 71.5090 
KO -VE 33.93489* 14.64698 .039 2.0219 65.8479 
*. The mean difference is significant at the 0.05 level. 
 
Immunoblotting 





t-Test: Two-Sample Assuming Equal Variances 






Mean 1 3.108567 
Variance 0 0.566065 
Observations 3 3 
Pooled Variance 0.283032 
 Hypothesized Mean 
Difference 0 
 Df 4 
 t Stat -4.85417 
 P(T<=t) one-tail 0.004157 
 t Critical one-tail 2.131847 
 P(T<=t) two-tail 0.008314 
 t Critical two-tail 2.776445   
 
2) GATA4 cytoplasmic protein levels in NFATc2+/+ and NFATc2-/- hearts: 
t-Test: Two-Sample Assuming Equal Variances 






Mean 1 0.974108 
Variance 0 0.172746 
Observations 3 3 
Pooled Variance 0.086373 
 Hypothesized Mean 
Difference 0 
 df 4 
 t Stat 0.107902 
 P(T<=t) one-tail 0.459635 
 t Critical one-tail 2.131846 
 P(T<=t) two-tail 0.919269 
 t Critical two-tail 2.776451   
 






t-Test: Two-Sample Assuming Equal Variances 






Mean 1 1.697305 
Variance 0 0.017893 
Observations 3 3 
Pooled Variance 0.008946 
 Hypothesized Mean 
Difference 0 
 df 4 
 t Stat -9.02909 
 P(T<=t) one-tail 0.000417 
 t Critical one-tail 2.131846 
 P(T<=t) two-tail 0.000833 
 t Critical two-tail 2.776451   
 
4) pAkt Ser 473 protein levels in normotensive and 14 day stimulated hearts: 
 
Descriptives 
pAkt Ser 473 











WT -VE 4 1.1732 .34647 .17324 .6219 1.7245 1.00 1.69 
WT +VE 14 days 4 1.8466 .60999 .30500 .8760 2.8173 1.03 2.50 
KO -VE 4 1.2184 .18837 .09418 .9186 1.5181 .94 1.35 
KO +VE 14 days 4 1.6098 .28669 .14334 1.1536 2.0660 1.36 1.97 
Total 16 1.4620 .45310 .11327 1.2206 1.7034 .94 2.50 
 
 
Test of Homogeneity of Variances 
pAkt  Ser 473  
Levene Statistic df1 df2 Sig. 







pAkt Ser 473 
 Sum of Squares df Mean Square F Sig. 
Between Groups 1.250 3 .417 2.733 .090 
Within Groups 1.829 12 .152   
Total 3.079 15    
 
Multiple Comparisons 
Dependent Variable: pAkt  Ser 473 
(I) Genotype (J) Genotype Mean 
Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT -VE 
WT +VE 14 days -.67339* .27609 .031 -1.2749 -.0718 
KO -VE -.04514 .27609 .873 -.6467 .5564 
KO +VE 14 days -.43655 .27609 .140 -1.0381 .1650 
WT +VE 14 days 
WT -VE .67339* .27609 .031 .0718 1.2749 
KO -VE .62824* .27609 .042 .0267 1.2298 
KO +VE 14 days .23684 .27609 .408 -.3647 .8384 
KO -VE 
WT -VE .04514 .27609 .873 -.5564 .6467 
WT +VE 14 days -.62824* .27609 .042 -1.2298 -.0267 
KO +VE 14 days -.39141 .27609 .182 -.9930 .2101 
KO +VE 14 days 
WT -VE .43655 .27609 .140 -.1650 1.0381 
WT +VE 14 days -.23684 .27609 .408 -.8384 .3647 
KO -VE .39141 .27609 .182 -.2101 .9930 
*. The mean difference is significant at the 0.05 level. 
 
5) α-SMA protein levels in normotensive and 14 day stimulated hearts: 
Note: Each set of α-SMA was carried out on a separate gel, quantified and normalized to WT, 
which is standardized to 1. Therefore multiple student-t-tests were performed. 
t-Test: Two-Sample Assuming Equal Variances 




Ang II -ve 
Variable 
NFATc2+/+ 
Ang II +ve 
Mean 1 1.738549 
Variance 0 0.638017 
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Observations 4 4 
Pooled Variance 0.319009 
 Hypothesized Mean 
Difference 0 
 Df 6 
 t Stat -1.84924 
 P(T<=t) one-tail 0.056955 
 t Critical one-tail 1.94318 
 P(T<=t) two-tail 0.11391 
 t Critical two-tail 2.446912   
 
t-Test: Two-Sample Assuming Equal Variances 




Ang II -ve 
Variable 
NFATc2-/- 
Ang II -ve 
Mean 1 0.909822 
Variance 0 0.134441 
Observations 4 4 
Pooled Variance 0.067221 
 Hypothesized Mean 
Difference 0 
 df 6 
 t Stat 0.491887 
 P(T<=t) one-tail 0.320138 
 t Critical one-tail 1.94318 
 P(T<=t) two-tail 0.640276 
 t Critical two-tail 2.446912   
 
t-Test: Two-Sample Assuming Equal Variances 




Ang II +ve 
Variable 
NFATc2-/- 
Ang II +ve 
Mean 1.738549 1.958736 
Variance 0.638017 1.422662 
Observations 4 4 
Pooled Variance 1.03034 
 Hypothesized Mean 
Difference 0 
 df 6 
 t Stat -0.30677 
 P(T<=t) one-tail 0.384692 
 t Critical one-tail 1.94318 




t Critical two-tail 2.446912   
 
t-Test: Two-Sample Assuming Equal Variances 




Ang II -ve 
Variable 
NFATc2-/- 
Ang II +ve 
Mean 0.909822 1.958736 
Variance 0.134441 1.422662 
Observations 4 4 
Pooled Variance 0.778552 
 Hypothesized Mean 
Difference 0 
 df 6 
 t Stat -1.68117 
 P(T<=t) one-tail 0.071863 
 t Critical one-tail 1.94318 
 P(T<=t) two-tail 0.143727 
 t Critical two-tail 2.446912   
 
6) pFoxo3a Ser 253 protein levels in normotensive and 14 day stimulated hearts: 
 
Descriptives 
pFoxo3a Ser 253 











WT -VE 4 .9164 .40502 .20251 .2720 1.5609 .35 1.31 
WT +VE 14 days 4 .9370 .37434 .18717 .3413 1.5327 .57 1.46 
KO -VE 4 1.0469 .31270 .15635 .5494 1.5445 .74 1.35 
KO +VE 14 days 4 1.0462 .52232 .26116 .2150 1.8773 .55 1.73 
Total 16 .9866 .37261 .09315 .7881 1.1852 .35 1.73 
 
 
Test of Homogeneity of Variances 
pFoxo3a Ser 253 
Levene Statistic df1 df2 Sig. 





pFoxo3a Ser 253 
 Sum of Squares df Mean Square F Sig. 
Between Groups .058 3 .019 .115 .950 
Within Groups 2.024 12 .169   
Total 2.083 15    
 
Multiple Comparisons 
Dependent Variable: pFoxo3a Ser 253 
(I) Genotype (J) Genotype Mean 
Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT -VE 
WT +VE 14 days -.02056 .29042 .945 -.6533 .6122 
KO -VE -.13051 .29042 .661 -.7633 .5023 
KO +VE 14 days -.12972 .29042 .663 -.7625 .5031 
WT +VE 14 days 
WT -VE .02056 .29042 .945 -.6122 .6533 
KO -VE -.10994 .29042 .712 -.7427 .5228 
KO +VE 14 days -.10916 .29042 .714 -.7419 .5236 
KO -VE 
WT -VE .13051 .29042 .661 -.5023 .7633 
WT +VE 14 days .10994 .29042 .712 -.5228 .7427 
KO +VE 14 days .00079 .29042 .998 -.6320 .6336 
KO +VE 14 days 
WT -VE .12972 .29042 .663 -.5031 .7625 
WT +VE 14 days .10916 .29042 .714 -.5236 .7419 
KO -VE -.00079 .29042 .998 -.6336 .6320 
 















WT -VE 4 .9419 .25013 .12506 .5439 1.3399 .59 1.18 
WT +VE 14 days 4 1.1188 .10512 .05256 .9515 1.2861 1.01 1.26 
KO -VE 4 .9706 .14524 .07262 .7395 1.2017 .86 1.17 
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KO +VE 14 days 4 .8841 .14826 .07413 .6481 1.1200 .68 .99 




Test of Homogeneity of Variances 
Vimentin 
Levene Statistic df1 df2 Sig. 




 Sum of Squares df Mean Square F Sig. 
Between Groups .120 3 .040 1.371 .299 
Within Groups .350 12 .029   




Dependent Variable: Vimentin  
(I) Genotype (J) Genotype Mean 
Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT -VE 
WT +VE 14 days -.17689 .12077 .169 -.4400 .0863 
KO -VE -.02866 .12077 .816 -.2918 .2345 
KO +VE 14 days .05786 .12077 .641 -.2053 .3210 
WT +VE 14 days 
WT -VE .17689 .12077 .169 -.0863 .4400 
KO -VE .14823 .12077 .243 -.1149 .4114 
KO +VE 14 days .23475 .12077 .076 -.0284 .4979 
KO -VE 
WT -VE .02866 .12077 .816 -.2345 .2918 
WT +VE 14 days -.14823 .12077 .243 -.4114 .1149 
KO +VE 14 days .08652 .12077 .487 -.1766 .3497 
KO +VE 14 days 
WT -VE -.05786 .12077 .641 -.3210 .2053 
WT +VE 14 days -.23475 .12077 .076 -.4979 .0284 



















WT -VE 4 .9412 .08517 .04258 .8057 1.0768 .82 1.00 
WT +VE 14 days 4 .8757 .10636 .05318 .7064 1.0449 .75 .99 
KO -VE 4 .9958 .10367 .05183 .8309 1.1608 .87 1.12 
KO +VE 14 days 4 .7428 .17940 .08970 .4573 1.0283 .52 .96 
Total 16 .8889 .14771 .03693 .8102 .9676 .52 1.12 
 
 
Test of Homogeneity of Variances 
CnAβ 
Levene Statistic df1 df2 Sig. 





 Sum of Squares df Mean Square F Sig. 
Between Groups .143 3 .048 3.096 .068 
Within Groups .184 12 .015   




Dependent Variable: CnAβ 
(I) Genotype (J) Genotype Mean 
Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT -VE 
WT +VE 14 days .06555 .08768 .469 -.1255 .2566 
KO -VE -.05460 .08768 .545 -.2456 .1364 
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KO +VE 14 days .19844* .08768 .043 .0074 .3895 
WT +VE 14 days 
WT -VE -.06555 .08768 .469 -.2566 .1255 
KO -VE -.12015 .08768 .196 -.3112 .0709 
KO +VE 14 days .13289 .08768 .155 -.0581 .3239 
KO -VE 
WT -VE .05460 .08768 .545 -.1364 .2456 
WT +VE 14 days .12015 .08768 .196 -.0709 .3112 
KO +VE 14 days .25304* .08768 .014 .0620 .4441 
KO +VE 14 days 
WT -VE -.19844* .08768 .043 -.3895 -.0074 
WT +VE 14 days -.13289 .08768 .155 -.3239 .0581 
KO -VE -.25304* .08768 .014 -.4441 -.0620 
*. The mean difference is significant at the 0.05 level. 
 




pAkt Ser 473 











WT -VE 3 .9637 .06288 .03631 .8075 1.1199 .89 1.00 
WT +VE 28 days 3 1.2035 .88883 .51317 -1.0045 3.4115 .65 2.23 
KO -VE 3 .9035 .17538 .10125 .4678 1.3392 .79 1.11 
KO +VE 28 days 3 1.9697 .98267 .56734 -.4714 4.4108 1.00 2.97 
Total 12 1.2601 .72274 .20864 .8009 1.7193 .65 2.97 
 
 
Test of Homogeneity of Variances 
pAkt Ser 473 
Levene Statistic df1 df2 Sig. 








pAkt Ser 473 
 Sum of Squares df Mean Square F Sig. 
Between Groups 2.165 3 .722 1.612 .262 
Within Groups 3.581 8 .448   
Total 5.746 11    
 
Multiple Comparisons 
Dependent Variable: pAkt Ser 473 
(I) Genotype (J) Genotype Mean 
Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT -VE 
WT +VE 28 days -.23981 .54625 .672 -1.4995 1.0198 
KO -VE .06019 .54625 .915 -1.1995 1.3199 
KO +VE 28 days -1.00600 .54625 .103 -2.2657 .2537 
WT +VE 28 days 
WT -VE .23981 .54625 .672 -1.0198 1.4995 
KO -VE .30000 .54625 .598 -.9597 1.5597 
KO +VE 28 days -.76618 .54625 .198 -2.0258 .4935 
KO -VE 
WT -VE -.06019 .54625 .915 -1.3199 1.1995 
WT +VE 28 days -.30000 .54625 .598 -1.5597 .9597 
KO +VE 28 days -1.06618 .54625 .087 -2.3258 .1935 
KO +VE 28 days 
WT -VE 1.00600 .54625 .103 -.2537 2.2657 
WT +VE 28 days .76618 .54625 .198 -.4935 2.0258 
KO -VE 1.06618 .54625 .087 -.1935 2.3258 
 
10) pFoxo3a Ser 253 protein levels in normotensive and 28 day stimulated hearts: 
 
Descriptives 
pFoxo3a Ser 253 











WT -VE 3 1.0593 .10270 .05930 .8042 1.3144 1.00 1.18 
WT +VE 28 days 3 1.3651 .06523 .03766 1.2031 1.5271 1.29 1.42 
KO -VE 3 1.3827 .61963 .35775 -.1566 2.9219 .79 2.03 
KO +VE 28 days 3 1.6639 .68462 .39527 -.0368 3.3646 .95 2.32 
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Total 12 1.3678 .45569 .13155 1.0782 1.6573 .79 2.32 
 
 
Test of Homogeneity of Variances 
pFoxo3a Ser 253 
Levene Statistic df1 df2 Sig. 
2.535 3 8 .130 
 
ANOVA 
pFoxo3a Ser 253 
 Sum of Squares df Mean Square F Sig. 
Between Groups .549 3 .183 .844 .507 
Within Groups 1.735 8 .217   




Dependent Variable: pFoxo3a Ser 253 
(I) Genotype (J) Genotype Mean 
Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT -VE 
WT +VE 28 days -.30581 .38023 .444 -1.1826 .5710 
KO -VE -.32340 .38023 .420 -1.2002 .5534 
KO +VE 28 days -.60465 .38023 .150 -1.4815 .2722 
WT +VE 28 days 
WT -VE .30581 .38023 .444 -.5710 1.1826 
KO -VE -.01758 .38023 .964 -.8944 .8592 
KO +VE 28 days -.29884 .38023 .455 -1.1757 .5780 
KO -VE 
WT -VE .32340 .38023 .420 -.5534 1.2002 
WT +VE 28 days .01758 .38023 .964 -.8592 .8944 
KO +VE 28 days -.28125 .38023 .481 -1.1581 .5956 
KO +VE 28 days 
WT -VE .60465 .38023 .150 -.2722 1.4815 
WT +VE 28 days .29884 .38023 .455 -.5780 1.1757 
KO -VE .28125 .38023 .481 -.5956 1.1581 
 

















WT -VE 3 1.0433 .07504 .04332 .8569 1.2297 1.00 1.13 
WT +VE 28 days 3 1.1546 .21383 .12346 .6234 1.6858 .96 1.38 
KO -VE 3 1.2340 .21624 .12485 .6969 1.7712 1.07 1.48 
KO +VE 28 days 3 1.3625 .37953 .21912 .4197 2.3053 .93 1.62 
Total 12 1.1986 .24248 .07000 1.0445 1.3527 .93 1.62 
 
Test of Homogeneity of Variances 
Vimentin 
Levene Statistic df1 df2 Sig. 





 Sum of Squares df Mean Square F Sig. 
Between Groups .162 3 .054 .895 .485 
Within Groups .484 8 .061   




Dependent Variable: Vimentin  
(I) Genotype (J) Genotype Mean 
Difference (I-
J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT -VE 
WT +VE 28 days -.11127 .20090 .595 -.5745 .3520 
KO -VE -.19070 .20090 .370 -.6540 .2726 
KO +VE 28 days -.31914 .20090 .151 -.7824 .1441 
WT +VE 28 days 
WT -VE .11127 .20090 .595 -.3520 .5745 
KO -VE -.07943 .20090 .703 -.5427 .3838 




WT -VE .19070 .20090 .370 -.2726 .6540 
WT +VE 28 days .07943 .20090 .703 -.3838 .5427 
KO +VE 28 days -.12845 .20090 .540 -.5917 .3348 
KO +VE 28 days 
WT -VE .31914 .20090 .151 -.1441 .7824 
WT +VE 28 days .20787 .20090 .331 -.2554 .6711 
KO -VE .12845 .20090 .540 -.3348 .5917 
 















WT -VE 3 1.0496 .08583 .04955 .8363 1.2628 1.00 1.15 
WT +VE 28 days 3 2.9670 .21094 .12179 2.4430 3.4911 2.74 3.15 
KO -VE 3 1.0185 .22951 .13251 .4483 1.5886 .78 1.24 
KO +VE 28 days 3 2.5772 .44401 .25635 1.4742 3.6802 2.15 3.04 
Total 12 1.9031 .94848 .27380 1.3004 2.5057 .78 3.15 
 
 
Test of Homogeneity of Variances 
α-SMA 
Levene Statistic df1 df2 Sig. 





 Sum of Squares df Mean Square F Sig. 
Between Groups 9.292 3 3.097 41.069 .000 
Within Groups .603 8 .075   






Dependent Variable: α-SMA  
(I) Genotype (J) Genotype Mean 
Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT -VE 
WT +VE 28 days -1.91749* .22423 .000 -2.4346 -1.4004 
KO -VE .03108 .22423 .893 -.4860 .5482 
KO +VE 28 days -1.52763* .22423 .000 -2.0447 -1.0105 
WT +VE 28 days 
WT -VE 1.91749* .22423 .000 1.4004 2.4346 
KO -VE 1.94857* .22423 .000 1.4315 2.4657 
KO +VE 28 days .38985 .22423 .120 -.1272 .9069 
KO -VE 
WT -VE -.03108 .22423 .893 -.5482 .4860 
WT +VE 28 days -1.94857* .22423 .000 -2.4657 -1.4315 
KO +VE 28 days -1.55872* .22423 .000 -2.0758 -1.0416 
KO +VE 28 days 
WT -VE 1.52763* .22423 .000 1.0105 2.0447 
WT +VE 28 days -.38985 .22423 .120 -.9069 .1272 
KO -VE 1.55872* .22423 .000 1.0416 2.0758 
*. The mean difference is significant at the 0.05 level. 
 















WT -VE 3 1.0240 .04153 .02397 .9208 1.1271 1.00 1.07 
WT +VE 28 days 3 .3904 .02677 .01546 .3239 .4569 .36 .41 
KO -VE 3 1.2490 .34750 .20063 .3858 2.1123 .86 1.54 
KO +VE 28 days 3 .4412 .25662 .14816 -.1962 1.0787 .28 .74 
Total 12 .7761 .42812 .12359 .5041 1.0482 .28 1.54 
 
Test of Homogeneity of Variances 
Calsarcin-1 
Levene Statistic df1 df2 Sig. 






 Sum of Squares df Mean Square F Sig. 
Between Groups 1.638 3 .546 11.552 .003 
Within Groups .378 8 .047   




Dependent Variable: Calsarcin-1  
(I) Genotype (J) Genotype Mean 
Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT -VE 
WT +VE 28 days .63361* .17751 .007 .2243 1.0429 
KO -VE -.22503 .17751 .241 -.6344 .1843 
KO +VE 28 days .58274* .17751 .011 .1734 .9921 
WT +VE 28 days 
WT -VE -.63361* .17751 .007 -1.0429 -.2243 
KO -VE -.85864* .17751 .001 -1.2680 -.4493 
KO +VE 28 days -.05087 .17751 .782 -.4602 .3585 
KO -VE 
WT -VE .22503 .17751 .241 -.1843 .6344 
WT +VE 28 days .85864* .17751 .001 .4493 1.2680 
KO +VE 28 days .80777* .17751 .002 .3984 1.2171 
KO +VE 28 days 
WT -VE -.58274* .17751 .011 -.9921 -.1734 
WT +VE 28 days .05087 .17751 .782 -.3585 .4602 
KO -VE -.80777* .17751 .002 -1.2171 -.3984 
*. The mean difference is significant at the 0.05 level. 
 

















WT -VE 3 1.0618 .10700 .06178 .7960 1.3276 1.00 1.19 
WT +VE 28 days 3 1.2472 .48079 .27758 .0529 2.4415 .72 1.67 
KO -VE 3 1.3794 .40255 .23241 .3794 2.3793 1.07 1.83 
KO +VE 28 days 3 .9959 .19514 .11266 .5112 1.4807 .86 1.22 
Total 12 1.1711 .32486 .09378 .9647 1.3775 .72 1.83 
 
 
Test of Homogeneity of Variances 
CnAβ 
Levene Statistic df1 df2 Sig. 




 Sum of Squares df Mean Square F Sig. 
Between Groups .275 3 .092 .829 .514 
Within Groups .885 8 .111   
Total 1.161 11    
 
Multiple Comparisons 
Dependent Variable: CnAβ 
(I) Genotype (J) Genotype Mean 
Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT -VE 
WT +VE 28 days -.18543 .27164 .514 -.8118 .4410 
KO -VE -.31758 .27164 .276 -.9440 .3088 
KO +VE 28 days .06585 .27164 .815 -.5606 .6922 
WT +VE 28 days 
WT -VE .18543 .27164 .514 -.4410 .8118 
KO -VE -.13215 .27164 .640 -.7586 .4942 
KO +VE 28 days .25127 .27164 .382 -.3751 .8777 
KO -VE 
WT -VE .31758 .27164 .276 -.3088 .9440 
WT +VE 28 days .13215 .27164 .640 -.4942 .7586 
KO +VE 28 days .38343 .27164 .196 -.2430 1.0098 
KO +VE 28 days 
WT -VE -.06585 .27164 .815 -.6922 .5606 
WT +VE 28 days -.25127 .27164 .382 -.8777 .3751 




1) Relative HW/BW in normotensive NFATc2+/+ and NFATc2-/- hearts: 
t-Test: Two-Sample Assuming Equal Variances 






Mean 5.018853 4.756885 
Variance 0.600745 0.206136 
Observations 7 7 
Pooled Variance 0.40344 
 Hypothesized Mean 
Difference 0 
 df 12 
 t Stat 0.771602 
 P(T<=t) one-tail 0.227638 
 t Critical one-tail 1.782288 
 P(T<=t) two-tail 0.455277 
 t Critical two-tail 2.178813   
 















WT -VE 7 5.0189 .77508 .29295 4.3020 5.7357 4.48 6.56 
WT +VE 14 days 7 6.0967 .82406 .31146 5.3345 6.8588 5.13 7.74 
KO -VE 7 4.7569 .45402 .17160 4.3370 5.1768 4.35 5.70 
KO +VE 14 days 7 5.9283 .92318 .34893 5.0745 6.7821 4.61 7.26 
Total 28 5.4502 .92740 .17526 5.0906 5.8098 4.35 7.74 
 
Test of Homogeneity of Variances 
HW 
Levene Statistic df1 df2 Sig. 






 Sum of Squares df Mean Square F Sig. 
Between Groups 9.193 3 3.064 5.242 .006 
Within Groups 14.029 24 .585   
Total 23.222 27    
 
Multiple Comparisons 
Dependent Variable: HW  
(I) Genotype (J) Genotype Mean 
Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT -VE 
WT +VE 14 days -1.07780* .40868 .014 -1.9213 -.2343 
KO-VE .26197 .40868 .528 -.5815 1.1054 
KO +VE 14 days -.90943* .40868 .036 -1.7529 -.0660 
WT +VE 14 days 
WT -VE 1.07780* .40868 .014 .2343 1.9213 
KO -VE 1.33977* .40868 .003 .4963 2.1832 
KO +VE 14 days .16837 .40868 .684 -.6751 1.0118 
KO -VE 
WT -VE -.26197 .40868 .528 -1.1054 .5815 
WT +VE 14 days -1.33977* .40868 .003 -2.1832 -.4963 
KO +VE 14 days -1.17140* .40868 .009 -2.0149 -.3279 
KO +VE 14 days 
WT -VE .90943* .40868 .036 .0660 1.7529 
WT +VE 14 days -.16837 .40868 .684 -1.0118 .6751 
KO -VE 1.17140* .40868 .009 .3279 2.0149 
*. The mean difference is significant at the 0.05 level. 
 
3) Left ventricle inner chamber diameter: Total heart diameter in NFATc2+/+ and NFATc2-/- 
hearts: 
t-Test: Two-Sample Assuming Equal Variances 






Mean 0.457415 0.586696 
Variance 0.00228 0.001459 
Observations 3 3 
Pooled Variance 0.001869  
Hypothesized Mean Difference 0  
df 4  
t Stat -3.66221  
P(T<=t) one-tail 0.010769  
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t Critical one-tail 2.131847  
P(T<=t) two-tail 0.021538  
t Critical two-tail 2.776445   
 
4) Right ventricular wall diameter: Total heart diameter in NFATc2+/+ and NFATc2-/- hearts: 
t-Test: Two-Sample Assuming Equal Variances 






Mean 0.114921 0.086165 
Variance 0.001145 0.000353 
Observations 3 3 
Pooled Variance 0.000749  
Hypothesized Mean Difference 0  
df 4  
t Stat 1.286941  
P(T<=t) one-tail 0.13377  
t Critical one-tail 2.131847  
P(T<=t) two-tail 0.26754  
t Critical two-tail 2.776445   
 
5) NFAT nuclear localization in NFATc2+/+ and NFATc2-/- hearts: 
t-Test: Two-Sample Assuming Equal Variances  






Mean 14.36666667 22 
Variance 0.253333333 0.67 
Observations 3 3 
Pooled Variance 0.461666667  
Hypothesized Mean Difference 0  
df 4  
t Stat -13.75927649  
P(T<=t) one-tail 8.08348E-05  
t Critical one-tail 2.131846486  
P(T<=t) two-tail 0.00016167  
t Critical two-tail 2.776450856   
 
t-Test: Two-Sample Assuming Equal Variances  






Mean 8.14 4.26 
Variance 0.7284 1.7553 
Observations 3 3 
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Pooled Variance 1.24185  
Hypothesized Mean Difference 0  
df 4  
t Stat 4.264251239  
P(T<=t) one-tail 0.006504748  
t Critical one-tail 2.131846486  
P(T<=t) two-tail 0.013009496  
t Critical two-tail 2.776450856   
 
t-Test: Two-Sample Assuming Equal Variances  






Mean 10.12 9.776667 
Variance 0.3292 6.892433 
Observations 3 3 
Pooled Variance 3.610816667  
Hypothesized Mean Difference 0  
df 4  
t Stat 0.221288518  
P(T<=t) one-tail 0.417852642  
t Critical one-tail 2.131846486  
P(T<=t) two-tail 0.835705284  
t Critical two-tail 2.776450856   
 
-Test: Two-Sample Assuming Equal Variances 






Mean 10.64333 10.56 
Variance 5.754633 8.5783 
Observations 3 3 
Pooled Variance 7.166467 
 Hypothesized Mean Difference 0 
 df 4 
 t Stat 0.038125 
 P(T<=t) one-tail 0.485707 
 t Critical one-tail 2.131846 
 P(T<=t) two-tail 0.971415 










NFATc1 nuclear localization 











WT -VE 3 8.8480 1.08445 .62611 6.1541 11.5419 7.64 9.74 
WT +VE 14 days 3 14.6195 4.14565 2.39349 4.3211 24.9179 10.64 18.91 
KO -VE 3 18.0189 3.67902 2.12408 8.8797 27.1581 13.82 20.68 
KO +VE 14 days 3 22.5326 6.53823 3.77485 6.2907 38.7745 16.13 29.20 
Total 12 16.0048 6.38688 1.84373 11.9467 20.0628 7.64 29.20 
 
 
Test of Homogeneity of Variances 
NFATc1 nuclear localization 
Levene Statistic df1 df2 Sig. 




NFATc1 nuclear localization 
 Sum of Squares df Mean Square F Sig. 
Between Groups 299.423 3 99.808 5.348 .026 
Within Groups 149.292 8 18.662   





Dependent Variable: NFATc1 nuclear localization 
(I) Genotype (J) Genotype Mean 
Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
WT -VE 
WT +VE 14 days -5.77148 3.52718 .140 -13.9052 2.3622 
KO-VE -9.17091* 3.52718 .032 -17.3046 -1.0372 
KO +VE 14 days -13.68460* 3.52718 .005 -21.8183 -5.5509 
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WT +VE 14 days 
WT -VE 5.77148 3.52718 .140 -2.3622 13.9052 
KO -VE -3.39943 3.52718 .363 -11.5331 4.7343 
KO +VE 14 days -7.91311 3.52718 .055 -16.0468 .2206 
KO -VE 
WT -VE 9.17091* 3.52718 .032 1.0372 17.3046 
WT +VE 14 days 3.39943 3.52718 .363 -4.7343 11.5331 
KO +VE 14 days -4.51369 3.52718 .237 -12.6474 3.6200 
KO +VE 14 days 
WT -VE 13.68460* 3.52718 .005 5.5509 21.8183 
WT +VE 14 days 7.91311 3.52718 .055 -.2206 16.0468 
KO -VE 4.51369 3.52718 .237 -3.6200 12.6474 






















Appendix IV: Chapter 4-Additional Figures 
 
 
Figure 1: NFATc2-/- mice have similar relative heart weights but different morphological 
characteristics to those of NFATc2+/+ mice  
 (a) Representative photomicrographs of ethidium bromide-stained agarose gels depicting DNA 
products of the Wild-Type (NFATc2+/+), NFATc2 knockout (NFATc2-/-) and heterozygous 
genotypes (NFATc2+/-); NFATc2+/+ bands are shown at 500 bp and NFATc2-/- bands are shown 
at 390 bp. (b) Freshly extracted mice hearts. (c) Quantification of the relative HW/BW for 
NFATc2+/+ and NFATc2-/- (n=7) mice. (d) Representative photomicrographs of cross sections 
from NFATc2+/+ and NFATc2-/- hearts processed for hematoxylin and eosin staining and 
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quantification of the left ventricular chamber inner wall diameter (e) and  right ventricular wall 
diameter (f) normalized to total heart diameter (n=3; P<0.05). *compared to NFATc2+/+. Scale 








Figure 2: NFATc1 nuclear localization in the hearts of NFATc2+/+ and NFATc2-/- mice  
(a) Representative photomicrographs of ethidium bromide-stained agarose gels depicting PCR 
products for NFATc1-c4 showing no significant differences between NFATc2+/+ and NFATc2-/-
hearts (n=3). (b) Representative photomicrographs depicting nuclear localization of NFAT 
isoforms in the heart. Arrows indicate nuclei positively stained for NFATc1-4 isoforms. To 
control for unspecific secondary antibody staining, the Dapi images have only the secondary 
antibody conjugated to the fluorophore Alexa 488 added, without a primary antibody. Scale bars, 
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20µm. (c) Quantification of the percentage of myonuclei stained for NFATc1-4 reveals 
significant increase in NFATc1 nuclear localization of NFATc2-/- hearts compared to NFATc2+/+ 
hearts (n=3; p<0.05). *compared to NFATc2+/+. Means ± SEM are shown. (Figure 2 is taken 













Figure 3: GATA4 has higher nuclear expression in the hearts of NFATc2-/- mice 
(a-b) Representative immunoblot of GATA4 expression in whole heart protein homogenate and 
its quantification normalized to α-tubulin expression (n=3; P<0.05). (c-e) Representative 
immunoblot and respective quantifications of hearts fractionated in cytoplasmic and nuclear 
protein extracts. A double band is visualized in the nuclear fraction possibly due to additional 
phosphorylated sites on GATA4 (n=3; P<0.05). *compared to NFATc2+/+. Means ± SEM are 




Figure 4: The 14 day Ang II-stimulated mice display more severe heart pathology 
(a) HW/BW ratio of normotensive and Ang II-stimulated adult NFATc2+/+ and NFATc2-/- mice 
(n=7; P<0.05). (b) Representative photomicrographs of cross sections from 14 day Ang II-
stimulated NFATc2+/+ and NFATc2-/- hearts processed for hematoxylin and eosin staining. Scale 
bars, 1mm. (c) Representative photomicrographs of ethidium bromide-stained agarose gels 
depicting PCR products for β-MyHC, ANP and BNP. (d-f) Quantifications of β-MyHC, ANP and 
BNP transcript levels normalized to 28S housekeeping gene (n=3; P<0.05). AU represents 
Arbitrary Units. *compared to normotensive NFATc2+/+, $compared to stimulated NFATc2+/+ 
and #compared to normotensive NFATc2-/-. Means ± SEM are shown. (Figure 4 except 4a, is 
taken from Patrick Sin-Chan, MSc thesis, 2011). 
 
